Optimized recovery and minimally invasive liver surgery by Wong-Lun-Hing, Edgar Marinus
  
 
Optimized recovery and minimally invasive liver
surgery
Citation for published version (APA):
Wong-Lun-Hing, E. M. (2017). Optimized recovery and minimally invasive liver surgery. Maastricht:
Datawyse / Universitaire Pers Maastricht. https://doi.org/10.26481/dis.20170519ewlh
Document status and date:
Published: 01/01/2017
DOI:
10.26481/dis.20170519ewlh
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Unspecified
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
VERRECOPTIMIZEDY                           MINIMALLYINVASIVELIVERSURGERY
AND
EDGAR M.
WONG-LUN-
HING
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the research described in this thesis were financially supported by grants 
from Profiling Fund (Maastricht UMC+) and EAES Research. The author of the thesis 
was funded by NUTRIM, School for Nutrition, Toxocology and Metabolism of Maas-
tricht University. 
 
 
 
Cover: Juul Langenberg 
Lay-out: Datawyse, Universitaire Pers Maastricht 
Printed by: Datawyse, Universitaire Pers Maastricht 
ISBN: 978 94 6159 691 8 
 
© E.M. Wong-Lun-Hing, 2017 
 
All rights reserved. No part of this publication may be reproduced, stored in a retriev-
al system or transmitted in any form or by any means, without permission of the 
author, or, when appropriate, of the publishers of the publications. 
 
The publication of this theis was financially supported by: Applied Medical, Nutricia, 
Covidien, ChipSoft, JBA, Afdeling Chirurgie Jeroen Bosch Ziekenhuis, NUTRIM, Maas-
tricht University, MEMIC and CTCM. 
  
  
 
OPTIMIZED RECOVERY AND MINIMALLY 
INVASIVE LIVER SURGERY 
 
 
PROEFSCHRIFT 
 
 
Ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, Prof. dr. Rianne Letschert, 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen 
op vrijdag 19 mei 2017 om 12:00 uur 
 
door 
 
 
Edgar Marinus Wong-Lun-Hing 
 
geboren op 22 september 1984 te ‘s-Hertogenbosch 
 
 
 
 
 
 
 
   
 Promotor 
Prof. dr. C.H.C. Dejong 
 
Copromotor 
Dr. R.M. van Dam 
 
Beoordelingscommissie 
Prof. dr. G.L. Beets (voorzitter )  
Dr. M.T. de Boer (UMCG) 
Prof. dr. W.F.F.A. Buhre 
Prof. dr. R.W.J. van der Hulst   
Prof. dr. J.N. Primrose (University Hospital Southampton) 
 
 
 
   
 5 
TABLE OF CONTENTS 
Chapter 1  General introduction and outline of thesis 7 
 
Part I  OPTIMIZED RECOVERY AFTER HEPATIC SURGERY 35 
Chapter 2  A survey in the hepatopancreatobiliary community on ways to 
enhance patient recovery 37 
Chapter 3  A systematic review of outcomes in patients undergoing liver 
surgery in an enhanced recovery after surgery pathways 51 
Chapter 4  Is current perioperative practice in hepatic surgery based on 
enhanced recovery after surgery (ERAS) principles? 65 
Chapter 5  Post-operative pain control using continuous i.m. bupivacaine 
infusion plus patient-controlled analgesia compared with epidural 
analgesia after major hepatectomy 85 
Chapter 6  Abandoning prophylactic abdominal drainage after hepatic surgery: 
10 years of no-drain policy in an ERAS environment 101 
 
Part II  LAPAROSCOPIC LIVER SURGERY 121 
Chapter 7  Laparoscopic liver resection in the Netherlands: how far are we? 123 
Chapter 8  Open versus laparoscopic left lateral hepatic sectionectomy within 
an enhanced recovery ERAS programme (ORANGE II – Trial): study 
protocol for a randomised controlled trial 143 
Chapter 9  Randomised controlled trial of open versus laparoscopic left lateral 
hepatic sectionectomy within an enhanced recovery ERAS® 
programme (ORANGE II – Study) 165 
Chapter 10  Open versus laparoscopic hemihepatectomy within an ERAS 
programme (ORANGE II PLUS – Trial): study protocol for a 
randomised controlled trial 187 
 6 
Chapter 11  Summary, discussion and future perspectives 207 
Chapter 12  Nederlandse samenvatting 219 
Chapter 13  Valorisation 233 
  Dankwoord 237 
  List of Publications 243 
  Curriculum Vitae 247 
 
  
7 
Chapter 1 
General introduction and outline of thesis 
   
General introduction and outline of thesis 
9 
SECTION 1: LIVER SURGERY 
Partly adapted from “Laparoscopic liver surgery in the Netherlands: how far are we?” 
Dig Surg. 2012;29(1):70-8. 
HISTORY OF LIVER SURGERY AND ANATOMY 
For any type of surgical intervention intricate knowledge and understanding of the 
anatomy is of key importance. This is also true for liver surgery. Ancient Mesopotami-
an clay liver models were the first to describe the liver anatomy.[1] Among the early 
pioneers in the field of liver surgery were Glisson, Wendel and Cantlie[2, 3], but the 
first “real” liver resection was performed by Langenbuch in 1887.[4, 5] It took until the 
1950’s before a detailed understanding of liver anatomy became available through 
the work of Couinaud.[6] He made casts of the liver and found that the liver could be 
divided into eight segments based on the portal and hepatic vein blood distribution. 
Each segment is numbered and has its own specific in- and outflow structures: portal 
triad and hepatic vein. The portal vein divides the liver into inferior and superior 
segments, whereas the hepatic veins demarcate the right and left hepatic lobes. The 
right lobe is divided by the right hepatic vein into an anterior and posterior segment. 
The left hepatic vein divides the left lobe into the medial and lateral segments. In the 
portal triad itself an efferent bile duct and an afferent hepatic artery and portal vein 
(Figure 1) can be recognised. This understanding now forms the basis of modern 
functional and surgical liver anatomy.[5]  
There are now two widely accepted terminology systems: the Bismuth[7] and Bris-
bane 2000[8, 9] nomenclature. They both have evolved from Couinaud’s and Takasa-
ki’s[10] work, but the suggested nomenclatures are still not completely appropriate 
and both require further revisions. The nomenclatures still contain segmentations 
that are inappropriate for embryological and surgical reasons. There is a demand for 
a uniform nomenclature.[11] 
Two other major developments that made liver surgery evolve into a widely accept-
ed intervention were the introduction of ultrasound and the improved control of 
bleeding. With ultrasound during surgery clinicians were able to find small liver tu-
mours[12] and the anatomy of biliary and vascular structures could be exactly de-
fined[13-15] and allowed anatomical resections.[16] Control of bleeding during he-
patic surgery added to increased safety and can be achieved in various ways, but 
depends on the quality of the liver parenchyma, characteristics of the tumour to be 
resected and of course the preference and experience of the surgeon. Most tech-
niques have arisen from the original Pringle maneuver[17] and can be divided into 
inflow occlusion alone or combined in- and outflow occlusion. The most commonly 
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used occlusion methods are hepatic pedicle clamping (continuous or intermittent 
Pringle maneuver[18, 19]) and selective inflow occlusion (segmental or hemihepat-
ic[20, 21]). Occasionally, e.g. in cases of extreme bleeding or major liver resection, 
also total or selective hepatic vascular exclusion (THVE or SHVE, inflow and outflow 
occlusion of the whole liver or the lobe to be resected), or hepatic vascular exclusion 
with preservation of caval flow (HVEPC).can be used.[22-24] 
 
 
Figure 1. Segments of the human liver and current surgical nomenclature of liver sections.  
Reprinted with permission from Macmillan Publishers Ltd:, Siriwardena A.K. et al. Management of colorec-
tal cancer presenting with synchronous liver metastases, Nature Reviews Clinical Oncology, 11(8):446-59, 
2014 
 
Technology has driven the majority of advances in surgery over the past decade. At 
first significant advantages (e.g. smaller incisions, fewer incisional hernias and adhe-
sions, reduced post-operative morbidity) that laparoscopy brought to performing 
gallbladder surgery were recognized, and along came the desire to apply this inno-
vation in surgery to all operations, limited only by the imagination and the surgeon’s 
technical ability.[25] Until fairly recently, only open liver resections were performed, 
but during the last decade of the 20th century the first laparoscopic liver resections 
were successfully completed. No prospective or randomised controlled evidence to 
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support a wide adoption of the laparoscopic technique in liver surgery is available, 
but many expert centres have retrospectively shown benefits in liver surgery. The 
assumed benefits will be discussed later in this chapter. 
The surgical anatomy for laparoscopic hepatectomy is in principle the same as during 
open procedures. However, the minimally invasive approach can be more difficult 
due to a lack of experience compared to open liver surgery, even if surgeons have 
prior laparoscopic experiences. The difference in access to the abdominal cavity and 
the resulting difference in intra-abdominal perspective, with a more caudate view 
from videoendoscope to the surgical field, require surgeons to operate in difficult 
angles with instruments that only allow for limited range of motion and tactile feed-
back. In addition, the laparoscopic approach further limits optimal exposure by pre-
senting a two-dimensional image to the surgeon. 
Laparoscopic resection for tumours located in the posterior parts of the liver (seg-
ments: I, VI and VII) is more difficult than for tumours in anterior locations (segments: 
II, III, IV, V, VIII).[26-30] The difficulties relate to maintaining hemostasis at the transec-
tion plane, controlling hemorrhage, mobilizing the liver and visualizing and working 
within the deeper regions of the liver.[27, 31-35] Essential for laparoscopic liver sur-
gery is the positioning of trocars and adequate mobilization of the liver. This not only 
depends on the location of the tumour[26, 36] and the type of resection to be per-
formed, but also on the surgeon’s preference. For laparoscopic procedures of anteri-
or segments the laparoscope is usually inserted at the umbilicus, and two to four 
trocars for manipulation are additionally placed.[27, 36, 37] For resection of the supe-
rior or posterior segment of the right hepatic lobe, a lateral approach is considered 
more convenient.[27, 38] Key to success in all procedures is to achieve triangulation 
for good access and visualization of the liver anatomy. 
RELUCTANCE OF DUTCH SURGEONS 
Compared to countries that have traditionally always played a pioneering role in liver 
surgery, such as France, the Netherlands lagged behind concerning the implementa-
tion of liver surgery. Many surgeons considered an open partial liver resection to be 
major surgery, associated with considerable mortality and morbidity. Dutch surgeons 
remained reluctant to perform this type of surgery.[39] This is illustrated by the fact 
that only 10 to 130 partial liver resections (including benign tumours) were per-
formed between 1984 and 1987. During the end of the 1980’s and 1990’s several 
series on the experience with open hepatic resection were published by different 
Dutch centres.[40, 41] 
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The laparoscopic technique for liver resections was introduced in the Netherlands 
during the 1990’s, but it was mainly used for diagnostic laparoscopies and liver biop-
sies. Later the indications were extended to fenestration of liver cysts and anatomic 
liver resections [42-47]. The group of Cuesta et al. was in 1995 the first to report two 
cases of limited laparoscopic liver surgery of segment II and IV in the Netherlands.[48] 
In the years thereafter only one article from the same group was published reporting 
on a series of laparoscopically operated patients (n=10). A few years later, in 2001, a 
small retrospective series (n=10) was published that demonstrated encouraging 
results concerning operative blood loss, post-operative complications and hospital 
length of stay after wedge and left lateral hepatectomy. Seven patients underwent a 
minor laparoscopic resection and three underwent fenestration of hepatic cysts. The 
authors concluded that laparoscopic treatment should be considered in selected 
patients with benign and malignant lesions in the left lobe or anterior segments of 
the liver.[49] The foundation of the Dutch Liver Collaborative Group in 2003 gave a 
new impulse to minimally invasive liver surgery and after the initial reports on mini-
mally invasive liver surgery three articles were published on laparoscopic treatment 
of polycystic liver disease.[50-52] Later series of 26 laparoscopic liver resections pro-
vided evidence that this procedure could be performed safely in the Netherlands.[53] 
OPEN VS. LAPAROSCOPIC HEPATECTOMY 
Today liver surgery is predominantly performed for malignant indications, resection 
of colorectal liver metastases (CLM) in particular, as it offers the only changes of cure 
and long-term survival. Operative techniques, chemotherapy and perioperative care 
have evolved and have resulted in post-operative mortality rates of <5%, morbidity 
rates ranging between 30% and 50%[54-57], and with 5-year survival rates of approx-
imately 30-60%.[57-63] The “cure” rate based on actual 10-year survivors is around 
25-35%.[57, 63, 64] 
While the first limited laparoscopic liver resection in the Netherlands was performed 
in 1995, the first laparoscopic liver resections had already been performed 5 years 
earlier by Reich[65] and Gagner.[66] Four years thereafter, Azagra et al.[67] reported 
the first anatomic liver resection (segment 2-3 resection). In the following years the 
minimally invasive technique was further developed and adopted, resulting in the 
first laparoscopic left lateral sectionectomy for living liver donation[68, 69] and the 
first reports on robotic liver surgery.[70, 71] Initially, laparoscopic liver resection was 
challenging because of the difficulties concerning safe mobilization and exposure of 
this fragile and heavy organ.[35, 72, 73] In expert centres laparoscopic resection of 
benign liver tumours seemed feasible and safe.[38, 74] Also for malignant tumours 
there appeared to be a benefit with regards to short-term post-operative outcomes 
and adequate surgical margins could be achieved.[75, 76] Surgeons with extensive 
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experience in laparoscopy and hepatic surgery have also performed laparoscopic 
major hepatic resections with satisfactory outcomes.[47, 77, 78] 
Overall the quality of evidence on the merits of laparoscopic liver surgery is low 
(GRADE C).[79] Reviews by Nguyen et al. and Reddy et al. showed favourable out-
comes after laparoscopic resection.[80, 81] Patient benefits included less operative 
blood loss[31, 82], less post-operative pain[27, 33, 83] and narcotic requirement, im-
proved cosmetic aspects[27, 28], and a shorter length of hospital stay[27, 28, 33, 82-
85] with post-operative morbidity and mortality comparable to open liver resection. In 
addition, the minimally invasive approach seems to be cost-effective.[86, 87] The de-
creased cost is based on savings in hospital ward costs and likely related to a signifi-
cantly shorter hospital stay for laparoscopic liver surgery.[88] Potential limitations and 
disadvantages of laparoscopic liver resection include a considerable learning curve, 
potential bleeding which may be more difficult to control laparoscopically, inade-
quate assessment of the liver for additional lesions, and increased risk for gas embo-
lism.[81, 89] Carbon dioxide (CO2) embolism may occur when high-pressure pneu-
moperitoneum is used.[72, 90] However, CO2 embolism is rare and usually well toler-
ated, as the gas dissolves rapidly.[83] Other concerns have been raised about the po-
tential dissemination of malignant cells during laparoscopic resection.[91-93] Some 
authors have suggested that tumour dissemination does not increase by laparosco-
py[32, 94, 95], and recent reports regarding this subject show long term survival rates 
comparable with open surgery.[28, 73, 75, 96] In line with this, during a consensus 
meeting of over 300 experts in 2008 (The Louisville Statement), it was concluded, 
based on the available evidence and expert opinions, that laparoscopic liver surgery 
was a safe and effective approach to the management of surgical liver disease in the 
hands of trained surgeons with experience in hepatobiliary and laparoscopic surgery. 
However, the experts also concluded that there is still a need for controlled prospec-
tive trials, and that prudent dissemination is warranted with adequate training stand-
ards and credentialing to ensure consistent standards and clinical outcomes.[97] 
In parallel to these refinements in surgical technique, considerable changes in peri-
operative care were witnessed in the last decade of the previous millennium. Among 
these was the introduction of multimodal perioperative care, which will be ad-
dressed in the next section. 
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SECTION 2: ENHANCED RECOVERY AFTER SURGERY (ERAS®) 
MULTIMODAL CARE PROGRAMME 
The concept of a multimodal approach in perioperative surgical care originated from 
the Danish surgeon Henrik Kehlet. During the 1990’s he pioneered in this field by 
investigating the surgical stress response caused by anaesthesia or analgesia[98-100] 
and the influence of exercise on post-operative fatigue.[101] By continuing his efforts 
he became the first to describe a combination of several elements in a multimodal 
protocol that reduced post-operative surgical stress-induced dysfunction and mor-
bidity.[102-104] 
His work culminated in the publication of a multimodal “fast-track” strategy that 
optimized several aspects of the perioperative management of patients undergoing 
major abdominal surgery[105-107] and the foundation of the Enhanced Recovery 
After Surgery (ERAS®) collaboration of five European centres in 2001. The ERAS pro-
tocol consists of about 20 elements during the pre-, intra- or post-operative phase, 
see Figure 2. At first this fast-track concept was explored and tested in colorectal sur-
gery. Several groups have since then demonstrated that recovery could be accelerat-
ed with reduced length of hospital stay and post-operative morbidity in colorectal 
surgery.[108-119] Consequently, these results were bundled with expert opinions in 
evidence-based consensus guidelines in 2005[117] and 2009[120]. 
ERAS® ELEMENTS 
Encouraged by good results in colorectal surgery[119] liver surgeons of the ERAS® 
group in Maastricht, Edinburgh and Tromsö undertook to implement the ERAS con-
cept for patients undergoing open hepatic resection. Elements in the protocol were 
evaluated and adjusted to provide optimal care to liver surgical patients. Each item of 
the ERAS liver programme is presented below with a recommendation based on 
scientific evidence. 
PREOPERATIVE EDUCATION 
During counselling there should be emphasis on the recovery period and expecta-
tions of the patient, concerning pain control, early mobilization, resumption of intake 
and time of discharge. This has been demonstrated to allow earlier recovery.[121-
124] Patients exhibiting denial or anxiety can also profit from extensive counsel-
ling.[125, 126] 
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Figure 2. Elements of the ERAS liver programme 
 
PREOPERATIVE FASTING & CARBOHYDRATE LOADING 
Where patients used to be denied intake of food from the night before surgery, it is 
now generally recommended to allow patients to be fasted for liquids only for 2 
hours and for solids for 6 hours preoperatively.[127-129] Reviews have demonstrated 
that preoperative fasting does not prevent complications, e.g. aspiration. [130, 131] 
On the contrary, patients able to have a normal preoperative intake are in a more 
anabolic state to benefit from post-operative nutrition and have less risk of insulin 
resistance and post-operative hyperglycaemia.[132-134] 
PREANAESTHETIC MEDICATION 
Provision of long-acting anxiolytic premedication could negatively influence gastro-
intestinal motility and, although it is safe to use short-acting benzodiazepines in day 
surgery[135], its efficacy for major surgery remains unclear. Patients who receive 
sleeping medication at home can continue this in hospital. In addition, analgesic 
premedication has no demonstrated effect on post-operative pain relief.[136] 
ANTITHROMBOTIC PROPHYLAXIS 
As for most major surgical procedures, antithrombotic prophylaxis should be provid-
ed in liver surgery. Low molecular weight heparin (LMWH) has been demonstrated to 
be safe and effective[137-140] and should be preferred over unfractionated heparin 
due to an increased compliance.[141] It has even been proposed to prolong throm-
boprophylaxis with LMWH after major abdominal or pelvic surgery since it signifi-
cantly reduces the risk of venous thromboembolism (VTE) without increasing mor-
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bidity. However, with an increased number of minimally invasive surgical procedures 
and the current trend for fast-track recovery the risk of post-operative VTE may be 
lower.[142] However, there is the risk of developing an epidural hematoma when 
epidural analgesia is used. Prophylactic doses of LMWH should be given no later than 
12 hours prior to insertion and removal of epidural catheters.[143, 144] An alternative 
to LMWH thrombotic prophylaxis, so called mechanical prophylaxis (elastic compres-
sion stockings), can also be (additionally) used until patients are fully mobilized. 
ANTIBIOTIC PROPHYLAXIS 
The optimal antibiotic regimen has not been described, but prophylaxis should be 
active against both aerobic and anaerobic bacteria. In colorectal surgery it has been 
frequently demonstrated that antibiotic prophylaxis is effective in reducing infec-
tious complications.[145] Two studies investigating the use of antibiotic prophylaxis 
after liver surgery have shown contradicting data.[146, 147] However, for hepatecto-
my (clean-contaminated surgery) antimicrobial prophylaxis may be essential, be-
cause of the relatively long operation time and relatively large blood loss.[148] A 
systemic infection after liver surgery can lead to liver failure, as sepsis could further 
jeopardize the liver function, already at risk after major resection. In addition, hyper-
glycemia induced by surgical stress and reduced liver function may cause dysregula-
tion of liver metabolism and immune function resulting in adverse post-operative 
outcomes.[149] Newer generations of antibiotics should be avoided and reserved for 
secondary infectious complications. 
ANAESTHESIA 
The optimal anaesthetic method for liver resection is yet to be described in literature, 
however it is important to provide well balanced anaesthesia. The hepatic clearance 
of drugs may be diminished after parenchymal resection.[150] A frequently used 
technique is intravenous induction of anaesthesia with short-acting drugs like 
propofol and remifentanil[151], and maintenance of anaesthesia with a volatile agent 
such as isoflurane or sevoflurane.[152] Infusion of fluids should be restricted until 
after the parenchymal resection. Peripheral vasodilatation may be helpful to lower 
the central venous pressure (<5 mmHg) as this has been associated with decreased 
blood loss. Also, vasopressors like phenylephrine or norepinephrine may be consid-
ered to maintain an adequate mean arterial blood pressure.[153] Intraoperative use 
of epidural analgesia has not been shown to improve recovery after liver surgery, but 
it may prevent gastrointestinal paralysis[154, 155], block stress hormone release and 
attenuate post-operative insulin resistance.[156] 
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INTRAOPERATIVE FLUID MANAGEMENT 
The discussion on optimal intraoperative i.v. fluid management is currently hotly 
debated. Post-operative complication rates and hospital stay seem to be reduced 
after elective surgery, if patients are not fluid overloaded and are only subjected to 
more restrictive, but balanced fluid therapy.[157-159] The problem lies in the type of 
protocol that needs to be followed (definition of restrictive management) and in the 
way of monitoring the response to fluid administration. Especially during major 
hepatectomy it necessary to expand the intravascular volume, but maintain a low 
central venous pressure (CVP). A high CVP may increase blood loss, transfusion re-
quirements and length of hospital stay.[160] From a surgical perspective, CVP moni-
toring is recommended to minimize back bleeding during parenchymal transection 
(CVP <5 mmHg)[161-164] and anaesthesiologists use it to avoid the administration of 
excessive IV fluids.[159] It may however not be necessary at all to monitor the CVP 
and less invasive and peripheral monitoring may be sufficient to provide adequate 
fluid management.[153, 165-167] A monitoring device to consider for use and rec-
ommended in a guideline of the National Institute for Health and Care Excellence 
(NICE) is the CardioQ-ODM (Deltex Medical). This device assesses cardiac output and 
intravascular fluid status. The available data support a clinical benefit and a cost sav-
ing when the CardioQ-ODM is used in patients undergoing major or high-risk surgery 
in whom a clinician would consider using invasive cardiac monitoring.[168] 
PREVENTION OF INTRAOPERATIVE HYPOTHERMIA 
Maintenance of intraoperative normothermia (>36 0C) is an important target. Hypo-
thermia is known to induce endocrine-metabolic responses and sympathetic reflex-
es, and negatively affects the fibrinolytic-coagulatory balance resulting in increased 
bleeding. Infusion of warmed fluids and use of upper-body forced-air heating covers 
has demonstrated to help maintain a normal body temperature. This resulted in 
fewer wound infections[169], less cardiac complications[170] and reduced bleeding 
and transfusion requirements.[171] 
POST-OPERATIVE NAUSEA AND VOMITING (PONV) PROPHYLAXIS 
To enable an early start of intake after surgery and to facilitate a quick return to a nor-
mal diet it is important to identify possible risk factors (e.g. history of motion sickness or 
PONV, female sex, opioid analgesia, certain volatile anaesthesia) that may induce nau-
sea and vomiting.[172, 173] Convincing evidence is available to suggest that several 
drugs, such as cyclizine, droperidol, granisetron, metoclopramide, ondansetron and 
dexamethasone, reduce PONV. Treatment should be given using a multimodal ap-
proach and should be based on the risks per individual patient.[174, 175] 
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SURGICAL INCISIONS 
The type and length of the incision used for surgery may affect patient recovery.[176] 
Transverse or curved incisions may reduce pain, pulmonary dysfunction and inci-
dence of incisional hernia after abdominal procedures [177, 178], while other trials 
have found no advantage of transverse incisions.[179, 180] It is also to be expected 
that laparoscopic resections will lead to a lower incidence of incisional hernia com-
pared with the open surgical technique.[181] Depending on the type of hepatic re-
section a bilateral subcostal or J-shaped incision can be used to gain sufficient access. 
The length of incision should be reduced to an incision of minimum length. 
USE OF INTRA-ABDOMINAL DRAINS AND SEALANTS 
Drainage of the peritoneal cavity after elective liver surgery is still routinely used. 
Advantages of drain placement, such as removal of bile due to leakage and tissue 
debris to prevent subphrenic infection, detection of post-operative haemorrhage 
and removal of ascites in patients with liver cirrhosis, have been reported.[182, 183] 
Other studies have indicated that the risks (high rates of intra-abdominal and wound 
infections by retrograde contamination, impaired pulmonary function, increased 
pain and discomfort) may be greater than the benefits.[184] A meta-analysis by Gu-
rusamy et al [185] showed that there were no significant differences in morbidity, 
mortality and reoperation rates between patients with or without an abdominal 
drain after uncomplicated elective hepatic surgery. Alternatives to prevent leakage of 
bile or blood in the form of sealants applied to the resectional plane of the liver have 
not been proven to be of additional value.[186] Therefore, drains and sealants should 
no longer be used as a standard. If a drain is placed, close monitoring of the drain 
production is needed to allow removal as quickly as possible. 
NASOGASTRIC INTUBATION 
After liver surgery nasogastric tubes (NGT) should not be used routinely. Evidence 
has clearly demonstrated that routine nasogastric decompression must be avoid-
ed.[187, 188] The use of an NGT is even associated with an increased risk of develop-
ing post-operative pulmonary complications.[189, 190] If a tube is placed it should be 
removed immediately after surgery. 
POST-OPERATIVE ANALGESIA 
Post-operative pain control should aim at sparing opioids.[191] Effective analgesia 
may reduce the incidence of post-operative complications and may facilitate early 
recovery and mobilization.[106, 192] Epidural analgesia has been considered superi-
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or to patient-controlled intravenous analgesia for post-operative pain relief after 
major upper abdominal operations[154, 193] and may reduce pulmonary morbidi-
ty.[194] However, the use of epidural analgesia after hepatectomy is still debated. 
Epidural analgesia may not function adequately in up to 30% of the patients[195] 
and can lead to serious complications (epidural abscess or haematoma[196]). There-
fore, other analgesic options must not be excluded. Safe and effective alternatives to 
epidural analgesia after liver surgery are wound catheters with a local anaesthet-
ic[197-199] or intrathecal morphine.[200, 201] If a mid-thoracic epidural analgesia is 
used, evidence has indicated that removal after a two-day period is feasible.[202] 
Additional combined oral analgesia (paracetamol and an non-steroidal anti-
inflammatory drug) should be standardly provided, although the synergetic effect for 
major abdominal procedures has yet to be established.[203, 204] 
PREVENTION OF POST-OPERATIVE ILEUS 
Delayed gastrointestinal functioning should be prevented, as it is an important cause 
of delayed discharge after abdominal surgery. No single approach has demonstrated 
the ability to prevent or treat post-operative ileus.[205, 206] Interventions that may 
help are avoidance of preoperative fasting[207, 208] and avoiding mechanical bowel 
preparation[209], use of epidural-local anaesthetics[154], avoidance of fluid over-
load[159], implementation of minimally-invasive surgical techniques[210], use of oral 
magnesium oxide (1g twice daily commenced on the evening of surgery and used 
until discharge)[202, 211], coffee intake[212], use of chewing gum [213]and modifica-
tion of pain management strategies to limit opioid administration.[214, 215] 
URINARY CATHETER 
If epidural catheters are used, patients are also given urinary catheters to avoid uri-
nary retention. However, the risk of urinary retention after only 24 hours urinary 
bladder catheterisation has been reported to be low and removal of catheter the day 
after surgery does not seem to increase the recatheterisation rate.[216, 217] Other 
studies support the use of suprapubic bladder drainage instead of urethral catheteri-
sation. Suprapubic catheters are associated with lower rates of urinary tract infection 
and less discomfort in patients undergoing abdominal surgery.[218-220] It is recom-
mended to use urinary bladder drainage for the duration of thoracic epidural analge-
sia. Earlier removal of urinary drainage may be considered before the epidural is 
stopped to allow early mobilization. 
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START OF ORAL INTAKE 
Denying patients early feeding and keeping them on a ‘nil by mouth’ regimen has no 
clear advantage. A quick return to a normal diet has been shown to be safe for both 
major upper abdominal, colorectal and liver surgery and it may reduce the risk of 
infection and length of hospital stay.[188, 221-223] In 2009 the European Society for 
Clinical Nutrition and Metabolism (ESPEN) has advised to manage patients in modern 
surgical practice within an enhanced recovery protocol and thereby have them eat-
ing normal food within 1-3 days. Also, routine perioperative nutritional supplementa-
tion is advised to be only used for patients with severe preoperative undernutrition 
or in patients who cannot meet their caloric requirements within 7-10 days after sur-
gery.[224] 
MOBILISATION 
Early mobilization is essential to prevent increased insulin resistance and muscle loss, 
decreases muscle strength, pulmonary function, and tissue oxygenation[113], and to 
decrease the risk of thromboembolism. However, this can only be facilitated with 
adequate post-operative pain control and, if possible, absence of abdominal drains 
and urinary catheters. Therefore, daily goals for mobilization with assistance from 
nurses or physiotherapists must be defined. 
ERAS PROGRAMME FOR LIVER SURGERY 
In line with earlier results from colorectal surgery, van Dam et al. [225] and Koea et 
al.[201] showed a significantly reduced length of hospital stay when patients were 
managed within a multimodal enhanced recovery programme for liver surgery. In 
addition to this, a further reduction in length of stay was possible when patients 
undergoing liver surgery were operated laparoscopically.[53] 
Considering the aforementioned evidence for the specific perioperative care ele-
ments, a multimodal evidence-based ERAS programme for liver surgery can be pro-
posed. Table 1 shows a summary of the elements with their respective level of rec-
ommendation. If these elements are combined with clear discharge criteria and ade-
quate minimization of delay after functional recovery[226] (often linked to social or 
logistic problems or problems in homecare support), patients may be offered the 
optimal strategy for a safe and rapid recovery and consequent discharge. 
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Table1. ERAS liver programme recommendations 
Element Evidence level Recommendation grade 
Preoperative counselling B Strong 
Minimal preoperative fasting B Strong 
No pre-anaesthetic premedication B Moderate 
Antithrombotic prophylaxis A Strong 
Antibiotic prophylaxis A Strong 
Balanced anaesthesia with short-acting agents C Strong 
Epidural anaesthesia / analgesia B Weak 
Balanced intraoperative fluid management A Strong 
Prevention of hypothermia A Strong 
PONV prophylaxis B Strong 
Incision of minimal length C Strong 
No routine drainage of the peritoneal cavity C Low 
No nasogastric drainage A Strong 
Provision of oral analgesia A Strong 
Prevention of post-operative ileus B Moderate 
Early removal of urinary catheter D Weak 
Early start oral intake A Strong 
Early mobilisation C Moderate 
Quality of evidence and recommendations were evaluated according to the GRADE guidelines[227]: A = 
High, B = Moderate, C = Low, D = Very low. 
SECTION 3: EVIDENCE-BASED MEDICINE (EBM) IN SURGERY 
Performing surgery and providing perioperative care based on evidence-based prin-
ciples[228] has not always been standard. An EBM approach has been lacking for 
years and there are still many surgeons and centres that work with dogmatic routines 
for which often no evidence is available, rather than routines based on sound re-
search and evidence. In 1996 Horton[229] already described the absence of well 
designed studies in the surgical community. A vast majority of research articles pub-
lished in surgical journals at that time were case series. Nowadays we value case 
series as the weakest evidence available. Therefore, a large proportion of early surgi-
cal literature may be considered to be of questionable value.[229] 
Slowly the opinion and attitude of surgeons has changed, and the evidence-based 
approach is now part of daily practice in various fields of surgery by quality improve-
ments through well-designed trials, study groups, auditing[230-235] and adoption of 
consensus guidelines.[97, 117, 236-242] Many surgeons are eager to try and adopt 
new techniques. Minimally invasive surgery has become popular among surgeons. 
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This is of course inherent to the aim of improving surgical techniques and outcome, 
but should not lead to over enthusiastic adoption and dissemination of innovations 
without good evidence. A good example of this so-called overadoption is the laparo-
scopic cholecystectomy. This procedure was quickly adopted and became the domi-
nant technique for removal of the gallbladder with no or ambiguous evidence in fa-
vour of it and increase in procedure related morbidity.[243] Nowadays it is seemingly 
without a doubt that laparoscopic cholecystectomy is to be preferred over open chol-
ecystectomy, however the route to this adoption is questionable. Practice in the surgi-
cal community should be driven by evidence first with high respect for patient safety 
and surgeon preference should come second. In liver surgery a similar trend can be 
observed. Despite the consensus that laparoscopic liver surgery is only safe and effec-
tive in experienced hands and the urgent need for trials providing level A evi-
dence[97], many surgeons have started to use the technique without evidence to 
support this. Not only are there no definitive conclusions regarding the short-term 
efficacy of laparoscopic liver resection, but also data on oncological outcomes, such as 
survival and resection margins, costs, patient-reported outcomes and incidence of 
incisional hernia are inconclusive or have yet to be presented. 
The opposite may be true for the adoption of an enhanced recovery programme in 
liver surgery. As described in the previous section of this chapter, perioperative care 
has changed significantly. The multimodal concept has been extensively studied in 
colorectal surgery and has disseminated to other disciplines.[53, 225, 244-251] In 
addition, for most elements in the ERAS programme there is solid evidence.[238] To 
date such ERAS protocols seem underadopted, also in hepatic surgery. In many cen-
tres a formal standardized care pathway has not been implemented and, although 
some evidence-based elements may be adopted as part of “modern” current prac-
tice, perioperative care can still be further optimized to attenuate stress, improve 
recovery, lower morbidity and improve cost efficiency.[226] 
The surgical community has become aware that it is necessary to improve surgical 
practice based on properly obtained data and to develop methods to implement this 
evidence.[252] Standardization of surgical techniques and perioperative care based 
on evidence will help to eliminated bias and confounding, will allow comparison in 
trials and will increase the external validity of study results. Surely, as is known from 
literature and the different elements in the ERAS programme, there is abundant 
knowledge available. Urbach et al.[253] have nicely stipulated: “The immediate chal-
lenge to improving the quality of surgical care is not discovering new knowledge, but 
rather how to integrate what we already know into practice”. The delay of integrating 
this evidence in practice is multifactorial and may be dependent on the professional 
setting (attitude and culture), patients, organization of care processes, resources, 
leadership, cultural and social settings, and the political environment.[254, 255] 
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SECTION 4: OUTLINE OF THE THESIS 
The aim of this thesis was to explore the current role, dissemination and worldwide 
adoption of an ERAS programme in liver surgery, to investigate and evaluate the 
potential role of specific (new) elements of the ERAS programme, to evaluated the 
implementation status of (laparoscopic) liver surgery from a Dutch as well as an in-
ternational perspective, and to compare open and laparoscopic liver surgery in a 
randomised controlled setting. 
PART I: OPTIMIZED RECOVERY AFTER HEPATIC SURGEY 
We explore the role of the ways to enhanced patient recovery with an international 
survey (Chapter 2). A systematic review of patients undergoing liver surgery in an 
enhanced recovery after surgery pathways systematically examines the outcome 
(Chapter 3). We evaluate whether the current perioperative practice in hepatic sur-
gery is actually based on the ERAS principles (Chapter 4). The last two chapters of 
part I of this thesis explore specific elements of the ERAS programme: post-operative 
analgesia and abdominal drainage. We explore an alternative for epidural analgesia 
after major hepatectomy (Chapter 5). Finally, we describe and investigate the results 
of a standard no-drain policy after hepatectomy (Chapter 6). 
PART II: LAPAROSCOPIC LIVER SURGERY 
In the second part of this thesis we provide a systematic review on the introduction 
of laparoscopic liver surgery, investigate the initial experience with laparoscopic liver 
resections and report on the current status of laparoscopic liver surgery in the Neth-
erlands (Chapter 7). In the aim to compare open and laparoscopic liver surgery in a 
randomised controlled study we present the study protocol for the ORANGE II – Trial 
and the primary results (Chapter 8 – 9). Finally, we present the protocol of an ongo-
ing RCT comparing open versus laparoscopic hemihepatectomy within an ERAS pro-
gramme (Chapter 10). 
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ABSTRACT 
OBJECTIVE 
Both laparoscopic techniques and multimodal enhanced recovery (ERAS) pro-
grammes have been shown to improve recovery and reduce length of hospital stay. 
Interestingly, evidence-based care programmes are not widely implemented, where-
as new, minimally invasive surgical procedures are often adopted with very little 
evidence to support their effectiveness. The present survey aimed to shed light on 
experiences of the adoption of both methods of optimizing recovery. 
 
METHODS 
An international, web-based, 18-question, electronic survey was composed in 2010. 
The survey was sent out to 673 hepatopancreatobiliary (HPB) centres worldwide in 
June 2010 to investigate experiences with laparoscopic liver surgery, fast-track re-
covery programmes and surgery-related equipoise in open and laparoscopic tech-
niques and to assess opinions on strategies for adopting laparoscopic liver surgery in 
HPB surgical practice. 
 
RESULTS 
A total of 507 centres responded (response rate: 75.3%), 161 of which finished the 
survey completely. All units reported performing open liver resections, 24.2% per-
formed open living donor resections, 39.1% carried out orthotopic liver transplanta-
tions, 87.6% had experience with laparoscopic resections and 2.5% performed lapa-
roscopic living donor resections. A median of 50 (range: 2–560) open and 9.5 (range: 
1–80) laparoscopic liver resections per surgical unit were performed in 2009. Patients 
stayed in hospital for a median of 7 days (range: 2–15 days) after uncomplicated 
open liver resection and a median of 4 days (range: 1–10 days) after uncomplicated 
laparoscopic liver resection. Only 28.0% of centres reported experience with fast-
track programmes in liver surgery. The majority considered the instigation of a RCT or 
a prospective register comparing the outcomes of open and laparoscopic techniques 
to be necessary. 
 
CONCLUSION 
Worldwide dissemination of laparoscopic liver resection is substantial, although lapa-
roscopic volumes are low in the majority of HPB centres. The adoption of ERAS pro-
grammes in liver surgery is limited and should be given greater attention. 
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INTRODUCTION 
In recent years, laparoscopic liver resection and enhanced recovery programmes 
have been introduced in liver surgery with the aim of accelerating post-operative 
recovery and shortening hospital length of stay (LoS). Like open liver resection, lapa-
roscopic resection of liver lesions can be applied safely in both malignant and benign 
disease.[1–7] Large prospective case series suggest that laparoscopic liver surgery 
may be superior to open liver surgery in terms of perioperative blood loss, post-
operative pain, time to recovery, LoS, cosmetic appearance and quality of life.[5,8–10] 
Survival rates after laparoscopic and open resection of hepatocellular carcinoma and 
hepatic colorectal metastases seem to be comparable.[1,5] 
Similarly, fast-track programmes have proven to be useful, feasible and safe in liver 
surgery.[11–15] Such programmes can also enhance recovery and reduce LoS. En-
hanced recovery after surgery (ERAS) programmes rely mainly on optimizing periop-
erative care and reducing stress responses to surgery through the provision of ade-
quate preoperative patient counselling, optimized anaesthesia and analgesia, quick 
resumption of oral intake and early mobilization.[12,16–18] In liver resection, earlier 
resumption of oral intake, faster post-operative recovery and a significant reduction 
in median LoS (from 8 days to 6 days) was shown when patients were managed with-
in a multimodal ERAS programme.[12] 
A small pilot study in liver surgery suggested that laparoscopic liver surgery within an 
ERAS setting led to a potentially accelerated recovery and further reduction in LoS 
from7 days to 5 days.[11] Moreover, the combining of laparoscopy and an ERAS 
strategy is most likely to result in a synergetic effect, as recently proven in a random-
ized controlled trial (RCT) in the context of colonic surgery.[19] 
Despite the fairly robust evidence that many specific elements of fast-track pro-
grammes can enhance recovery and reduce LoS, little evidence on the use of these 
programmes in liver surgery has been published. This suggests that the adoption of 
ERAS programmes in liver surgery worldwide is low. Current surgical practice is 
based on evidence and any change in daily routines should be supported by sound 
data.[20] In this respect, the current fairly liberal adoption of laparoscopic liver sur-
gery contrasts with the relative lack of adoption of enhanced recovery programmes. 
An international web-based survey was composed to evaluate worldwide experienc-
es with laparoscopic liver surgery and fast-track recovery programmes, and surgery-
related equipoise in open and laparoscopic strategies, and to assess opinions on 
strategies for the adoption of laparoscopic liver surgery in daily hepatopancreatobili-
ary (HPB) surgical practice. 
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METHODS 
STUDY DESIGN 
An online electronic survey, consisting of 18 questions subdivided according to five 
main domains, was developed. Questions on the different topics were initially com-
posed by two research fellows (EMW-L-H and TML) and two liver surgeons (RMvD 
and JHMBS). The definitive set of questions was then administered using Survey-
Monkey™ (SurveyMonkey, Inc., Palo Alto, CA, USA). Items in the first domain included 
several questions on experience in open and laparoscopic liver surgery and covered 
types and numbers of liver resections. Items in the second domain concerned recov-
ery and LoS after uncomplicated open or laparoscopic liver resection. Items in the 
third domain surveyed experience with enhanced recovery or fast-track periopera-
tive care programmes such as ERAS programmes. The fourth part of the survey was 
developed to evaluate opinions on the necessity of an RCT and on the value of a 
prospective registry comparing outcomes in open and laparoscopic liver surgery. 
Items in the final domain evaluated current opinions on and considerations for par-
ticipating in such a trial. Incomplete responses were excluded from analysis. 
STUDY POPULATION 
An invitation to complete this survey was sent by e-mail to 673 HPB centres world-
wide in June 2010. Subsequent e-mail reminders were sent out in August and Sep-
tember 2010. Only one surgeon per HPB unit was asked to participate. Figure 1 de-
scribes the respondent inclusion and exclusion process. The participation period 
closed and analyses were conducted in November 2010. 
STATISTICS 
Survey data were extracted into an Excel database. Statistical analysis was performed 
using SPSS Version 18.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism Version 5 
(GraphPad Software, Inc., La Jolla, CA, USA). Basic analyses were performed using 
descriptive statistics including counts, percentages, means with standard deviations 
and medians with ranges and interquartile ranges (IQRs). Subgroup analysis was 
performed to investigate potentially relevant differences among regions and centre 
experiences using the Mann–Whitney U-test or chi-squared test. All countries were 
assigned to one of the following six regions: Europe; North America; Central and 
South America; Asia; Oceania, and Africa. An experienced laparoscopic HPB centre 
was defined as a surgical unit performing 20 or more laparoscopic liver resections 
annually.[21] 
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Figure 1. Flowchart showing the respondent inclusion and exclusion process. 
RESULTS 
PARTICIPATION 
A total of 507 centres (one surgeon per centre) responded (response rate 75.3%). 
Incomplete responses were excluded from data analysis, leaving complete responses 
from 161 centres. Centres in 39 different countries participated; these were divided 
into groups according to the six global regions (Fig. 2). The regions that provided the 
highest response rates were Europe (45%) and North America (26%), with the USA (n 
= 34), Italy (n = 16), Canada (n = 8) and the Netherlands (n = 8) representing the top 
four countries providing complete responses. 
HBP centres approached (n = 673)
First invitation (n = 208)
First reminder (n = 260)
Second reminder (n = 507)
Response rate = 75.3%
HPB centres (n = 479)
Complete responses 
included for
data analysis 
(n = 161)
Incomplete responses 
(n = 318)
No response (n = 166)
Excluded (n = 28)
Retired (n = 10)
Only pancreatic surgery (n =18)
Chapter 2 
42 
 
Figure 2. Centres (n = 161) included in the data analysis by region 
TYPES OF LIVER RESECTION 
Open resection of liver lesions was performed by 100% of the units. Overall, 87.6% of 
responding units reported experience with laparoscopic resection of liver lesions, 
39.1% with orthotopic liver transplantation, 24.2% with open living donor resection 
and 2.5% with laparoscopic living donor resection. Table 1 shows the percentages of 
HPB centres performing different types of liver surgery and the differences among 
regions. 
EXPERIENCE 
A total of 42.0% of responding centres indicated that their data represented precise 
numbers. The remaining centres provided estimations that were as accurate as pos-
sible. A wide range in the number of resections performed was observed among HPB 
centres. In 2009, the median number of open resections for liver lesions performed 
was 50 (range: 2–560; IQR = 50) per surgical unit. In the same year, the median num-
ber of laparoscopic resections of liver lesions performed was 9.5 (range: 1–80; IQR = 
15) per centre. Worldwide figures for open and laparoscopic liver resections and 
differences among regions are shown in Table 2. Of the participating centres, 26.6% 
could be classified as experienced laparoscopic liver centres based on their comple-
tion of at least 20 laparoscopic liver resections per year (Table 3). Experienced laparo-
scopic centres seemed to be more frequently located in the Americas than in other 
continents (44.2% vs. 13.5%; P < 0.001). 
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Table 1. Centres performing types of procedure, by region, n (%) 
 Europe North 
America 
Central and 
South America 
Asia Oceania Africa Worldwide 
Open resection of liver lesions 72 42 10 24 8 5 161 (100.0) 
Laparoscopic resection of liver lesions 61 41 10 19 7 3 141 (87.6) 
Orthotopic liver transplantation 29 17 5 7 4 1 63 (39.1) 
Open living donor resection 15 10 4 7 2 1 39 (24.2) 
Laparoscopic living donor resection 1 1 1 1 0 0 4 (2.5) 
 
Table 2. Number of resections per surgical unit per year (2009) liver resection 
Region Liver resections performed in 2009, median (range)/IQR 
 Open resection Laparoscopic liver resection 
Europe 5.0 (1–61)/9.0 5.0 (1–61)/9.0 
North America 45.0 (6–200)/42.5 19.0 (2–80)/21.0 
Central and South America 32.5 (12–80)/23.5 10.0 (3–30)/18.0 
Asia 50.0 (5–560)/62.3 6.0 (1–80)/5.0 
Oceania 57.5 (15–150)/110.0 9.0 (1–20)/7.0 
Africa 50.0 (5–120)/115.0 4.5 (3–13)/7.8 
Worldwide 50.0 (2–560)/50.0 9.5 (1–80)/15.0 
IQR, interquartile range. 
 
HOSPITAL LENGTH OF STAY AND FAST-TRACK CARE PROGRAMMES 
The reported median hospital LoS after uncomplicated liver resection was 7 days 
(range: 2–15 days) after open surgery and 4 days (range: 1–10 days) after laparoscopic 
surgery. Differences among regions are shown in Table 4. In addition, a subgroup 
analysis showed that experienced centres achieved a significantly shorter median LoS 
after laparoscopic liver resection compared with inexperience centres [3.4 days 
(range: 1–7 days) vs. 4.2 days (range: 1–10 days); P = 0.013]. Half of the HPB centres 
(50.1%) had experience with fast-track perioperative care programmes in colonic, 
hepatic or pancreatic surgery or a combination of these fields. Only 28.0% had experi-
ence with these programmes in liver surgery. Results per region are shown in Table 5. 
  
Chapter 2 
44 
Table 3. Numbers of laparoscopic liver surgery centres demonstrating experience defined by a volume of 
>20 laparoscopic resections per year 
Region Experienced laparoscopic liver centres, n/laparoscopic liver centres, (%) 
Europe 10/59 (16.9%) 
North America 20/41 (48.8%) 
Central and South America 3/9 (33.3%) 
Asia 3/19 (15.8%) 
Oceania 1/7 (14.3%) 
Africa 0/4 
Worldwide 37/139 (26.6%) 
IQR, interquartile range. 
NECESSITY FOR AN RCT 
The majority (59.4%) of HPB centres considered that an RCT comparing outcomes in 
open and laparoscopic liver surgery prior to the further adoption of laparoscopic liver 
surgery was necessary. A total of 49.1% considered that a combination of such an RCT 
and a prospective multicentre registry should be mandatory; 36.4% considered that a 
prospective multicentre registry alone would be sufficient and 4.2% deemed a pro-
spective hospital registry adequate. Of the surgical units that performed both open and 
laparoscopic left lateral sectionectomy (LLS) within a fast-track/ ERAS programme, 
82.9% indicated that they would consider participating in an RCT. Level A evidence to 
support the superiority of the laparoscopic technique was still considered necessary by 
the majority of respondents. A total of 94.3% of participants with experience in both 
open and laparoscopic LLS, both within and without fast-track or ERAS programmes, 
would also consider participating in a prospective registry. Overall, 83.3% of liver units 
without experience in laparoscopic liver surgery indicated a desire to participate in 
hands-on training in laparoscopic liver surgery and/or a proctor programme. 
 
Table 4. Length of stay after uncomplicated liver resection 
Region Length of stay, days, median (range)/IQR 
 After open resection After laparoscopic resection 
Europe 7.0 (4–12)/3.0 5.0 (2–10)/1.0 
North America 5.0 (4–8)/2.0 3.0 (1–5)/1.5 
Central and South America 5.0 (2–7)/1.8 2.5 (1–5)/2.0 
Asia 7.0 (5–15)/2.0 4.0 (3–10)/2.0 
Oceania 5.0 (3–7)/1.8 4.0 (2–5)/1.5 
Africa 8.0 (4–10)/5.5 4.5 (2–7)/4.5 
Worldwide 7.0 (2–15)/3.0 4.0 (1–10)/2.0 
IQR, interquartile range. 
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Table 5. Centres with experience in fast-track perioperative care programmes 
Region Experience with ERAS programmes in a specific type of surgery, n/total n (%) 
 No experience In colon surgery In liver surgery In pancreatic surgery 
Europe 31/72 (43.1%) 36/72 (50.0%) 22/72 (30.6%) 14/72 (19.4%) 
North America 25/42 (59.5%) 6/42 (14.3%) 9/42 (21.4%) 8/42 (19.0%) 
Central and South 
America 
5/10 (50.0%) 4/10 (40.0%) 3/10 (30.0%) 1/10 (10.0%) 
Asia 15/24 (62.5%) 8/24 (33.3%) 4/24 (16.7%) 3/24 (12.5%) 
Oceania 2/8 (25.0%) 5/8 (62.5%) 6/8 (75.0%) 2/8 (25.0%) 
Africa 4/5 (80.0%) 1/5 (20.0%) 1/5 (20.0%) 0/5 
Worldwide 82/161 (50.9%) 60/161 (37.3%) 45/161 (28.0%) 28/161 (17.4%) 
ERAS, enhanced recovery after surgery. 
DISCUSSION 
This study aimed to assess the worldwide experience and dissemination of two re-
cently introduced strategies to accelerate recovery after liver surgery. It demon-
strates that the majority of HPB centres perform liver surgery in the absence of an 
enhanced recovery perioperative care programme, and that the majority of HPB 
centres perform laparoscopic liver surgery. This study also shows substantial variance 
in hospital LoS among centres and regions. Lastly, this study demonstrates the pres-
ence of clinical equipoise in laparoscopic and open liver resection in the HPB com-
munity.[22,23] Clinical equipoise refers to a context in which there is no preference or 
certainty of therapeutic superiority for either laparoscopic or open liver surgery. The 
majority of liver centres considered that an RCT was necessary to prove the laparo-
scopic technique to be equal or superior to open surgery. 
The results show a high level of dissemination of laparoscopic liver surgery. Both low- 
and high-volume centres, amounting to 87.6% of HPB units, perform liver resections 
laparoscopically. Although the laparoscopic procedure is frequently used, many cen-
tres in this study have limited experience in laparoscopic liver resection. By contrast, 
responding centres displayed limited adoption of enhanced recovery programmes in 
liver surgery (one in four). The liberal adoption of laparoscopic liver surgery, even in 
low-volume HPB centres, is seemingly in conflict with current standards of evidence-
based practice in the medical community. Neither is it in keeping with recommenda-
tions expressed in an expert consensus (the Louisville Consensus), which concluded 
that laparoscopic liver surgery was safe and effective in the hands of experienced 
and trained surgeons.[24] In line with the available evidence for fast-track principles 
in liver surgery,[11–15] proof of the merits of laparoscopic vs. open liver surgery is 
also limited and no RCTs have been undertaken. However, a recent literature review 
and meta-analysis of available prospective and retrospective studies comparing 
Chapter 2 
46 
open with laparoscopic liver resections both found short- and long-term outcomes 
favourable for the laparoscopic procedure. Not only was LoS markedly shorter, but 
blood loss and complications were found to be reduced and oncologic outcomes did 
not differ between the two techniques.[25,26] 
Low-volume centres in this study reported a significantly longer hospital LoS com-
pared with high-volume centres. In addition, LoS after open and laparoscopic liver 
surgery varied substantially among regions. The surgeon’s progress along the lapa-
roscopic learning curve influences LoS because laparoscopic liver resection is techni-
cally demanding and requires expertise in both advanced laparoscopic skills and 
open liver surgery.[27] This is in line with the findings of a meta-analysis of studies 
reporting on 20 or more laparoscopic procedures, which indicated that a laparoscop-
ic approach led to a significant reduction in morbidity and LoS.[21] In addition, dif-
ferences in standard of care and discharge criteria may also contribute to the vari-
ance in LoS reported in the literature (3–20 days after open and 6–32 days after lapa-
roscopic liver resection).[25] Substantial distinctions at a cultural level may lie at the 
root of the observed variance in LoS. In some regions patients are discharged to a 
home care institution early in their recovery process (e.g. in North America), whereas 
in other world regions the provision of protocol-based care and the associated logis-
tics may be lacking. This may lead to a difference in expectations on both the pa-
tient’s and surgeon’s part as to when a patient might be ready for discharge. Thus, 
LoS is a poor outcome parameter that hampers comparison and is hard to interpret. 
The implementation of a structured care programme with well-defined recovery and 
discharge criteria, as used within ERAS protocols, might improve the comparability of 
clinical outcomes in future (multicentre) trials. 
Laparoscopy and enhanced recovery programmes should not be seen as separate 
methods of improving post-operative recovery and outcomes such as morbidity 
rates and LoS. On the contrary, it is likely that the implementation of both will result 
in a synergetic improvement. Enhanced recovery programmes in liver surgery have 
already been shown to reduce hospital LoS.[12–15] The additional benefit of an ERAS 
strategy in a laparoscopic setting was recently demonstrated in a trial in colonic sur-
gery and a small pilot study in liver surgery.[11,19] This worldwide survey unveils 
experiences in enhanced recovery programmes and laparoscopic liver surgery, and 
deliberations on the need for RCTs in liver surgery. Although the present study 
achieved a response rate of >75%, only 23.9% of respondents completed the survey 
in full, which limited the study findings. However, representatives of 161 liver surgery 
centres worldwide shared their results and opinions. 
The use of a survey may be seen as limiting the study because results are strongly 
dependent on the type of respondents, questions and response rate. In addition, the 
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group profile of responding centres may have been subject to response bias. Centres 
of considerable volume and those performing laparoscopic liver surgery may have 
been more likely to respond. 
The issue of importance does not concern a choice between laparoscopic liver resec-
tion and an ERAS strategy, but, rather, how both paths can be adequately adopted. 
The majority of responders still consider an RCT of laparoscopic surgery to be neces-
sary. It could be argued that as more liver centres adopt laparoscopic techniques, 
opportunities to conduct an RCT may be diminished by patient and surgeon prefer-
ences. According to some surgeons, laparoscopic liver resection is without doubt 
therapeutically superior, whereas for others this remains to be proven. In addition, in 
the Louisville Consensus of 2008, experts concluded that the accrual of patients for 
an RCT would be slow as a result of low overall numbers. 
The ORANGE II Trial, currently enrolling patients, will be the first RCT (combined with 
a prospective registry) to provide evidence on laparoscopic vs. open liver resec-
tion.[28] As for enhanced recovery programmes, many centres are likely to have al-
ready implemented multiple ERAS elements as part of modern care. Further trials are 
needed to assess compliance with recovery protocols[29,30], specific elements of 
enhanced recovery programmes and the possible reduction of medical expenses. 
CONCLUSION 
The worldwide dissemination of laparoscopic liver resection is substantial, although 
the average volume of laparoscopic resections carried out in the majority of HPB 
centres is low. The adoption of enhanced recovery programmes in liver surgery is 
limited and the issue warrants greater attention. Both strategies are associated with 
faster recovery and may work synergistically. Given the increasing strength of the 
role of evidence-based medicine in current surgical practice, more evidence is re-
quired. 
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ABSTRACT 
OBJECTIVE 
Enhanced recovery after surgery (ERAS) or fast-track protocols have been imple-
mented in different fields of surgery to attenuate the surgical stress response and 
accelerate recovery. The objective of this study was to systematically review the liter-
ature on outcomes of ERAS protocols applied in liver surgery. 
 
METHODS 
The MEDLINE, EMBASE, PubMed and Cochrane Library databases were searched for 
randomized controlled trials (RCTs), case–control studies and case series published 
between January 1966 and October 201 comparing adult patients undergoing elec-
tive liver surgery in an ERAS programme with those treated in a conventional man-
ner. The primary outcome measure was hospital length of stay (LoS). Secondary out-
come measures were time to functional recovery, and complication, readmission and 
mortality rates. 
 
RESULTS 
A total of 307 articles were found, six of which were included in the review. These 
comprised two RCTs, three case–control studies and one retrospective case series. 
Median LoS ranged from 4 days in an ERAS group to 1 days in a control group. Mor-
bidity, mortality and readmission rates did not differ significantly between the 
groups. Only two studies assessed time to functional recovery. Functional recovery in 
these studies was reached 2 days before discharge. 
 
CONCLUSION 
This systematic review suggests that ERAS protocols can be successfully implement-
ed in liver surgery. Length of stay is reduced without compromising morbidity, mor-
tality or readmission rates. 
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INTRODUCTION 
Liver resection is the preferred treatment for a variety of primary and secondary liver 
tumours. Major abdominal surgical procedures such as hepatic resections cause a 
considerable surgical stress reaction and possible derangements in metabolic and 
pulmonary functions. Specific complications after hepatic resection include post-
operative haemorrhage in the first hours to days after surgery, biliary leakage, intra-
abdominal abscess and liver failure in a later post-operative stage.[1] Improved oper-
ative techniques and insight into perioperative management have lowered mortality 
after liver resection to its current level of well below 5%, but morbidity rates remain 
high and range between 30% and 50%.[2–4] 
In the past decade, multimodal enhanced recovery after surgery (ERAS) protocols or 
fast-track pathways have been applied in different forms of surgery. These pathways 
were developed to attenuate the surgical stress response and improve recovery, 
thereby decreasing post-operative complications and post-operative length of stay 
(LoS) in hospital.[5] ERAS protocols have gained territory quickly because of the asso-
ciated cost efficiency derived from the reduction in LoS, an important issue in today’s 
context of rapidly increasing health care costs and the consequent need for optimi-
zation. To date, studies that show ERAS protocols that reduce LoS and morbidity 
rates and improve patient satisfaction have been published in the contexts of vascu-
lar surgery[6,7], musculoskeletal surgery[8],breast surgery[9] and different forms of 
abdominal surgery.[10–12] 
Enhanced recovery after surgery protocols have also been implemented in liver sur-
gery, but their effectiveness has not been studied extensively. The present systematic 
review was performed to evaluate the effects of ERAS protocols in liver surgery on 
time to recovery following surgery and post-operative hospital LoS, and to examine 
the effects of the implementation of such protocols on complication and readmis-
sion rates following liver surgery. 
METHODS 
SEARCH STRATEGY 
A systematic search was performed in PubMed, the Cochrane Library, EMBASE and 
MEDLINE for studies published between January 1966 and October 2011. Languages 
were restricted to English, Dutch and German. The following search terms were ap-
plied using the Boolean operators ‘AND’ and ‘OR’: ‘clinical pathway’, ‘critical path-
way’, ‘enhanced recovery’, ‘accelerated’, ‘perioperative’ and ‘fast track’, combined 
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with ‘liver’, ‘hepatic’ and ‘resection’. Synonyms of terms were also used in the search. 
The reference lists of selected papers were hand- searched for articles that were not 
retrieved in the database search. If necessary, authors of relevant articles were con-
tacted to obtain additional information. 
INCLUSION AND EXCLUSION CRITERIA 
Studies were considered eligible for inclusion if they met all of the following inclu-
sion criteria: (i) they reported on adult patients undergoing elective open or laparo-
scopic liver surgery; (ii) they described an enhanced recovery programme with at 
least four different perioperative elements, and (iii) they reported outcomes includ-
ing LoS, post-operative morbidity and mortality, and readmission rates. Studies were 
excluded if they: (i) described a single intervention in perioperative care rather than a 
group of interventions combined in an enhanced recovery programme; (ii) reported 
on emergency, non-elective or transplantation surgery, and (iii) reported a non-
systematic review. Table 1 lists a summary of ERAS items applicable to liver surgery. 
The items are supported by varying levels of evidence.[13] Perioperative care is con-
sidered to fall within an ERAS protocol when at least four different items are includ-
ed, covering the pre-, intra- and post-operative periods. [14,15] 
OUTCOME MEASURES 
The primary outcome measure of this systematic review was hospital LoS. Secondary 
outcome measures were time to functional recovery, complication rates, readmis-
sions and mortality rates. Criteria for functional recovery were: good pain control 
with oral analgesia only; tolerance for solid food; no requirement for i.v. fluids; pas-
sage of stool, and independent mobility at the preoperative level.[16] Study selection 
and data selection Abstracts and titles of studies identified by the search were read 
by two authors (MMEC and AAvdW), each of whom independently made a first selec-
tion of studies. These first selections were compared and, in the event that the inclu-
sion of a study required discussion, a third reviewer (RMvD) was consulted. Second 
and final selections were made independently by each of the two authors after read-
ing the full-text articles. Both randomized as well as non-randomized studies were 
eligible for inclusion as long as they met the inclusion criteria. The methodological 
quality of the included studies was assessed using the MINORS (methodological 
index for non-randomized studies) criteria[17], a checklist scoring eight methodolog-
ical items for non-comparative studies (maximum of 16 points) and an additional 
four items for comparative studies (maximum of 24 points). Missing data were ob-
tained by contacting the authors of the relevant studies. 
 
 
Systematic review of enhanced recovery in liver surgery 
55 
Table 1. Summary of ERAS elements applicable to liver surgery 
Evidence based Probably useful 
No oral bowel prep Preoperative counseling 
Preop feeding: CHO loading up to 2h before surgery Intravenous analgesia 
No pre-anaesthetic medication Stimulation of bowel movement with laxatives 
Anti-thrombotic Prophylaxis Early and scheduled mobilisation 
Single dose antibiotics Audit 
Epidural analgesia  
Prevention of Post-operative Nausea and Vomiting (PONV)  
Avoiding hypothermia  
No routine drainage of peritoneal cavity  
No post-operative nasogastric intubation  
Good fluid balance   
Removal of urinary catheter on day 1  
Normal food at will after surgery from day 1  
Evidence based: separate items are graded level 1 or level 2 evidence (according to the guidelines of the 
Oxford Centre for Evidence Based Medicine13). 
Probably useful: evidence is less strong, but felt to be useful since the items are most probably quality 
enhancing, are associated generally with a low incidence of adverse effects and low costs. 
 
Data on the following factors were extracted from the included articles: post-
operative LoS; number of patients included; patient ages; types of surgery; discharge 
criteria; functional recovery; mortality; morbidity; readmissions, and protocol adher-
ence. 
STATISTICAL ANALYSIS 
As the search strategy did not identify any randomized controlled trials (RCTs) evalu-
ating the outcomes of ERAS protocols against those of traditional care, the MOOSE 
(meta-analysis of observational studies in epidemiology) checklist for meta-analysis 
of observational studies was used to assess the possibility of conducting a meta-
analysis.[18] The included studies were considered to be too heterogeneous to sup-
port this and therefore no attempt at meta-analysis was made. Results are subse-
quently presented in tables and figures. 
RESULTS 
SELECTED ARTICLES AND CHARACTERISTICS OF THE STUDIES 
The literature search produced 307 articles, of which 300 were excluded after their 
abstracts had been read in the first round of selection because they did not concern the 
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evaluation of a fast-track programme in liver surgery (Fig. 1). After evaluation of the 
remaining seven papers, one was excluded because it was a nonsystematic review.[19] 
 
 
Figure 1. Selection of studies for systematic review 
 
Finally, six papers were included in this systematic review. The details of the included 
studies are shown in Table 2.  
There were no reports of RCTs evaluating the outcomes of an ERAS programme 
against those of traditional care. In two RCTs, both study groups were treated in an 
ERAS programme. One of these RC evaluated the use of laxatives and oral nutritional 
supplements within an ERAS programme[20] and one assessed different forms of 
post-operative analgesia in two groups managed in a fast-track programme.[21] 
Three case–control studies and one retrospective case series were also includ-
ed.[16,22–24] All studies included patients undergoing various forms of liver resec-
tion, including (extended) hemi-hepatectomy, metastasectomy, sectionectomy, cen-
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tral resection and repeat hepatectomy. One study did not include major hepatecto-
mies; all patients in this study underwent laparoscopic liver resection.[20]  
 
Table 2. Study characteristics and quality assessment 
Study Type of 
surgery 
Study 
design 
Patients in 
study/control 
groups, n 
Consecutive 
series of 
patients 
Length of 
follow-up 
Age, years, median 
(years) 
MINORS 
score 
ERAS 
group 
Control 
group 
 
Van Dam 
et al. 
2008 
HE, EHE, ME, 
SE, CR, RHE 
CC 61/100 Yes 30 62 (24-82) 60 (20-81) 18/24 
Lin et al. 
2011 
SE, HE, EHE, 
CR 
CC 56/61 Yes 30 57 (23-73) 55 (22-81) 17/24 
Stoot et 
al. 2009 
Laparoscopic: 
ME, SE, LLS 
CC 13/13 Yes 3-6 
months 
55 (34-82) 45 (26-70) 19/24 
Hendry 
et al 
2010 
HE, ME, SE, 
CR 
RCT 68* Yes 30 62 (53–69) - 13/16 
Koea et 
al. 2009 
HE, EHE, ME, 
SE 
RCT 100* Yes 30 60 (23-83) - 11/16 
McKay et 
al. 2008 
HE, SE RS case 
series 
12 yes ? 60 (43-74) - 8/16 
aPatients in the control and experimental arms were all treated according to ERAS protocols. 
ERAS, enhanced recovery after surgery; HE, hemi-hepatectomy; EHE, extended hemi-hepatectomy; ME, 
metastasectomy; SE, segmentectomy; CR, central resection; RHE, repeat hemi-hepatectomy; LLS, left 
lateral sectionectomy; CC, Case-controle; RCT, randomized controlled trial; RS, Retrospective. 
 
All studies included a consecutive series of patients. Follow-up was 30 days in four 
studies and 3–6 months in one study. One study did not report the duration of fol-
low-up. 
Age and other patient characteristics did not differ significantly among the patient 
groups described in the selected studies. Methodological quality assessed using the 
MINORS criteria was scored in the range of 17–19 points (of a maximum of 24 points) 
in case–control studies. Non-comparative studies achieved MINORS scores in the 
range of 8–13 points (of a maximum of 16 points). 
Most studies described the enhanced recovery programme in detail. A summary of 
the specific ERAS elements included in the different studies is shown in Table 3. Four-
teen protocol elements were identified. Most studies included the majority of these 
elements; one study included only seven elements. 
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PRIMARY AND SECUNDARY OUTCOME MEASURES 
Table 4 outlines post-operative outcomes after implementation of an ERAS pro-
gramme. Hospital LoS decreased significantly in the three comparative studies after 
ERAS implementation, in which median LoS was 5–7 days in the ERAS groups and 7–
11 days in the traditional care groups. 
In the non-comparative studies, post-operative LoS after liver resection ranged be-
tween 4 days and 7 days. In the study by Stoot et al.[21], all patients underwent lapa-
roscopic liver resection. The median post-operative LoS was 5 days in the ERAS group 
and 7 days in the traditional care group; however, this difference was not statistically 
significant and the study did not include major liver resections. It is noteworthy that 
only two studies[17,20] assessed time to functional recovery and the reasons for 
delayed discharge. In both studies time to functional recovery was achieved 2 days 
prior to actual discharge from hospital. The main reasons for later discharge were 
concern for complications or extensive surgery, low patient confidence, and 
transport-related or other social problems. 
 
Table 4. Post-operative outcome after implementation of a clinical pathway 
Study Type of surgery   Length of hospital 
stay (days; Study 
group vs control) 
Morbidity  
(%; Study group 
vs control)  
Mortality (%; 
Study group 
vs control) 
Readmissions 
(%; Study group 
vs control) 
Van Dam et al. 
2008 
HE, EHE, ME, SE, 
CR, RHE 
6 vs 8 (p<0.001) 41 vs 31 (ns) 0 vs 2 (ns) 13 vs 10 (ns) 
Lin et al. 2011 SE, HE, EHE, CR 7 vs 11 (p<0.001) 46.4 vs 43.3 (ns) 1.8 vs 1.6 (ns) 7.1 vs 3.3 (ns) 
Stoot et al. 2009 Laparoscopic:  
ME, SE, LLS 
5 vs 7 (ns) 
Functional recovery:  
3 vs 5 (p= 0.04) 
15.3 vs 15.3 (ns) 0 vs 0 (ns) 0 vs 0 (ns) 
Hendry et al 2010 HE, ME, SE, CR 6 
Functional recovery: 
4 
17 2 5 
Koea et al. 2009 HE, EHE, ME, SE 4.7 ± 0.9 (intrathecal 
morphine)  
6.8 ± 1.2 (epidural) 
19 0 4 
McKay et al. 2008 HE, SE 4 (2-7) 16.6 0 0 
[HE: hemihepatectomy, EHE, extended hemihepatectomy, ME: metastasectomy, SE: segmentectomy, CR: 
central resection, RHE, repeat hemihepatectomy, LLS: left lateral sectionectomy] 
 
Table 5 shows the extent of protocol adherence. The level of adherence to protocol 
was moderate in the studies included. Generally, nasogastric tubes were either not 
used or were immediately removed after surgery. The proportion of patients requir-
ing the reinsertion of a nasogastric tube was low. In the study groups, intra- ab-
dominal drains were used in only 2–13% of patients. The majority of patients re-
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sumed oral fluid intake on the day of surgery and achieved a normal diet on days 1 or 
2. The percentage of patients mobilized on the first post-operative day was low, with 
rates of 20–28% reported in only two studies.[20,21] In one study full mobilization 
was achieved on day 3 by 85% of patients.[16] 
 
Tabel 5. Adherence to protocol 
Protocol element Van Dam et 
al. 2008 16 
(ERAS vs 
control) 
Lin et al. 
2011 22 
(ERAS vs 
control) 
Stoot et al. 
2009 23 
(ERAS vs 
control) 
Koea et al. 
2009 21 (ERAS, 
n=100) 
Hendry et al. 
2010 20 
(ERAS, n=68) 
McKay et al. 
2008 24 
(ERAS, n=12) 
No NG tube or 
removed directly 
after surgery 
92 vs 0% NA 0 vs 38% 100% 100% NA 
NG tube reinserted 4 vs 0% 3.5 vs 1.6% 0 vs 15% NA NA NA 
Intra-abdominal 
drain 
2 vs 66% 0 vs 1.6%  0 vs 46% 2% 13% 0% 
Oral fluid intake POD 
0 (ERAS), % or days, 
median (range) 
92% NA 1 (0-2) vs  
1 (0-6) 
NA 94% 100% 
Resumption normal 
food, % or days, 
median (range) 
1 (0-3) vs  
3 (0-14) 
NA 1 (0-2) vs  
1 (0-6) 
20% on day 1 37% on day 1 
91% on day 2 
NA 
Full mobilisation 
(ERAS) 
85% on day 
3 
NA NA 20% on day 1 28% on day 1 NA 
Functional recovery 
criteria met on day 
NA NA 3 vs 5 NA 4 NA 
NG, nasogastric; PoD, post-operative day; NA = data not available] 
DISCUSSION 
This systematic review examined the use of ERAS protocols in liver surgery in three 
case–control studies, two RCTs and one case series. The results suggest that an en-
hanced recovery protocol can be successfully implemented in liver surgery. Hospital 
LoS was reduced and functional recovery was accelerated without compromising 
morbidity or mortality rates, and readmission rates were not significantly increased. 
The present results are in line with a recent review describing the use of fast-track 
protocols in hepatopancreatic resections.[25] 
At least four items in the pre-, peri- and post-operative periods must be included in 
an ERAS protocol for the protocol to be considered of value.[14,15] The studies in this 
review incorporated an average of 12 of 14 items (range: 7–14 items). In large series 
of patients undergoing liver surgery, LoS varies between 8 days and 14 days.[3,4] All 
of the studies included in this review reported a shorter LoS in the ERAS study group. 
Two studies assessed time to functional recovery, which was significantly lower than 
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total LoS. In many studies, LoS is reported as a primary outcome parameter. However, 
the use of this outcome may not always be appropriate as discharge is often delayed 
by a variety of other factors that may be unrelated to the true outcomes of the pro-
cedure.[26] The present authors therefore propose that time to functional recovery 
should be used as an outcome measure rather than LoS. 
Morbidity rates reported in the literature vary from 38% to 45%[4,27] and are compa-
rable with the complication rates reported in the studies in the present review. How-
ever, it should be noted that complications in the studies included here were not 
always reported using a validated classification system (e.g. Clavien–Dindo or Accor-
dion classification [28,29]). This makes it more difficult to make meaningful compari-
sons of morbidity among the different centres. 
The reporting of adherence to the various elements of the protocol was rather low in 
the included studies, especially as far as the introduction of normal diet and fluids 
was concerned. As Maessen et al.[30] have observed, the reporting of adherence to 
protocol seems to be problematic in a considerable number of international studies. 
This impedes comparisons among studies.[30] The use of self-report patient diaries 
and continuous education of nurses and staff may represent strategies for overcom-
ing this difficulty. 
Overall, the methodological quality of the studies included in the present review, as 
assessed according to the MINORs criteria, was acceptable. However, this systematic 
review is limited by the fact that no RCTs comparing fast-track with standard care 
were available for inclusion (the RCTs included treated both the patient and control 
groups according to an ERAS protocol) and only case series and comparative studies 
using historical controls were included. The studies included were considered to be 
too heterogeneous to allow a meta-analysis. Another limitation of this review is that 
the individual studies used slightly different study protocols, with the result that the 
items incorporated in the various protocols are not identical and thus these studies 
are not fully comparable. However, a recent study by Ahmed et al.[31] compared 
adherence to protocol in two groups of patients undergoing colorectal surgery and 
showed that outcome was unaltered in the study group in which adherence to some 
elements of the study protocol (e.g. preoperative carbohydrate loading and early 
fluid and diet introduction) was significantly lower. From this, it seems reasonable to 
conclude that not every item of an ERAS protocol makes an independent contribu-
tion to enhanced recovery, but, rather, it is the combination of different items in a 
structured care pathway that determines the outcome. This might also to some de-
gree reflect a Hawthorne, or trial, effect, indicating a positive effect resulting from the 
implementation per se of a complex and comprehensive intervention. 
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Kehlet first introduced ERAS protocols in colon surgery in 1997.[32] Now, 15 years 
later, several items drawn from ERAS protocols are increasingly implemented in 
modern care worldwide. However, in many surgical fields, ERAS protocols have not 
yet been accepted as standard care. In the context of liver surgery, ERAS was first 
described in 2008 [24], since when only five studies examining an ERAS protocol in 
this field have been published[16,20–23] and three of these were performed by the 
same study group.[16,21,23] This seems to illustrate a limited international imple-
mentation of ERAS protocols in liver surgery. 
Although the methodology used in the studies included is not optimal, the results 
are consistent and seem to indicate clear advantages in terms of recovery. Although 
most centres today perform a proportion of resections laparoscopically, the present 
results serve to illustrate what can be achieved in open surgery and hence serve as a 
backdrop against which advances in technique and subsequent results can be com-
pared. 
In summary, this systematic review shows that it is feasible and safe to implement an 
ERAS protocol in hepatic surgery. The available evidence suggests that LoS is short-
ened without comprising morbidity, mortality or readmission rates. In view of the 
limited number of studies and the discrepancies in reporting among them, the pre-
sent authors recommend the application of a standardized system of classifying 
complications, the accurate reporting of adherence to protocol, and the use of time 
to functional recovery as a primary outcome measure in future studies in order to 
enhance quality and comparability. 
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ABSTRACT 
OBJECTIVE 
The worldwide introduction of multimodal enhanced recovery programs has also 
changed perioperative care in patients who undergo liver resection. This study was 
performed to assess current perioperative practice in liver surgery in 11 European 
HPB centres and compare it to enhanced recovery after surgery (ERAS) principles. 
 
METHODS 
In each unit, 15 consecutive patients (N = 165) who underwent hepatectomy be-
tween 2010 and 2012 were retrospectively analysed. Compliance was classified as 
‘‘full’,’ ‘‘partial’’, or ‘‘poor’’ whenever ≥80, ≥50, or <50 % of the 22 ERAS protocol core 
items were met. The primary study end point was overall compliance with the ERAS 
core program per unit and per perioperative phase. 
 
RESULTS 
Most patients were operated on for malignancy (91 %) and 56 % were minor hepa-
tectomies. The median number of implemented ERAS core items was 9 (range = 7–
12) across all centres. Compliance was partial in the preoperative (median 2 of 3 
items, range = 1–3) and perioperative phases (median 5 of 10 items, range: 4–7). 
Median post-operative compliance was poor (median 2 of 9 items, range = 0–4). A 
statistically significant difference was observed between median length of stay and 
median time to recovery (7 vs. 5 days, P<0.001). 
 
CONCLUSION 
Perioperative care among centres that perform liver resections varied substantially. 
In current HPB surgical practice, some elements of the ERAS program, e.g., preopera-
tive counselling and minimal fasting, have already been implemented. Elements in 
the perioperative phase (avoidance of drains and nasogastric tube) and post-
operative phase (early resumption of oral intake, early mobilization, and use of re-
covery criteria) should be further optimized. 
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INTRODUCTION 
A multimodal enhanced-recovery perioperative care program for elective abdominal 
surgery was introduced by Kehlet et al. [1] at the end of the last century. The en-
hanced-recovery concept combines several evidence-based aspects of perioperative 
care into a structured care pathway, thereby enabling accelerated post-operative 
recovery and potentially reducing post-operative morbidity. Within the surgical 
community, several groups, such as the international enhanced recovery after sur-
gery (ERAS) collaboration, have embraced and studied the enhanced recovery con-
cept. This led to the successful introduction of a new standard in perioperative care 
for colorectal surgery patients [2]. In recent years the same principles have also been 
applied in the perioperative care of liver surgery patients, and a few studies have 
shown that the program is feasible, safe, and effective for resection of hepatic tu-
mours [3–10]. 
Actual data on the status of current practice and whether multimodal clinical path-
ways in liver surgery have been implemented are scarce. Over time, several elements 
of the ERAS concept have probably been introduced without implementation of a 
fully formal enhanced-recovery program. A recent survey in the international HPB 
community showed marginal implementation of ERAS protocols worldwide [11]. 
Based on the successful introduction and implementation of ERAS programs in vari-
ous fields of surgery [12–17] and promising results in hepatic surgery, further dissem-
ination of the ERAS concept within the liver surgical field seems desirable. First, to 
accelerate recovery and reduce length of hospital stay, it is necessary to aim for uni-
form and evidence-based perioperative management. Moreover, a structured and 
detailed program with well-defined recovery and discharge criteria can improve 
comparability of clinical outcomes in clinical audits and future clinical trials. Finally, it 
is likely that implementation will have a synergetic effect with minimally invasive 
surgery, as shown in colorectal surgery [18]. 
It has been suggested that implementation of a structured enhanced-recovery pro-
gram in liver surgery is hard to achieve since multidisciplinary involvement is essen-
tial [19]. However, surgical practice has changed over the years and many ERAS ele-
ments may have already been introduced in current practice. Therefore, following an 
initial electronic survey [11], the aim of this study was to more accurately evaluate 
current perioperative care by assessing to what extent the different elements of an 
ERAS program have been implemented in liver surgery in a group of expert HPB units 
in Europe. 
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METHODS 
STUDY DESIGN 
A retrospective analysis of prospectively collected data was conducted to assess 
current perioperative practice in patients undergoing liver surgery in a number of 
expert HPB centres in Europe. Fifteen consecutive patients per centre were assessed. 
All available medical records (patient and nursing charts, surgery and anaesthesia 
reports) for the different elements in the pre-, intra-, and post-operative phases of 
admission were reviewed and evaluated using a detailed baseline checklist that con-
sisted of the previously described ERAS elements [4]. This checklist was further de-
veloped and adjusted by two hepatic surgeons (RMvD, CHCD) and two researchers 
(EMWLH, LH). Primary study endpoints were overall compliance with the ERAS core 
program per unit and per element. Secondary endpoints were day of discharge and 
time to functional recovery (FR). 
ERAS ELEMENTS AND COMPLIANCE 
The program’s core elements are displayed in Table 1 and are grouped as pre-, peri 
(day of surgery), and post-operative elements. If an element in the checklist was 
marked as ‘‘yes’’, the hospital was able to apply the ERAS element for a particular 
patient. Details explaining (non)compliance were also added to the ‘‘Comments’’ 
section of the checklist. Compliance was defined as the degree to which individual 
units or elements were in accordance with the ERAS program. Units were classified as 
‘‘fully’’, ‘‘partially’’ or ‘‘poorly’’ compliant whenever ≥80, ≥50, or >50 %, respectively, 
of the assessed 22 ERAS core items were met. Per individual element, an 80 % cut-off 
value was set to qualify a unit as ‘‘compliant.’’ In addition, time to FR was assessed 
with predefined and previously described criteria [4, 5] (Table 2). 
STUDY POPULATION 
Liver units with a declared interest to participate in a random controlled trial (RCT) on 
laparoscopic liver resection in an ERAS setting [20] were invited by email to partici-
pate in this retrospective study. A total of 11 European high-volume centres (25 cas-
es/year)[21] participated (see list below). The last 15 consecutive patients who un-
derwent liver surgery in each hospital were selected and reviewed (open– close pro-
cedures and biliodigestive /vascular anastomoses were excluded). Included patients 
were all admitted and operated on between 2010 and 2012. All patients received 
perioperative care according to local protocols. 
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Table 1. ERAS core protocol elements 
Preoperative 
Preoperative counselling 
Minimal preoperative fasting (solid food up to 6 h + clear fluids up to 2 h) + carbohydrate loading 
No anxiolytic premedication  
Perioperative 
Thoracic epidural analgesia 
Prevention of hypothermia 
CVP monitoring (CVP\5 mmHg) 
No routine drainage of the peritoneal cavity 
No standard nasogastric drainage 
Start intake of water and free fluids 
Early mobilization 
Post-operative nausea and vomiting (PONV) prophylaxis 
Antithrombotic prophylaxis 
Antibiotic prophylaxis 
Post-operative day 1 – 3 
Daily review of discharge criteria 
Ileus prevention (MgO/Macrogol/Lactulose) 
Free fluids/normal diet POD 1 
Intravenous fluids discontinued POD 1 
Oral analgesia POD 1 
Normal diet POD 2 
Removal of urinary catheter POD 2 
Stop epidural/intravenous analgesia POD 3 
Full mobilization POD 3 
 
Table 2. Functional recovery criteria 
1. Pain control with oral analgesia only 
2. No intra-venous fluid support 
3. Full mobilization to preoperative level 
4. Eating of solid food 
5. Normal serum bilirubin or returning toward normal ranges 
ERAS EXPERIENCE 
Three of the 11 centres indicated that they had formally implemented ERAS protocol 
for liver surgery. The implementation of ERAS principles in these three centres was 
achieved by multidisciplinary involvement, including a liver surgeon, an anaesthetist, 
recovery ward nursing staff, and a researcher. In addition, all Dutch centres in this 
study had already gained experience with the ERAS program for colonic surgery as 
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most of them participated in a nationwide structured implementation plan [22, 23]. 
The other hospitals were aware of the ERAS programs for liver and colonic surgery, 
but a structured implementation and evaluation had not yet been performed. Cen-
tres that had implemented the ERAS liver surgery program used the FR criteria (Table 
2) to assess readiness for discharge. In the other centres the operating surgeon or 
physician on call was responsible for discharge and no strict criteria were applied. 
DATA AND STATISTICS 
Data were anonymously collected in an Oracle 10 database (Oracle Corp., Redwood 
Shores, CA, USA) with OpenClinica trial software for online data capture and man-
agement (Ikaza Research, Cambridge, MA, USA) and analysed using SPSS ver. 19 
(SPSS Inc., Chicago, IL, USA). Basic analyses were performed using descriptive statis-
tics. To describe the compliance in the complete cohort based on results of individual 
centres, a random-effect logistic regression analysis was used. This adjusts for the 
heterogeneity of compliance among centres. The constant in the logistic regression 
model was transformed to an overall cohort compliance, except for three items that 
did not fit into the model (weighted median was used in these cases). Comparison 
between groups was performed using the Mann–Whitney U and Wilcoxon signed-
ranks tests as appropriate. All statistical tests were two-sided, and P<0.05 was con-
sidered statistically significant. 
RESULTS 
PATIENT AND SURGICAL CHARACTERISTICS 
A total of 165 patients were included in this study. Baseline patient characteristics are 
given in Table 3. Surgical details with regard to type of incision and resection are given 
in Table 4. Overall morbidity and the distribution of post-operative surgical complica-
tions according to the Clavien–Dindo grading system can be found in Table 5. 
PRIMARY ENDPOINTS 
Overall compliance with the ERAS core elements varied among the assessed centres 
(Fig. 1). None of the participating hospitals were shown to be ‘‘fully’’ compliant with the 
complete set of core ERAS elements. Centres provided a median number of 9 (range = 
7–12) of pre-, peri-, and post-operative care items according to the ERAS protocol. Five 
hospitals were partially compliant (11 or more items) and the remaining six hospitals 
were poorly compliant to the core elements. A summary of the overall compliance per 
ERAS element across all units (N = 165 patients) is given in Tables 6 and 7. 
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Table 3. Baseline characteristics of patients (N = 165) 
Median age, years (range) 62 (19 – 89) 
Male gender 83 (50) 
ASA grade  
I 21 (13) 
II 111 (67) 
III 32 (19) 
Missing 1 (1) 
Malignancy 150 (91) 
Values in parentheses are percentages, unless indicated otherwise.  
ASA American Society of Anaesthesiologists 
 
Table 4. Surgical characteristics of patients (N = 165) 
Incision  
Laparoscopic 22 (13) 
Kocher’s/J-shaped 81 (49) 
Bilateral subcostal 19 (12) 
Mercedes 12 (7) 
Median 13 (8) 
Othera 11 (7) 
NA 7 (4) 
Liver resection  
Minor (<3 segments or non-anatomical) 93 (56) 
Major (≥3 segments) 45 (27) 
Simultaneous non-hepatic 27 (16) 
Type  
Wedge resection/segmentectomy 46 (28) 
Bisegmentectomy 23 (14) 
Right hepatectomy 24 (15) 
Left hepatectomy 2 (1) 
Deroofing/enucleation 1 (1) 
Extended right hepatectomy 4 (2) 
Extended left hepatectomy 2 (1) 
Multiple wedge resections/segmentectomies 35 (21) 
Major (≥3 segments) 10 (6) 
Otherb 28 (17) 
Major (≥3 segments) 3 (2) 
Values in parentheses are percentages, NA not available 
a Thoracoabdominal and xiphopubic incisions 
b Hepatic resections combined with RFA or nonhepatic procedures 
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Table 5. Morbidity (N = 165) 
Overall morbidity 47 (28) 
Clavien–Dindo  
Grade I 8 (5) 
Grade II 26 (16) 
Grade IIIa 6 (4) 
Grade IIIb 2 (1) 
Grade IVa 5 (3) 
Grade IVb - 
Grade V (death) - 
Readmissions 3 (2) 
Values in parentheses are percentages 
 
 
Figure 1. Box plots of overall compliance per ERAS core elements of 11 participating centres. Box plots 
resemble the 25–75 % confidence intervals. Black vertical line within a box is the median value. The vertical 
dotted line represents the 80 % compliance cut-off value. 
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Table 6. Compliance with ERAS elements 
  
N/total 
N (%) 
Overall median 
compliance 
(range) 
Preoperative   
Preoperative counselling 162/165 (98) 96 (80-100) 
Assessment of discharge arrangements 120/165 (73) 73 (0-100)a 
Assessment of mobility 122/164 (74) 74 (0-100)a 
Daily review of discharge criteria 45/165 (27) 27 (0-100)a 
Normal oral diet up to 6 h + clear fluid intake up to 2 h 155/165 (94) 94 (60-100) 
No anxiolytic premedication 91/162 (56) 43 (13-100) 
Perioperative   
Thoracic epidural anaesthesia (EDA) 119/165 (72) 81 (80-100) 
Prevention of hypothermia 157/160 (98) 96 (80-100) 
Laparoscopy / right subcostal incision 102/159 (64) 65 (13-87) 
CVP monitoring (CVP < 5 mmHg) 47/102 (46) 47 (0-100) 
No post-operative nasogastric tube 72/161 (45) 53 (0-100) 
No routine use of abdominal drain 76/165 (46) 41 (7-100) 
Post-operative day (POD) 0   
PONV prophylaxis 110/164 (67) 82 (40-100) 
Antithrombotic prophylaxis 157/164 (96) 95 (80-100) 
Antibiotic prophylaxis 155/162 (96) 95 (87-100) 
Oral fluid intake 100/162 (62) 42 (7-87) 
Mobilisation at all 13/150 (9) 6 (7-87) 
Start oral analgesia 86/163 (51) 51 (7-100) 
Use of patient-controlled analgesia (EDA or IV) 132/165 (80) 83 (0-93) 
POD 1   
Nasogastric tube removed 107/160 (67) 66 (0-100) 
Tolerance of free fluids / normal diet 63/165 (38) 36 (0-73) 
Mobilisation at all / out of bed 82/160 (51) 50 (7-87) 
No intravenous fluids 17/165 (10) 10 (0-53) 
Oral analgesia 129/165 (78) 84 (13-93) 
Use of patient-controlled analgesia (EDA / IV) 114/165 (69) 75 (0-93) 
CAD removal 14/161 (9) 5 (0-60) 
Flatulence and/or stool 15/148 (10) 10 (0-20) 
POD 2   
Normal diet 101/165 (61) 54 (13-80) 
Mobilisation out of bed 118/159 (74) 76 (13-93) 
No intravenous fluids 34/165 (21) 19 (0-67) 
Oral analgesia 135/165 (82) 86 (13-93) 
Use of patient-controlled analgesia (EDA / IV) 91/165 (55) 54 (0-87) 
Urinary catheter removal 41/159 (26) 21 (0-93) 
Flatulence and/or stool 59/145 (41) 41 (0-67) 
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N/total 
N (%) 
Overall median 
compliance 
(range) 
POD 3   
Normal diet 120/165 (73) 73 (13-93) 
Full mobilisation 81/151 (57) 86 (27-93) 
No intravenous fluids 76/165 (46) 56 (0-73) 
Oral analgesia 139/165 (84) 90 (13-93) 
Use of Patient Controlled Analgesia (EDA / IV) 46/165 (28) 25 (0-87) 
Urinary catheter removal 85/157 (54) 52 (0-93) 
Flatulence and/or Stool 108/154 (70) 71 (13-93) 
Use of cathartics / laxatives 61/165 (37) 35 (0-87) 
Overall median compliance represents all assessed centres (N = 11) 
CVP central venous pressure, PONV post-operative nausea and vomiting, 
IV intravenous,. 
a Weighted median 
PRIMARY ENDPOINTS 
Overall compliance with the ERAS core elements varied among the assessed centres 
(Fig. 1). None of the participating hospitals were shown to be ‘‘fully’’ compliant with 
the complete set of core ERAS elements. Centres provided a median number of 9 
(range = 7–12) of pre-, peri-, and post-operative care items according to the ERAS 
protocol. Five hospitals were partially compliant (11 or more items) and the remain-
ing six hospitals were poorly compliant to the core elements. A summary of the over-
all compliance per ERAS element across all units (N = 165 patients) is given in Tables 6 
and 7. 
PREOPERATIVE 
Median compliance of the centres with preoperative core items was partial (66 %, 2 
of 3 elements, range = 1–3). All centres provided preoperative counselling, predomi-
nantly on procedural issues and complications. Three centres provided extensive 
counselling, with attention to post-operative elements such as early oral feeding and 
mobilization, FR, and discharge criteria. No record of preoperative counselling could 
be found for 2 % of the patients. For 94 % (60–100) of the patients, preoperative fast-
ing was reduced to a minimum. Anxiolytic premedication was not given to 43 % (13–
100) of the patients. 
 
 
 
 
Current perioperative practice in hepatic surgery 
75 
Table 7. Compliance with ERAS core elements per centre 
 Centres 
A B C D E F G H I J K 
Preoperative            
Preoperative counselling (%) 100 100 100 100 100 100 100 80 93 100 100 
Minimal preoperative fasting (%) 60 100 100 100 100 100 100 80 93 100 100 
No anxiolytic premedication (%) 13 67 80 40 40 27 80 100 87 20 53 
Perioperative            
Thoracic epidural analgesia (%) 100 93 100 80 87 93 100 53 7 0 80 
Prevention of hypothermia (%) 87 93 93 100 80 100 100 100 87 100 100 
CVP monitoring (%) 13 33 13 53 7 0 0 100 20 73 0 
No routine drainage of the peritoneal 
cavity (%) 
67 53 100 93 100 27 53 7 7 7 87 
No standard nasogastric drainage (%) 27 40 13 67 73 7 53 0 13 87 100 
Start intake of water/free fluids (%) 7 40 80 0 47 13 67 0 0 80 87 
Early mobilization (%) 7 47 33 53 20 13 80 87 40 87 73 
PONV prophylaxis (%) 80 27 93 73 93 47 100 40 93 33 60 
Antithrombotic prophylaxis (%) 93 80 93 93 100 100 100 100 100 93 100 
Antibiotic prophylaxis (%) 100 100 87 93 100 87 93 100 93 100 87 
Post-operative days 1–3            
Daily review of discharge criteria (%) 0 0 0 100 0 0 100 0 0 0 100 
Ileus prevention (%) 27 13 40 87 27 60 20 27 0 80 27 
Free fluids/normal diet POD 1 (%) 20 33 20 73 47 33 67 0 7 53 67 
Intravenous fluids discontinued POD 
1 (%) 
0 0 0 0 0 0 53 0 33 20 7 
Oral analgesia POD 1 (%) 100 87 93 100 60 93 93 13 73 53 93 
Normal diet POD 2 (%) 40 67 47 100 53 67 40 13 73 100 73 
Removal of urinary catheter POD 2 (%) 0 47 7 13 13 7 0 27 40 93 33 
Stop epidural/intravenous analgesia 
POD 3 (%) 
27 80 53 73 53 33 60 60 93 60 40 
Full mobilization POD 3 (%) 27 73 60 80 40 27 33 67 100 33 33 
Total N = 165, with 15 patients per centre 
CVP central venous pressure, PONV post-operative nausea and vomiting, POD post-operative day 
PERIOPERATIVE 
Median compliance with perioperative core items was partial (50 %, 5 of 10 elements, 
range = 4–7). Ninety-six per cent (87–100) of the patients received active prevention 
of hypothermia and 81 % (0–100) received thoracic epidural anaesthesia. In 13 % (0–
13), the procedure was laparoscopically performed, and in 49 % (26–100), a right 
subcostal incision was used. In 47 % (0–100) of the patients, the central venous pres-
sure (CVP) was closely monitored and kept below 5 mmHg during parenchymal tran-
Chapter 4 
76 
section. In 53 % (0–100) of the patients, nasogastric tubes (NGT) were removed im-
mediately after the operation, and in 41 % (7–100), abdominal drains were not used. 
In contrast to antithrombotic and antibiotic prophylaxes, prophylaxis for post-
operative nausea and vomiting (PONV) was frequently provided, but not as per rou-
tine in all patients. 
POST-OPERATIVE 
Median compliance of the centres with post-operative core items was poor (22 %, 2 
of 9 elements, range = 0–6). Early oral fluid intake, directly after surgery, was com-
menced in only 42 % (7–87) of the patients on POD 0, and only 36 % (0–73) tolerated 
free fluids or a normal diet on POD 1 (independent of the extent of liver surgery). 
After surgery patient-controlled intravenous (PCIA) or epidural analgesia (PCEA) was 
started in 83 % (0–93) of the patients as the standard of care. Oral analgesia was pro-
vided to 90 % (13–93) of patients, but in 14 % oral pain medication was not started 
until POD 2. Mobilization was achieved in only 50 % (13–93) of the patients on POD 1. 
In 56 % (0–73) of the patients, IV support was discontinued on POD 3. Urinary cathe-
ters were removed on POD 3 in 52 % (0– 93), and they were usually not removed 
until the day of or the day after thoracic epidural anaesthesia was discontinued. Signs 
of return of bowel function (flatulence and/or stool) were seen in 71 % (13–93) of 
patients on POD 3. 
SECONDARY ENDPOINTS 
Data on the day of discharge and the time to FR are depicted in Fig. 2. The median 
length of stay (LOS) after surgery was 7 (range = 1–27) days and 31, 49, and 64 % of 
all patients were discharged on POD 5, 6, and 7, respectively. Using the FR criteria, a 
majority of the patients could be considered functionally recovered on median POD 
5 (1–24). This difference between discharge and time to FR was statistically signifi-
cant (P<0.001). Eighty-one per cent (N = 133) of the patients were not discharged on 
the day that FR criteria were fulfilled. In 29 % of patients, complications were respon-
sible for prolonged hospitalization (Table 5). Although time to FR and LOS were in 
favour of the centres that were partially compliant with the ERAS program, differ-
ences did not reach statistical significance (Figs. 3, 4). 
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Figure 2. Discharge versus functional recovery, P < 0.001. Cumulative proportion of all patients (N = 165)
who were discharged on POD 2–7 and who were functionally recovered (FR). POD post-operative day 
 
 
Figure 3. Discharge in partial ERAS centres (N = 5) versus poor ERAS centres (N = 6), P = 0.166. Cumulative 
proportion of patients who were discharged on POD 2–7 
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Figure 4 Functional recovery in partial ERAS centres (N = 5) versus poor ERAS centres (N = 6), P = 0.149. 
Cumulative proportion of patients who were functionally recovered on POD 2–7 
DISCUSSION 
This study evaluated the current perioperative care in 11 high-volume European liver 
surgery centres by assessing compliance with an ERAS program. Perioperative care 
varied considerably among the centres. All of the participating institutions had al-
ready adopted a median of 9 (range = 7–12) elements of the ERAS care program as 
part of modern surgical practice. None of the centres had implemented the complete 
set of core elements. Interestingly, pre- and perioperative elements had the best 
implementation, but the centres were especially poor at complying with ERAS ele-
ments in the post-operative phase. In addition, a significant discrepancy between the 
patient’s recovery and actual discharge was observed. 
Every centre consistently provided preoperative counselling, limited the fasting peri-
od, actively prevented hypothermia during surgery, and systematically administered 
antithrombotic and antibiotic prophylaxes. Also, PONV prophylaxis, the use of epi-
dural anaesthesia, and patient-controlled analgesia already had a prominent place. In 
contrast to the aforementioned care elements, other ERAS components were absent 
or suboptimally implemented. The partial or poor compliance and wide variation 
among the centres mirror this. 
During the preoperative phase, anxiolytic medication was commonly used. Two strik-
ing perioperative observations were the widespread use of abdominal drains and 
NGT. In addition, the CVP during parenchymal transection was poorly documented. 
In the post-operative phase, the resumption of oral intake, removal of the urinary 
catheter, use of laxatives, and mobilization were only poorly implemented. 
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Based upon previous studies, it is known that preoperative counselling on the role 
and expectations of the patient in the recovery period could further optimize post-
operative recovery and satisfaction [24, 25]. Also, the use of anxiolytic premedication 
could negatively influence gastrointestinal motility and, although it is safe to use 
short-acting benzodiazepines in day surgery [26], their efficacy for major surgery 
remains unclear. 
Important accumulated evidence for the perioperative phase has shown that the 
necessity of abdominal drains can be questioned after uncomplicated liver resection 
[27]. Equally, it is well known that it is safe to remove NGTs directly after abdominal 
surgery [28]. The use of an NGT is even associated with an increased risk of develop-
ing post-operative pulmonary complications [28, 29]. 
There is an ongoing discussion concerning central venous pressure monitoring (CVP 
<5–10 mmHg). Low CVP can be utilized to minimize back bleeding during paren-
chymal transection and to avoid excessive administration of IV fluids [30– 32]. How-
ever, it could be argued that CVP monitoring is not strictly necessary in minor hepa-
tectomies, which represent a majority in the present study. 
Lastly, patient-controlled analgesia may help to reduce opioid use and its associated 
side effects [33]. However, there is debate concerning the role of epidural catheters 
(EDA). Although frequently used in the participating centres, they are no longer used 
in an increasing number of other hospitals that perform liver surgery. Not only can 
the technique be contraindicated, e.g., because of the presence of coagulopathy, it 
can also cause potentially serious complications such as epidural hematoma, abscess, 
or paralysis [34]. The epidural catheterization is more time-consuming than intrave-
nous analgesia and fails to provide adequate analgesia in 20 % of the patients [35]. 
It may be felt that ERAS principles are not uniformly applicable to all patients and 
other factors (e.g., age, comorbidity, indication for surgery, and extent of liver resec-
tion) could play a role. There are good alternatives to core elements that would not 
deter from the ERAS principles. Post-operative pain has traditionally been managed 
by intravenous or epidural analgesia. It can be argued whether the inclusion of tho-
racic epidural analgesia as a core element reflects current clinical practice. The use of 
wound catheters with a local anaesthetic [36–38] or the use of intrathecal morphine 
[39] has been shown to be safe and effective also in an ERAS setting for liver surgery 
[40, 41]. Furthermore, alternatives to reduce CVP or monitor it could serve as a substi-
tute and may be sufficient [42, 43]. 
In the post-operative phase, the still abundant use of NGTs could explain why early 
intake of water on POD 0 was achieved in only less than one third of the patients and 
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why only half of the patients tolerated a normal diet on POD 2. A quick return to a 
normal diet has been shown to be safe for both major upper abdominal and colorec-
tal surgeries [44, 45]. In addition, to promote the return of normal bowel function or 
prevent a post-operative ileus, standard use of laxatives has been shown to be effec-
tive [4, 5]. Lastly, few patients mobilized out of bed before POD 2. The use of drains, 
lack of daily mobilization goals, and relatively late removal of catheters can explain 
this observation. 
A secondary outcome was the length of hospital stay versus the time to FR. It is gen-
erally agreed that it is medically justified to discharge patients when criteria for full 
FR are met [4, 5, 20]. In keeping with literature data [4, 19], a discrepancy was found 
between discharge and time to FR. A majority of patients (63 %) principally were 
functionally recovered on median POD 5 (range = 1–24), while only 31 % were dis-
charged at that time. Factors influencing this delay could have been poor organiza-
tion of discharge logistics, cultural differences, and deviant patient expectations. 
Unfortunately, it was not possible to assess all five FR criteria because serum bilirubin 
values were inconsistently available. Bilirubin values were therefore assumed normal 
since the majority of the liver resections in this study were minor procedures. 
The retrospective assessment of the data, the selection of participating centres, and 
their varying experience with ERAS principles may have biased our results. However, 
this design was deliberately chosen so as to not influence the behaviour of medical 
and nursing staff in perioperative care during a full prospective assessment. Both 
large and small hepatic centres were allowed to participate and this could also have 
influenced our results. However, the large number of minor resections in this study 
and the participation of several high-volume European centres with varying experi-
ence with ERAS protocols do provide a reflection of daily practice in liver surgery and 
therefore increase external validity. 
Based on this study several recommendations can be made that could eventually 
lead to further optimization of care and potentially improve post-operative out-
comes. Change of current practice and implementation of an enhanced-recovery 
care pathway are desirable but will require multidisciplinary efforts [19, 46]. Although 
counselling is already part of preoperative care in that information on the procedure 
and possible complications is provided, there should be more emphasis on the re-
covery period with respect to pain control, early mobilization, resumption of intake, 
and time of discharge. Furthermore, administration of preoperative anxiolytic medi-
cation should not be the standard. Recommendations for the perioperative phase 
include the selective monitoring of the CVP and abandoning the standard use of 
abdominal drains and the dogmatic use of NGT. For patients undergoing liver sur-
gery, the use of NGTs is not needed at all and seems very conservative. In combina-
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tion with adequate PONV prophylaxis, a safe and quick return to a normal diet may 
be facilitated. In addition, laxatives can be provided in a standard manner, urinary 
catheters should be removed earlier, and daily mobilization goals should be deter-
mined. Lastly, predefined discharge criteria should be checked daily to minimize a 
delay in discharge after FR. 
The findings of this study are clinically relevant to liver surgeons as they aim for a 
universally accepted and standardized perioperative care program. The findings may 
help to provide the standardization needed for comparability in clinical audits and 
trials. Future research should clarify the role of the individual components in ERAS 
programs and investigate to what extent an element contributes to the improve-
ment of outcomes. Several recent studies [8–10] have already demonstrated the 
additional value of ERAS programs with predefined discharge criteria. In addition, 
safe and effective alternatives or new elements should be embraced. 
CONCLUSION 
Perioperative care among centres that perform liver resections varied substantially 
and elements of enhanced recovery programs had already been implemented as 
part of daily surgical practice. Other elements can be further optimized based on 
ERAS principles. This may standardize care and improve recovery after liver surgery. 
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ABSTRACT 
OBJECTIVE 
There is debate concerning the best mode of delivery of analgesia following liver 
resection, with continuous i.m. infusion of bupivacaine (CIB) plus patient-controlled 
i.v. analgesia (PCA) suggested as an alternative to continuous epidural analgesia 
(CEA). This study compares these two modalities. 
 
METHODS 
A total of 498 patients undergoing major hepatectomy between July 2004 and July 
2011 were included. Group 1 received CIB + PCA (n = 429) and Group 2 received CEA 
(n = 69). Groups were analysed on baseline patient and surgical characteristics. Pri-
mary endpoints were pain severity scores and total opioid consumption. Secondary 
endpoints were pain management failures, need for rescue medication, post-
operative (opioid-related) morbidity and hospital length of stay (LoS). 
 
RESULTS 
In both groups pain was well controlled and >70% of patients had no or minimal 
pain on PoDs 1 and 2. The numbers of patients experiencing severe pain were similar 
in both groups: PoD 1 at rest: 0.3% in Group 1 and 0% in Group 2 (P = 1.000); PoD 1 
on movement: 8% in Group 1 and 2% in Group 2 (P = 0.338); PoD 1 at rest: 0% in 
Group 1 and 2% in Group 2 (P = 0.126), and PoD 2 on movement: 5% in Group 1 and 
5% in Group 2 (P = 1.000). Although the CIB + PCA group required more opioid res-
cue medication on PoD 0 (53% versus 22%; P < 0.001), they used less opioids on PoDs 
0–3 (P ≤ 0.001), had lower morbidity (26% versus 39%; P = 0.018), and a shorter LoS (7 
days versus 8 days; P = 0.005). 
 
CONCLUSION 
The combination of CIB + PCA provides pain control similar to that provided by CEA, 
but facilitates lower opioid consumption after major hepatectomy. It has the poten-
tial to replace epidural analgesia, thereby avoiding the occurrence of rare but serious 
complications. 
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INTRODUCTION 
The upper abdominal wall incision is a major contributor to post-operative pain after 
liver resection.[1,2] Given the continuing increases in both the volume and extent of 
liver surgery, along with the introduction of enhanced recovery programmes[3–7], 
there is debate about the optimal method of delivering post-operative analgesia. 
Effective post-operative pain control will reduce the incidence of numerous post-
operative complications, can facilitate early mobilization and may result in earlier 
recovery.[8,9] Pain control is usually achieved by the administration of opioids, which 
may cause side-effects, such as sedation, respiratory depression, pruritus, hallucina-
tions and post-operative nausea and vomiting (PONV). 
Epidural analgesia has been considered superior to i.v. patient-controlled analgesia 
(PCA) for post-operative pain relief in patients recovering from major upper ab-
dominal operations[10,11], although patient satisfaction with i.v. PCA is higher.[11] 
However, the use of epidural analgesia after hepatectomy is still subject to debate. 
Because epidural analgesia can lead to serious complications, such as epidural ab-
scess or haematoma[12], it may be contraindicated when post-operative coagulopa-
thy is expected.[13,14] In addition, epidural methods take time to induce anaesthesia 
and may not function adequately in up to 30% of patients.[15] 
An alternative analgesic modality for the control of post-operative pain is the contin-
uous infiltration of local anaesthetic using wound catheters placed in the abdominal 
wall.[16–18] It is nearly a decade since this method of post-operative pain manage-
ment was introduced in liver surgery and it has shown promising results. [19,20] In 
other fields of surgery, the use of continuous wound infiltration has suggested a 
reduction in costs.[21–23] The most recent study, a randomized controlled trial (RCT) 
performed by Revie et al. in 2012, demonstrated that local wound infiltration com-
bined with i.v. PCA, compared with continuous epidural analgesia (CEA), reduced the 
time required to fulfil criteria for discharge from hospital, but provided inferior anal-
gesia.[24] 
This retrospective study provides insights into the post-operative analgesic merits of 
i.m. continuous infusion of bupivacaine (CIB) combined with i.v. PCA, compared with 
mid-thoracic CEA alone after major hepatic surgery. 
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METHODS 
PATIENTS 
All open major hepatectomies (n = 545) performed in the Hepatobiliary Unit of the 
North Hampshire Hospital in Basingstoke, UK, between July 2004 and July 2011 were 
included for screening. Data were prospectively collected and stored in a dedicated 
database by research staff blinded to the type of post-operative analgesia. Data on 
post-operative milestones, such as day of first oral intake and day of independent 
mobilization, were retrospectively added to the database after all available docu-
mentation for both living and deceased patients had been reviewed. Primary study 
endpoints were pain severity scores at rest and on movement during the first 48 h 
post-operatively, and total opioid requirements during the first 72 h post-operatively. 
Secondary endpoints were pain management failures, need for rescue medication, 
opioid-related morbidity and hospital length of stay (LoS). 
SURGERY 
General anaesthesia was induced with i.v. propofol (1.5–2.0 mg/kg) and fentanyl (1–2 
mcg/kg), with maintenance using volatile anaesthetics (iso-, des- or sevoflurane) in 
oxygen and air. For this study, major hepatectomy was defined as resection of at 
least three liver segments according to Couinaud’s classification.[25] Hepatectomies 
were performed by four liver surgeons (MR, FKSW, TGJ and ABC), of whom only one 
(TGJ) used epidural catheters as the preferred method of providing post-operative 
analgesia. Standard transection techniques were used for liver resection under total 
or selective hepatic vascular exclusion, as described previously.[26,27] Unfavourable 
intraoperative incidents were graded according to the Satava system for the evalua-
tion of surgical error, adapted for liver surgery.[28] Post-operative morbidity was 
classified and analysed using the Accordion system for grading surgical complica-
tions (with Clavien–Dindo modifications), as described by Strasberg et al.[29,30] Op-
erating time was defined as the time between the first induction of anaesthesia and 
the patient’s departure from the theatre. All patients received antibiotic, and nausea 
and vomitus (PONV) prophylaxis preoperatively. In the CIB + PCA group, PONV 
prophylaxis (cyclizine or dexamethason on induction, ondansetron post-operatively) 
was continued until PCA was removed. 
INCISION, WOUND CLOSURE AND CATHETER PLACEMENT 
Access to the abdominal cavity was achieved with a right subcostal incision[31,32] 
extended to the bed of the right 12th rib laterally and through the upper midline to 
the level of the xiphoid superiorly (‘L’ incision). The skin incision was made by knife; 
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diathermy was used through subcutaneous tissue and muscles. Wound closure and 
catheter placement techniques were also standardized and have been previously 
described by Basu et al.[19] 
DELIVERY OF ANALGESIC DRUGS 
Immediately after wound closure, the i.m. catheters were flushed with a 10-ml bolus 
of 0.25% bupivacaine, and continuous i.m. catheter infusions of 0.25% bupivacaine 
were commenced at a rate of 3 ml/h by syringe pump. This was continued for 72 h 
post-operatively. Patient-controlled analgesia using morphine (1 mg bolus with a 5-
min lockout) or a fentanyl infusion (20 mcg bolus with a 5-min lockout) was set up. In 
the CEA group, an epidural catheter was sited before surgery in the thoracic T5–T12 
region. This epidural catheter was also used to provide analgesia during surgery (20 
ml bupivacaine 0.25%). During emergence from anaesthesia, the patient was trans-
ferred to the recovery area, in which the PCA + CIB or CEA was started. The epidural 
infusion of bupivacaine 0.1% with 2 mcg/ml fentanyl was set at 5–15 ml/h. A dedi-
cated pain team unaware of the type of hepatic resection or any concomitant surgi-
cal procedure(s) assessed and scored the patients daily until the i.v. or epidural anal-
gesia could be stopped. Pain intensity was scored using a verbal rating scale (VRS) 
ranging from 0 (no pain) to 4 (worst imaginable pain). The level of sedation was also 
measured on a 5-point scale (0 = awake, 1 = dosing intermittently, 2 = sleeping and 
easy to wake, 3 = sleeping and difficult to wake, 4 = unarousable). Wound and urinary 
catheters were removed at the discretion of the operating surgeon, but usually after 
72 h [midnight on post-operative day (PoD) 3]. Pain management failures in both 
groups were defined as the need for rescue medication or a switch to a different 
opioid. The need for rescue medication was defined as any additional epidural, i.v., 
i.m. or oral administration of an opioid. A switch to a different analgesic protocol was 
defined as any change in analgesic medication, concentration or infusion rate. In the 
event of the technical failure of the epidural catheter, the patient was commenced 
on PCA with morphine or fentanyl. Oral analgesia [acetaminophen, non-steroidal 
anti-inflammatory drugs (NSAIDs) and opioids] was available in a standard manner to 
all patients. No standardized enhanced recovery after surgery (ERAS) programme 
was implemented during this study period. 
STATISTICS 
To facilitate comparisons between the two patient groups and the different opioids, 
all opioids required were converted to an i.v. morphine equivalent (Table 1). Compar-
isons between groups were performed using Pearson’s chi-squared or Fisher’s exact 
test for non-normally distributed categorical variables, as appropriate, and the 
Mann–Whitney U-test or Kruskal–Wallis test for continuous variables. All statistical 
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tests were two-sided. A P-value of < 0.05 was considered to indicate statistical signifi-
cance. Statistical analysis was performed using IBM SPSS Statistics for Windows Ver-
sion 19.0 (IBM Corp., Armonk, NY, USA). 
Table 1. Opioid conversion ratios 
Conversion ratio  Reference 
Intravenous 
Morphine 1:1 
Fentanyl (mcg/ml) 1:10 [34-36] 
Epidural 
Fentanyl (mcg/ml) 3:10 [37] 
Oral Medication 
Oxycodone 2:1 [34] 
Morphine 3:1 [38, 34, 36] 
Tramadol  15:1 [34] 
Codeine  24:1 [34] 
Opioid conversion ratios lead to an i.v. morphine (mg/ml) equivalent. 
RESULTS 
GENERAL AND SURGICAL CHARACTERISTICS 
Of 545 patients identified in the database for the study period, a total of 498 patients 
(CIB + PCA, n = 429; CEA, n = 69) underwent major liver resection and were included 
in this study. For 41 of the 47 patients excluded, no data on opioid requirements 
could be retrieved. This was mostly the result of either admission with sedation to 
the intensive care unit (ICU) or the absence of fluid balance/opioid infusion charts. Of 
the remaining six excluded patients, four received PCA without CIB, and one received 
epidural analgesia combined with CIB. No data at all could be retrieved for the final 
patient. General patient characteristics are shown in Table 2 and surgical characteris-
tics in Table 3. 
PRIMARY ENDPOINTS
The total median opioid consumption in milligrams (i.v. morphine equivalent) was 
markedly lower in the CIB + PCA group (for all time-points: P ≤ 0.001). However, post-
operative pain was equally well controlled in both groups (Table 4). The maximum 
percentages of pain scores missing for the complete group of included patients were 
27.7% and 28.3% on PoDs 1 and 2, respectively. 
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Table 2. General characteristics of patients undergoing major hepatectomy in the present series 
 Epidural group  
(n = 69) 
CIB + PCA group  
(n = 429) 
P-value 
Age, years, median (range) 63 (29–84) 63 (21–86) 0.695 
Male sex, n (%) 42 (60.9%) 269 (62.7%) 0.770 
BMI, kg/m2, median (range) 24.0 (20.0–33.5) 26.0 (16.0–44.0) 0.126 
ASA physical status, n (%)    
Class 1 2 (2.9%) 10 (2.3%) 0.673 
Class 2 51 (73.9%) 320 (74.6%) 0.924 
Class 3–5 13 (18.8%) 87 (20.3%) 0.828 
Number of comorbidities, n (%)    
0 37 (53.6%) 196 (45.7%) 0.240 
1 19 (27.5%) 136 (31.7%) 0.466 
2 6 (8.7%) 61 (14.2%) 0.190 
≥3 7 (10.1%) 33 (7.7%) 0.498 
Indication for surgery, n (%)    
Colorectal metastases 56 (81.2%) 369 (86.0%) 0.290 
Hepatocellular carcinoma 1 (1.4%) 4 (0.9%) 0.529 
Cholangiocarcinoma (intrahepatic and hilar) 1 (1.4%) 12 (2.8%) 1.000 
Other malignanciesa 3 (5.8%) 32 (7.4%) 0.453 
Benign diseaseb 8 (10.1%) 12 (2.6%) 0.003 
Previous abdominal surgery 59 (85.5%) 376 (87.6%) 0.324 
CIB + PCA, i.m. continuous infusion of bupivacaine plus i.v. patient-controlled analgesia; BMI, body mass 
index; ASA, American Society of Anesthesiologists. 
A P-value of < 0.05 was considered to indicate statistical significance. 
a Other malignancies include metastases of carcinoid, breast cancer, melanoma, neuroendocrine tumour, 
appendix carcinoma, ovarian carcinoma, squamous cell carcinoma of the vagina, renal cell carcinoma, 
lymphoma, endometrial carcinoma, gastrointestinal stromal tumour, mixed type hepatocellular carcino-
ma/cholangiocarcinoma, lymphoma and keratinizing squamous cell carcinoma. 
b Benign diseases include cyst(s), adenoma, focal nodular hyperplasia, haemangioma and angiomyolipoma. 
SECONDARY ENDPOINTS 
Intramuscular catheters were removed at a median of PoD 3 (range: PoD 2–5). Data 
on pain management failures, need for rescue medication and technical failures are 
shown in Table 4. Overall morbidity was higher in the epidural group (39.1%) than in 
the CIB + PCA group (26.1%) (P = 0.030). Complication grades rated on the Accordion 
system (with Clavien–Dindo modifications), length of hospital stay and readmissions 
are displayed in Table 5. One death occurred in the epidural group (1.4%) and two 
(0.5%) occurred in the CIB + PCA group (P = 0.361). The patient in the epidural group 
died from myocardial infarction. In the catheter group, one patient died from liver 
failure and the other from multi-organ failure caused by severe sepsis after endo-
scopic retrograde cholangiopancreatography (ERCP) for a bile leak. Specific compli-
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cations per group are shown in Table 6. No instances of respiratory depression were 
observed. There were no reported cases of epidural hematoma, abscess formation or 
paralysis in the group that received an epidural catheter. 
Table 3. Operative characteristics of patients undergoing major hepatectomy in the present series 
Epidural group 
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value
Operating time, min, median (range) 260 (150–475) 260 (28–480) 0.356 
Blood loss, ml, median (range) 295 (55–844) 369 (30–5344) 0.020 
Incision, n (%) 
Right subcostal 67 (97.1%) 425 (99.1%) 0.165 
Othera 2 (2.9%) 4 (0.9%) 0.196 
Segmental distribution of 
hepatectomies, n (%) 
3 segments 8 (11.6%) 65 (15.2%) 0.438 
3 segments + wedge 3 (4.3%) 26 (6.1%) 0.783 
3 segments + multiple wedge 1 (1.4%) 9 (2.1%) 1.000 
4 segments 40 (58.0%) 163 (38.0%) 0.002 
4 segments + wedge 5 (7.2%) 70 (16.3%) 0.051 
4 segments + multiple wedge 3 (4.3%) 25 (5.8%) 0.783 
5 segments 5 (7.2%) 49 (11.4%) 0.301 
5 segments + wedge 3 (4.3%) 13 (3.0%) 0.475 
5 segments + multiple wedge 1 (1.4%) 6 (1.4%) 1.000 
6 segments 0 3 (0.7%) 1.000 
Additional procedures, n (%) 
Cholecystectomy 13 (18.8%) 66 (15.4%) 0.478 
Lymph node sampling 0 12 (2.8%) 0.387 
Diaphragmatic resection 3 (4.3%) 18 (4.2%) 1.000 
Roux-en-Y reconstruction 1 (1.4%) 3 (0.7%) 0.450 
Right colectomy 1 (1.4%) 2 (0.5%) 0.361 
Incisional hernia repair 0 3 (0.7%) 1.000 
Ablation 0 6 (0.7%) 1.000 
Otherb 2 (2.9%) 45 (11.2%) 0.046 
Satava classification, n (%) 
Grade I 0 17 (4.0%) 0.147 
Grade II 0 2 (0.5%) 1.000 
Grade III 0 1 (0.2%) 1.000 
CIB + PCA, i.m. continuous infusion of bupivacaine plus i.v. patient-controlled analgesia. 
A P-value of < 0.05 was considered to indicate statistical significance. 
a Other incisions include abdominal longitudinal incision, Mercedes Benz incision and laparoscopic con-
verted to open surgery. 
b See Appendix 1 for details. 
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Table 4. Post-operative analgesia in patients undergoing major hepatectomy in the present series 
 Epidural group  
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value 
Time to discontinuation, days, median (range) 3 (1–5) 4 (1–8) 0.001 
Cumulative opioid consumptiona, mg, median 
(range) 
   
12 h 29.1 (0.0–266.0) 17.5 (0.0–1015.0) <0.001 
24 h 91.2 (5.0–1546.4) 43.0 (0.0–1225.0) <0.001 
48 h 148.4 (6.0–1952.8) 58.0 (0.0–1625.0) <0.001 
72 h 186.1 (4.0–1952.8) 61.0 (0.0–1650.0) <0.001 
VRS score at rest PoD 1, n (%)    
0 41 (89.1%) 234 (73.8%) 0.024 
1 4 (8.7%) 69 (21.8%) 0.047 
2 1 (2.2%) 13 (4.1%) 1.000 
3 0 1 (0.3%) 1.000 
4 0 0  
VRS score on movement PoD 1, n (%)    
0 29 (65.9%) 92 (29.4%) <0.001 
1 11 (19.4%) 148 (46.8%) 0.006 
2 3 (6.8%) 52 (16.4%) 0.118 
3 1 (2.3%) 20 (6.3%) 0.491 
4 0 4 (1.3%) 1.000 
VRS score at rest PoD 2, n (%)    
0 42 (93.3%) 273 (87.5%) 0.256 
1 2 (4.4%) 32 (10.3%) 0.284 
2 0 7 (2.2%) 0.603 
3 1 (2.2%) 0 0.126 
4 0 0  
VRS score on movement PoD 2, n (%)    
0 26 (59.1%) 134 (42.8%) 0.042 
1 15 (34.1%) 118 (37.7%) 0.632 
2 1 (2.3%) 45 (14.4%) 0.027 
3 1 (2.3%) 16 (5.1%) 0.706 
4 1 (2.3%) 0 0.124 
Pain management failures, PoD 0–3b, n (%) 22 (31.9%) 231 (53.8%) 0.001 
Opioid rescue medicationc, n (%)    
PoD 0 15 (21.7%) 228 (53.1%) <0.001 
PoD 1 3 (4.3%) 8 (1.9%) 0.185 
PoD 2 5 (7.2%) 6 (1.4%) 0.010 
PoD 3 6 (8.7%) 5 (1.2%) 0.002 
Switch to different analgesic protocold, n (%) 14 (20.3%) 6 (1.4%) <0.001 
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 Epidural group  
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value 
Technical failure 14 (20.3%) 114 (26.6%) 0.268 
Dislocation 7 (10.9%) 4 (0.9%)  
Leakage 4 (6.3%) 1 (0.2%)  
Occlusion 3 (4.7%%) 109 (25.8%)  
CIB + PCA, i.m. continuous infusion of bupivacaine plus i.v. patient-controlled analgesia; PoD, post-
operative day; VRS, verbal rating scale (0–4). 
A P-value of < 0.05 was considered to indicate statistical significance. 
aExpressed as i.v. morphine equivalent (any route). 
bPain management failure: need for rescue medication or switch to different opioid. 
cRescue medication: any additional intravenous, epidural, intramuscular or oral opioid. 
dSwitch to different analgesic protocol: change of drug, concentration or infusion rate. 
 
Table 5. Post-operative outcomes in patients undergoing major hepatectomy in the present series 
 Epidural group 
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value 
Complications (Accordion 
Classification), n (%) 
   
Grade I 3 (4.3%) 16 (3.7%) 0.737 
Grade II 10 (14.5%) 31 (7.2%) 0.057 
Grade III 0 14 (3.3%) 0.235 
Grade IV 11 (15.9%) 40 (9.3%) 0.130 
Grade V 2 (2.9%) 7 (1.6%) 0.361 
Grade VI (death) 1 (1.4%) 2 (0.5%) 0.361 
Length of stay, days, median 
(range) 
8 (3–80) 7 (3–95) 0.005 
Readmissions (<30 days), n (%) 2 (2.9%) 15 (3.5%) 1.000 
CIB + PCA, i.m. continuous infusion of bupivacaine plus i.v. patient-controlled analgesia.  
A P-value of < 0.05 was considered to indicate statistical significance. 
DISCUSSION 
This study compared the analgesic value of CEA with that of CIB + PCA following 
major hepatectomy. Data for this large, retrospective cohort show that CIB + PCA 
provided analgesic control equivalent to that of CEA. No significant differences in the 
numbers of patients experiencing severe pain were observed between the two 
groups and the majority of patients in both groups had no or minimal pain during 
the first 48 h post-operatively. Strikingly, the CIB + PCA group consumed significantly 
lower total volumes of opioids, had lower post-operative morbidity and a decreased 
hospital LoS. 
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The present findings would appear to indicate that post-operative pain was well 
controlled in both groups and that very few patients experienced severe pain on 
PoDs 1 and 2. In addition, most patients (>70%) in both groups had zero or minimal 
pain at rest or on movement. There is little practical difference between level 0 and 
level 1 pain, but ‘no pain’ and ‘severe pain’ lie at either end of any pain intensity scale 
and thus it seems safe to conclude that the present findings are reliable. The use of 
CIB + PCA also led to a substantial decrease in opioid consumption without com-
promising pain control. The decrease in opioid consumption was expected and can 
be explained by two factors. Unlike those in the CIB + PCA group, patients with epi-
durals were not able to control their opioid administration. In addition, the local an-
algesic effect of bupivacaine reduces the need for i.v. opioid infusion. Interestingly, 
patients with wound catheters were discharged 1 day earlier than those in the epi-
dural group, at a median of 7 days rather than 8 days (P = 0.005). 
 
Table 6. Morbidity in patients undergoing major hepatectomy in the present series 
 Epidural group 
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value 
Overall morbidity, n (%) 27 (39.1%) 112 (26.1%) 0.030 
Complications, n (%)    
Bile leak 2 (2.9%) 16 (3.7%)  
Liver failure 13 (18.8%) 43 (10.0%)  
Sepsis 0 5 (1.2%)  
Abdominal abscess 1 (1.4%) 4 (0.9%)  
Ileus  0 5 (1.2%)  
Pneumonia 3 (4.3%) 11 (2.6%)  
Pleural effusion 1 (1.4%) 4 (0.9%)  
Myocardial infarction 1 (1.4%) 2 (0.5%)  
Wound infection 1 (1.4%) 11 (2.6%)  
Renal failure 2 (2.9%) 7 (1.6%)  
Post-operative haemorrhage 0 4 (0.9%)  
Peritonitis 0 2 (0.5%)  
Ascites 1 (1.4%) 8 (1.9%)  
Biliary stricture/stenosis 0 4 (0.9%)  
Multi-organ failure 1 (1.4%) 4 (0.9%)  
Pneumothorax 0 2 (0.5%)  
Urinary tract infection 2 (2.9%) 6 (1.4%)  
Atrial fibrillation 3 (4.3%) 2 (0.5%)  
Other 2 (2.9%) 12 (2.8%)  
Analgesia-related morbidity (all), n (%) 29 (45.3%) 169 (41.4%) 0.558 
Pruritus 14 (20.3%) 92 (21.4%)  
Hallucinations 7 (10.1%) 80 (18.6%)  
Dizziness 4 (5.8%) 32 (7.5%)  
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 Epidural group 
(n = 69) 
CIB + PCA group 
(n = 429) 
P-value 
Hypotension requiring treatment 5 (7.2%) 0  
Acute confused episode 3 (4.3%) 4 (0.9%)  
Wound infection 1 (1.4%) 11 (2.6%)  
Urinary retention 0 3 (0.7%)  
Sedation score PoD 1    
0 37 (82.2%) 215 (59.9%) 0.004 
1 8 (17.8%) 129 (35.9%) 0.015 
2 0 15 (4.2%) 0.392 
CIB PCA, i.m. continuous infusion of bupivacaine plus i.v. patient-controlled analgesia; PoD, post-operative 
day. A P-value of 0.05 was considered to indicate statistical significance. 
Other complications include: haematoma at resection area (n 1), transient ischaemic attack (n 1), Horner's 
syndrome (n 1), pulmonary embolism (n 1), respiratory failure (n 1), alcohol withdrawal (n 1), deep vein 
thrombosis (n 1), infected line (n 1), allergic reaction (n 1), sacral pressure sore (n 1), cellulites (n 1), partial 
portal vein thrombosis (n 1), axillary nerve palsy (n 1) and cerebral infarct (n 1). 
 
An increased need for rescue medication in the CIB +PCA group was observed. In 
most patients rescue medication was given on the day of surgery (PoD 0), but this 
was countered by an increased need for rescue medication and a switch to i.v. opi-
oids in the CEA group on PoDs 1–3. In addition, CIB + PCA was continued for 1 day 
longer than epidural analgesia. This mainly reflects the practicalities of managing 
epidurals, as it is part of post-operative practice to remove the catheter after 72 h 
unless otherwise clinically indicated. The high percentage (53.1%) of patients requir-
ing rescue medication may be explained by the possibility that the local analgesic 
effect of the bupivacaine infusion may have been suboptimal directly after surgery. 
The epidural analgesia was started prior to the incision, whereas the wound catheters 
were commenced immediately after wound closure. It may take time for bupivacaine 
to reach all adjacent tissue and associated nerve endings. Unlike a correctly function-
ing epidural analgesic, which provides a complete block, bupivacaine infusion exhib-
its only a local effect and additional opioids may be required. 
Another important result refers to the finding that when one of the catheters was 
dislodged or occluded (often by a faulty connector or by the faulty insertion of the 
catheter into the connector), pain control was adequately maintained by just one 
catheter. This is supported by the stagnant opioid consumption on PoDs 2 and 3 
with adequate maintenance of pain control. This implies that a single infusing cathe-
ter combined with PCA may be sufficient to control post-operative pain. 
The findings of this study are in keeping with those of earlier reports on the benefi-
cial results of this technique with regard to pain control, opioid consumption and 
recovery.[16,19,24,33] It has been claimed that epidural analgesia is superior to PCA 
for post-operative pain relief in patients recovering from major upper abdominal 
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operations.[10,11] However, the present study shows that when PCA is combined 
with CIB via i.m. catheters, equivalent pain control can be achieved. As Khorgami et 
al.[34] demonstrated in a recent RCT, the technique of local interfascial analgesia is 
also feasible for midline incisions. 
The present results confirm the clinical applicability of wound catheters. Not only 
does this analgesic approach provide equivalent pain control with reduced opioid 
intake, but it also represents a quicker and very likely cheaper method of doing so. 
Abandoning the use of epidural analgesia eliminates the risk for epidural-related 
complications (haematoma, abscess and nerve damage) and may improve cost-
effectiveness as anaesthetic time may be shortened and the CIB + PCA combination 
does not require specialist supervision on the ward. The lower total opiate dose re-
ceived may also reduce opiate-associated side effects. In patients in whom experts 
aim to achieve faster post-operative recovery within the context of an ERAS pro-
gramme, the use of CIB + PCA may result in a further reduction in the time required 
to meet recovery criteria. The partly retrospective design of this study resulted in the 
incomplete availability of pain scores. The complete availability of pain data might 
have altered the comparability of the groups and might have implied an increased 
superiority or inferiority of either of the two analgesic modalities. In addition, an 
inherent bias of surgeon preference influencing outcomes cannot be excluded. The 
strengths of this study include its use of a large and uninterrupted cohort of patients 
submitted to major liver resection in an expert centre, whereas other prospective 
series are considerably smaller. The patients investigated in this study represent a 
population at risk for post-operative coagulopathy and the development of epidural 
hematoma. It would be interesting for future research to compare patient-controlled 
epidural analgesia with CIB + PCA and to look into the number and location of 
wound catheters needed to achieve the optimal local analgesic effect. Lastly, it 
would be interesting to compare the local wound infusion technique with that of the 
transversus abdominis plane block[35], which can also be regarded as safe and effec-
tive after abdominal surgery. 
CONCLUSION 
Continuous i.m. bupivacaine infusion with i.v. PCA provides equivalent pain control 
and a lower level of opioid consumption compared with CEA following major hepa-
tectomy. The CIB + PCA technique could replace that of epidural analgesia with the 
potential for greater safety, improved post-operative outcomes and a reduced hospi-
tal LoS. 
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Appendix 1.   
The following (combined) procedures were performed only twice in the study cohort: 
 Cholecystectomy + biliodigestive anastomosis, skeletonization of the hepatoduodenal ligament, closure 
of ileostomy, block dissection of the hepatoduodenal ligament, cava resection, node block dissection of 
the lesser sac, diaphragm + peritoneal nodule resection, cholecystectomy + hepatoduodenal ligament 
biopsy, deroofing of a liver cyst and excision of peritoneal deposits not in the lesser sac. 
 
The following (combined) procedures were performed only once in the study cohort:  
En bloc gastric resection + cholecystectomy, block dissection of the hepatoduodenal ligament + 
diathermy ablation, excision of aortocaval lymph node + peritoneal deposit resection, skeletonization of 
the hepatoduodenal ligament + Roux loop biliary reconstruction + cholecystectomy, block dissection of 
the lesser sac + excision of the common bile duct + Roux loop reconstruction, colon excision + 
cholecystectomy, reconstruction of the v. cava, right hemicolectomy + diathermy ablation, sleeve 
resection of the duodenum, posterior pelvic extenteration, en bloc total mesorectal excision + 
appendicectomy + excision of a mesenteric mass, diaphragm resection and repair of two incisional 
hernias, cholecystectomy + excision of the greater omentum, exploration of common bile duct + 
removal of a stone, splenectomy, insertion of terminal ileostomy, gastroduodenal ligament + 
cholecystectomy, vascular reconstructions, nephrectomy + adrenalectomy, block dissection of the lesser 
sac + excision of common bile duct + Roux loop reconstruction + repair of an incisional hernia, 
reconstruction of the bile duct, small bowel resection, small bowel biopsy and resection of part of the 
diaphragm and lung. 
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ABSTRACT 
BACKGROUND 
Routine prophylactic abdominal drainage after hepatic surgery is still debated, may 
be unnecessary, possibly harmful and uncomfortable for patients. This study evaluat-
ed the safety of a no-drain policy after liver resection within an ERAS- programme. 
 
METHODS 
All hepatectomies performed without prophylactic drainage during 2005 – 2014 
were included. Primary endpoints were resection-surface-related (RSR) morbidity, 
defined as the presence of post-operative biloma, haemorrhage or abscess, and rein-
terventions. Secondary endpoints were length of stay (LOS), total post-operative 
morbidity, the composite endpoint of liver surgery-specific complications, readmis-
sions and 90-day mortality. Uni- and multivariable analyses were performed to identi-
fy independent risk factors for RSR-morbidity. A systematic search was performed to 
compare the results of this study to literature. 
 
RESULTS 
A total of 538 resections were included in the study. The RSR-complication and rein-
tervention rate was 15% and 12%, respectively. Major liver resection (≥3 segments) 
was an independent risk factor for the development of RSR-morbidity (OR=3.01, 95% 
CI 1.61– 5.62; P=0.001) and need for RSR-reintervention (OR=3.02, 95% CI 1.59–5.73; 
P=0.001). 
 
CONCLUSION 
RSR-morbidity, mortality and reintervention rates after liver surgery without prophy-
lactic drainage in patients, treated within an ERAS programme, were comparable to 
previously published data. A no-drain policy after partial hepatectomy seems safe 
and feasible. 
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INTRODUCTION 
In the past decades, the quality of perioperative care for hepatic surgery has im-
proved dramatically due to improvements in surgical technique, risk assessment and 
perioperative care. Prophylactic intra-abdominal drainage is still routinely applied in 
many hospitals worldwide. However, prophylactic intra-abdominal drainage may be 
unnecessary[1], uncomfortable and even harmful for the patient. As early as 1915, 
the British surgeon Major Grey Turner already pointed out the dangers of routine 
drain use. One hundred years later, the routine use of prophylactic drains in liver 
surgery is still an on-going debate.[2] 
Some studies have reported advantages of prophylactic drain placement such as 
early drainage of bile leaks, preventing subphrenic collection, detecting post-
operative haemorrhage and removing ascites.[3-6] Other studies have indicated that 
the risks of prophylactic intra-abdominal drains, including drain-related bleeds, as-
cending intra- abdominal infections by retrograde contamination and impaired pul-
monary function, outweigh the benefits.[1, 7, 8] Furthermore, patients with a drain in 
place experience more abdominal pain and discomfort, have more difficulties to 
mobilize, need more nursing care and this could contribute to a longer admission 
and increased costs.[7] 
Currently, if used, drains are usually placed near the transection surface or in the sub-
phrenic space, and are often removed on post-operative day (POD) 3 to 5 depending 
on drain production.[7, 9, 10] Already in 2007, a meta-analysis [11] showed that there 
were no significant differences in morbidity, mortality and reoperation rates between 
patients with or without a prophylactic abdominal drain after uncomplicated elective 
hepatectomy. Post-operative mortality in patients undergoing liver surgery without a 
drain ranges between 0–3%. Percutaneous or operative reintervention rates in pa-
tients without a drain range from 0–18% and 0–10% respectively[1, 4, 7, 8, 12-14], and 
do not differ from outcomes after placement of an abdominal drain. Patients with a 
drain have reported mortality, percutaneous reintervention and reoperation rates 
between 0–6%, 0–36% and 0–6%, respectively.[1, 4, 7, 8, 12-14] The accumulating 
evidence suggests that routine abdominal drainage after liver resection is unneces-
sary and the benefit arguable, but it may be indicated in specific patients. 
The Enhanced Recovery After Surgery (ERAS) programme has shown a benefit for 
patient recovery after liver surgery in recent years.[15-17] The programme has been 
implemented to optimize pre-, peri- and post-operative care to facilitate a quicker 
recovery. With the introduction of this programme, the routine use of drains after 
liver surgery without biliary or vascular reconstruction has been abandoned.[15-17] 
Chapter 6 
104 
The aim of this study was to examine the post-operative complication and reinter-
vention rates in patients undergoing liver resection that were treated without 
prophylactic drains in an ERAS environment, to identify risk factors associated with 
reinterventions for specific complications and to compare the results to earlier stud-
ies on drainage following liver resection. 
METHODS 
STUDY DESIGN 
All patients undergoing hepatic resection between January 2005 and December 
2014 at Maastricht University Medical Centre (MUMC) were included in a prospective 
database. Patients were retrospectively identified and screened for eligibility in this 
study. Patients were excluded if a prophylactic abdominal drain was placed, e.g. in 
the case of hepatic resection traumatic lesions, or if a bilioenteric anastomosis was 
created. Primary endpoints of this study were RSR-morbidity and reinterventions for 
RSR-morbidity. RSR-morbidity was defined as the presence of bile leakage, intra-
abdominal abscess or/and haemorrhage.[18] Reinterventions for RSR-morbidity were 
considered to be CT- or US- guided percutaneous drainage, reoperation and ERCP 
with stenting. Data on reinterventions were retrospectively collected from individual 
patient charts. Secondary endpoints were hospital length of stay (LOS), post-
operative morbidity, readmission rate, 90-day mortality and the composite endpoint 
of liver surgery-specific complications (CEP). A composite endpoint consists of 2 or 
more specific complications that can be regarded as 1 dichotomous endpoint that 
occur in 1 patient. The liver surgery-specific CEP consists of ascites, postresectional 
liver failure, bile leakage, intra-abdominal haemorrhage, intra-abdominal abscess 
and/or post-operative mortality.[19] 
SURGICAL TECHIQUES 
All hepatic resections were performed by 1 of 4 hepatobiliary surgeons (CHCD, 
RMvD, SWMOD, MHB) or by a senior resident/fellow under the supervision of a 
hepatobiliary surgeon. Hepatectomies were performed as open or laparoscopic pro-
cedures as published previously.[20] 
For open procedures, a unilateral right subcostal, a bilateral subcostal (right extend-
ed to left), J-shaped or midline incision was used. Intraoperative ultrasound was rou-
tinely performed to examine the location of lesions in the liver and the relation to 
surrounding biliary and vascular structures. Hepatic resection was performed by 
using a Cavitron Ultrasonic Surgical Aspirator (CUSA system 200 macrodissector, 
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Cavitron Surgical Systems, USA) and Argon beam coagulation (Force GSU System, 
Valleylab, USA), with or without Pringle’s manoeuvre. Ultracision Harmonic ACE (Eth-
icon Endosurgery, Johnson & Johnson, USA). Central venous pressure was main-
tained ≤5 cm H2O during transection to reduce excessive blood loss. During transec-
tion, clips and ligatures were used to treat vessels and bile ducts at the resection 
surface. To avoid post-operative haemorrhage and bile leakage, the resection surface 
was treated with argon beam coagulation and or sealants at the discretion of the 
surgeon, although the effectiveness has never been proven.[18] 
For laparoscopic procedures patients were placed in supine French position. Access 
to the abdomen was created by open transumbilical insertion of a 30° laparoscope. 
Three or four additional trocars were inserted. The pressure of the pneumoperitone-
um was kept <12 mmHg. Parenchymal transection was performed using the Ligasure 
5mm blunt tip (Covidien, USA) laparoscopic CUSA (Cavitron Surgical Systems, USA) or 
Harmonic scalpel (Ultracision, Ethicon Endosurgery, Johnson & Johnson, USA). The 
portal pedicles were stapled using a vascular stapler (EndoGIA Autosuture, Covidien, 
USA). Resected specimens were placed in a plastic bag (Endocatch Autosuture, 
Covidien, USA) and removed through a separate usually suprapubic muscle sparing 
incision. 
NO-DRAIN POLICY 
Since the introduction of ERAS in liver surgery in 2005, the MUMC has a no- drain 
policy; abdominal drains are no longer part of standard management after hepatec-
tomy. The use of prophylactic abdominal drains was limited to a selected group of 
indications. They were routinely placed after the creation of bilioenteric anastomoses 
or biliary reconstructions and in the case of traumatic liver lesions. In some cases, 
placement of a prophylactic abdominal drain could be considered by the surgeon 
when a high risk of intra- abdominal fluid collection was expected, e.g. when per-
forming combined procedures, in the case of intra-operative iatrogenic laceration 
that required drainage, repeat hepatectomies, excessively large resection surfaces or 
central liver resections. Furthermore, all patients were treated within the ERAS pro-
gramme. Key principles of this programme have been previously described.[21] Pa-
tients were closely monitored during hospitalization based on clinical presentation, 
vital parameters and standard diagnostic laboratory results. Additional imaging (CT 
or US) was only performed on clinical findings indicative of post-operative complica-
tions. All complications, defined as any deviation from the expected post-operative 
course <30 days and graded according to the Dindo-Clavien classification sys-
tem[22], were recorded in the electronic patient record system and in a prospectively 
maintained research database. Data from the electronic patient record system and 
the research database were crosschecked for missing data. 
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SYSTEMATIC LITERATURE SEARCH 
A systematic search was conducted to compare the results of this study with litera-
ture following the current recommendations of Preferred Reporting Items for Sys-
tematic Reviews and Meta-analysis Approach (PRISMA). Two authors (E.M.W.-L.-H. 
and V.W.) independently performed the search, study selection, data extraction and 
critical appraisal of the studies. 
Eligibility criteria 
After review of the abstract, the remaining studies were selected for full- text evalua-
tion and inclusion, if: 1) The subject of the study was comparison of the routine use of 
an abdominal drain versus no-drainage after hepatectomy; 2) the study was not an 
editorial, systematic review or meta-analysis; 3) the study compared clinical outcome 
after abdominal drain versus no-drainage after hepatectomy; and 4) the study was in 
the English language. 
Study selection and quality appraisal 
The search was conducted in Ovid MEDLINE, Embase, PubMed databases to identify 
all studies comparing the routine use of an abdominal drain versus no-drainage after 
hepatectomy between 1st January 1990 and 31st December 2014. The following 
search strategy was used: ([[“Hepatectomy”[Mesh] OR “liver resection” OR “liver sur-
gery”]] AND [“Drainage”[Mesh] OR “drain*”] NOT [“preoperative drainage” OR “pre-
operative biliary drainage”]). After removal of duplicates, articles were screened by 
title, abstract and subsequently full text. In addition, reference lists of all included 
studies were screened for missed but relevant studies. The methodological quality 
and risk of bias of the studies was assessed using the Cochrane Handbook for Sys-
tematic Reviews.[23] All included studies were consequently graded by using the 
Oxford Centre for Evidence-Based Medicine levels of evidence.[24] Furthermore, 
clinical trial registers were searched for ongoing studies. 
Data collection 
Two reviewers (E.M.W.-L.-H. and V.W.) independently extracted data from the select-
ed studies on study design, participant characteristics, mortality, image-guided 
drainage, reoperation, bile leakage / fistula, infected collections, post-operative 
bleeding and wound infection. 
STATISTICAL ANALYSIS 
Continuous data are described as median (range) and categorical data are presented 
as percentages. The Chi-square / Fisher’s exact and Mann-Whitney U tests were used 
to compare categorical data and continuous data, respectively. Results were consid-
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ered significant when P ≤ 0.05. Uni- and multivariable analyses were performed to 
define specific independent risk factors for RSR-reinterventions. Variables included in 
the univariable analysis: sex, ASA class ≥III, age <65  or ≥70 years, median BMI, type of 
liver resection (major, caudate, repeat, central), blood loss >2,000 ml, preoperative 
chemotherapy, Pringle manoeuvre and operating time >240 min. Multivariable anal-
ysis was performed with binary logistic regression and P ≤ 0.10 was used to select 
variables from univariable analysis. All statistical analyses were performed using IBM 
SPSS Statistics for Windows, Version 20.0. (Armonk, NY, USA: IBM Corp.). 
RESULTS 
GENERAL AND SURGICAL CHARACTERISTICS 
A total of 606 hepatic resections were performed in the study period. All 66 patients 
that received a drain were excluded from further analysis. Details of this drain group 
will be addressed later in this section. Furthermore, two patients with missing data 
were excluded from analysis. A total of 538 patients were analysed. General and sur-
gical characteristics are shown in Table 1. 
PRIMARY OUTCOME 
Seventy-nine (15%) of the 538 patients without a drain developed post-operative 
RSR-complications. Sixty-seven (12%) of these patients required surgical, radiological 
or endoscopic reintervention (Table 2). 
Of the variables included in the univariable analyses (Table 3,4), only age <65 years, 
major liver resection, blood loss >2000 ml, Pringle manoeuvre, operating time >240 
minutes, and preoperative chemotherapy were significantly (P<0.1) associated with 
the development major RSR-morbidity (≥Dindo-Clavien grade 3a) or the need for 
post-operative RSR-reinterventions. After multivariable analyses major liver resection 
was an independent risk factor (OR = 3.01, 95% CI 1.61–5.62; P=0.001) for the devel-
opment of major RSR-morbidity, and was also associated with an increased risk of 
RSR-reinterventions (OR = 3.02, 95% CI 1.59–5.73; P=0.001). 
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Table 1. Baseline patient and surgical characteristics 
 All patients 
N=538 (%) 
Sex (male) 308 (57) 
Age, years 64 (55-70) 
BMI, kg/m2 25.6 (22.9-28.5) 
ASA physical status  
I  85 (16) 
II  339 (63) 
≥III 114 (21) 
Indications  
Colorectal metastasis 421 (78) 
Benign lesions 47 (9) 
Other malignancy 29 (5) 
HCC 24 (5) 
Gallbladder carcinoma 7 (1) 
CCC  5 (1) 
Other  5 (1) 
Preoperative chemotherapy 271 (50) 
Resection Type  
<1 segment/ metastasectomy 213 (40) 
Multisegmentectomy 173 (32) 
Right hemihepatectomy 74 (14) 
Right hemihepatectomy + 1 segment 31 (6) 
Left hemihepatectomy 16 (3) 
Left hemihepatectomy + 1 segment 2 (0.4) 
Right extended hemihepatectomy 12 (2) 
Left extended hemihepatectomy 3 (0.6) 
Central resection 18 (3) 
Caudate lobe resection 25 (5) 
Major hepatectomy (≥3 segments) 226 (42) 
Repeat hepatectomy 57 (11) 
Total operating time, min 200 (150-270) 
Intraoperative blood loss, ml 500 (269-1000) 
Pringle 118 (22) 
Values in parentheses are percentages, unless indicated otherwise. Numeric data are presented as median 
(interquartile range). BMI, Body Mass Index. ASA, American Society of Anaesthesiologists. HCC, Hepatocel-
lular carcinoma. CCC, Cholangiocellular carcinoma.  
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Table 2. Primary endpoints 
 All patients 
N=538 (%) 
Resection surface-related (RSR) complication rate 79 (15) 
All surgery-related complication rate 90 (20) 
Bile leakage (RSR)  35 (7) 
Haemorrhage (RSR) 9 (2) 
Intra-abdominal abscess (RSR) 44 (8) 
Ascites 12 (2) 
Post-operative liver failure 17 (3) 
Pleural effusion 18 (3) 
Sepsis 15 (3) 
Wound infection 28 (5) 
Reintervention rate for RSR complications 67 (12) 
Reintervention rate 72 (13) 
CT drainage 55 (10) 
ECRP with stenting 9 (2) 
US drainage  8 (2) 
Relaparotomy 11 (2) 
Relaparoscopy 1 (0.2) 
Thoracotomy 1 (0.2) 
Thoracic drainage 8 (2) 
Values in parentheses are percentages.  
Multiple complications or reinterventions per patient were possible. 
A total of 178 surgery-related complications occurred in 90 patients. 
A total of 93 reinterventions occurred in 72 patients.  
RSR, Resection surface-related. CT, Computer Tomography. ERCP, Endoscopic Retrograde Cholangiopan-
creaticography. US, Ultrasound. 
SECONDARY OUTCOME MEASURES 
The median LOS was 8 days (6-11). Fifty patients (9%) were readmitted within 30 days 
after surgery (Table 5). Mortality within 90 days after surgery was observed in fifteen 
patients (2.8%). Within this group, five patients died from sepsis following an intra-
abdominal abscess or biloma, three patients died from multi-organ failure induced 
by postresectional liver failure, three patients died from extensive extra-hepatic met-
astatic disease and subsequent multi-organ failure and four patients died of an acute 
cardiac arrest of which one was proven in autopsy to be caused by myocardial infarc-
tion. 
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Table 5. Secondary outcomes 
 All patientsN=538 (%) 
Readmission rate 50 (9) 
Length of stay, days 8 (6-11) 
Dindo-Clavien classification  
Grade 1 33 (6) 
Grade 2 71 (13) 
Grade 3a 55 (10) 
Grade 3b 12 (2) 
Grade 4 14 (3) 
Grade 5 (30-day mortality) 13 (2) 
All reported post-operative morbidity 202 (38) 
Major morbidity ≥ Dindo-Clavien 3a  92 (17) 
Major RSR morbidity ≥ Dindo-Clavien 3a 70 (13) 
Liver surgery-specific CEP 84 (16) 
90-day mortality 15 (2.8) 
Liver related 90-day mortality  13 (2.4) 
Values in parentheses are percentages, unless indicated otherwise. Numeric data are presented as median 
(interquartile range). RSR, Resection surface-related. CEP, liver surgery-specific composite endpoint (asci-
tes, postresectional liver failure, bile leakage, intra-abdominal haemorrhage, intra-abdominal abscess and 
operative mortality). 
PROPHYLACTIC ABDOMINAL DRAIN GROUP 
Sixty-six patients received a prophylactic abdominal drain and were excluded from 
this study. Among them were twenty-five patients that required a drain after a bili-
oenteric anastomosis or another form of biliary reconstruction was created. One 
patient received a drain after liver surgery for a traumatic lesion. Eight patients ob-
tained a drain because of a difficult repeat hepatectomy. Seven patients received a 
drain for combined procedures (four colorectal resections, two pancreatic resections 
and one kidney resection). In five patients a drain was placed after intraoperative 
iatrogenic lesions of the bile duct, pancreas or spleen. Central resections and large 
resection surfaces after surgery were indications for drain placement in nine patients. 
Vascular involvement required drain placement in two patients. Two patients with 
liver cirrhosis received a prophylactic drain after surgery because of an expected high 
risk of ascites and subsequent infection. Another two patients received a drain in 
early 2005 because of protocol deviation by the surgeon. Lastly, in five patients an 
abdominal drain was placed without any specified indication. In this selected drain 
group, excluded from analysis, morbidity and mortality were high (10.0% mortality, 
30.0% RSR-morbidity, 37.5% major morbidity, 27.5% reinterventions). 
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LITERATURE REVIEW 
The PRISMA flow diagram of the literature search and inclusion of relevant studies is 
shown in Figure 1. The search resulted in 27 studies that were assessed for eligibility. 
Finally, ten studies, including five RCT’s and five cohort studies (two prospective and 
three retrospective series), were used to compare the results with those of the pre-
sent study. The majority of studies included all types of liver resection, except two 
RCT’s that only included patients with an underlying liver disease or a hepatocellular 
carcinoma in cirrhotic livers. Four studies[1, 4, 7, 8] were graded as level 1b evidence, 
one study[13] was grade level 2b evidence, and the remaining studies[5, 12, 25-27] 
were cohort studies of grade 4 evidence. No ongoing studies could be identified in 
clinical trial registers. Table 6 shows a comparison of this study with results from liter-
ature. 
DISCUSSION 
The use of post-operative drains after liver resection is still subject of debate. This 
study evaluated a no-drain policy, as part of the ERAS programme, in a tertiary refer-
ral centre during 2005–2014. Implementation of a no-drain policy has resulted in an 
overall surgical morbidity rate of 20%, RSR-complication rate of 15% and RSR-
reintervention rate of 12%. 
This implies that 88% of all patients did not require any form of abdominal drainage 
in the post-operative phase. By not placing a prophylactic drain, they were spared 
from possible discomfort and harmful drain-related complications. Moreover, in the 
group of patients that did have an intra-abdominal collection, the majority of them 
could be treated well with CT- or US-guided drainage and rarely a reoperation was 
necessary, as is shown in Table 2. 
Comparison of results of this study with earlier publications, mainly summarized by 
Gurusamy et al.[11], confirms the safety and feasibility of the no-drain policy. The 90-
day mortality of 2.8% in this study was within the ranges reported in the literature for 
this type of liver surgery.[1, 4, 7, 8, 11, 13, 14]. Reintervention rates of previous stud-
ies[1, 4, 7, 8, 11, 13, 14] vary considerably in studies of both drain and no-drain 
groups. To date, there is no evidence that abandoning prophylactic drainage in-
creases the need for (radiological) reinterventions.[11] The RSR-reintervention rate of 
12% in this study demonstrates that a no-drain policy does not lead to more reinter-
ventions, higher morbidity or mortality compared to patient with a drain.[1, 4, 5, 7, 8, 
12, 13, 27] 
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Major liver resection is a known risk factor for post-operative complications[12, 13, 
28- 35]. In this study it was identified in multivariable analysis as an independent risk 
factor for RSR-significant morbidity and RSR-reinterventions. Other known intra- 
 
 
Figure 1. PRISMA flow diagram of the literature search and inclusion of relevant studies 
operative predictive determinants, such as prolonged operating time[12, 13, 28, 31, 
33, 35], repeat hepatectomy[35-37] and the use of Pringle manoeuvre[31, 38], were 
not confirmed in this cohort. Preoperative risk factors that have been suggested in 
preceding literature, among which are the presence of significant comorbidities / 
ASA III-IV[28-30, 32, 39], an abnormal liver function[13, 28, 30] and chemotherapy[40], 
were also not confirmed. The fact that major liver resection was found as a risk factor, 
does not mean that a prophylactic drain needs to be placed routinely. It suggests 
that there is a subset of patients in which routine post-operative imaging or an ag-
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gressive post-operative imaging strategy needs to be considered. When there is a 
clinically relevant intra-abdominal collection on ultrasound or CT, a therapeutic radi-
ologically-guided drain can then be placed. 
The expertise with and access to radiological reinterventions may vary substantially 
between institutions, it has changed over time in hospitals worldwide and it could be 
an important factor. In centres in which radiological reinterventions are less frequent-
ly performed, more collections may be inadequately drained. This could lead to a 
higher reoperation rate. When compared with patients receiving a drain in other 
studies, the patients from the present study had a low reoperation rate. This may 
imply that a no-drain placement policy does not lead to more reoperations. Finally, 
hospital length of stay in other studies was longer.[41] The ERAS-programme could 
explain this faster recovery.[21, 42] 
This study has several strengths that add to the existing body of evidence of RCT’s 
and a meta-analysis on the studied topic. An important strength of this study is the 
large cohort size. A total of 538 consecutive patients were treated without a drain 
after implementation of the no-drain policy. As is demonstrated in Table 6, this no-
drain cohort is one of the largest cohorts on the subject. In addition, the group of 
excluded patients with prophylactic drain placement is well described and provides 
detailed insight in the selection process. Furthermore, patients with bilioenteric anas-
tomoses were excluded from analysis to enable comparison with previously pub-
lished studies[7, 8, 13]. Among these patients, leakage rates are high, and may con-
found general results. Another strength of this study is the fact that uni- and multi-
variable analyses were performed for the identification of risk factors for surface-
related morbidity. This can aid in the decision making process of abandoning the use 
of drains after liver surgery. Lastly, all patients were prospectively registered and 
treated within an ERAS programme consisting of standardized care elements. The 
minimal use of prophylactic drains is an important element in ERAS programmes and 
this study advocates a no-drain policy after uncomplicated liver surgery. Drains are 
thought to affect post-operative mobility and pain control and drains could hamper 
a swift recovery in uncomplicated cases.
Ta
bl
e 
6.
 R
es
ul
ts
 o
f p
re
vi
ou
s 
st
ud
ie
s 
(R
CT
s 
an
d 
co
ho
rt
 s
tu
di
es
) c
om
pa
rin
g 
th
e 
us
e 
of
 a
bd
om
in
al
 d
ra
in
ag
e 
af
te
r h
ep
at
ec
to
m
y.
  
A
ut
ho
r 
Pe
rio
d 
Ty
pe
 o
f 
su
rg
er
y 
St
ud
y 
ty
pe
 
Ev
id
en
ce
 
le
ve
l 
Ri
sk
 o
f 
bi
as
 
A
rm
 
N
 
M
or
ta
lit
y 
(%
) 
CT
 o
r U
S 
dr
ai
n 
(%
) 
Re
-o
pe
ra
tio
n 
(%
) 
Bi
le
 le
ak
ag
e/
 
fis
tu
la
 
(%
) 
In
fe
ct
ed
 
co
lle
ct
io
n 
(%
) 
Po
st
op
. 
Bl
ee
di
ng
 
(%
) 
W
ou
nd
 
in
fe
ct
io
n 
(%
) 
Be
lg
hi
ti 
et
 a
l. 
[1
] 
19
90
 - 
19
91
 
A
 
1 
1b
 
Lo
w
 
D
 
42
 
2.
4 
35
.7
 
2.
4 
4.
8 
14
.3
 
4.
8 
N
A
 
N
D
 
39
 
2.
6 
15
.8
 
2.
5 
5.
1 
5.
3 
2.
5 
N
A
 
Fo
ng
 e
t a
l. 
[1
3]
 
19
92
 - 
19
94
 
A
 
1 
2b
 
U
nc
le
ar
 
D
 
60
 
3.
3 
8.
3 
1.
6 
5.
0 
5.
0 
0 
6.
6 
N
D
 
60
 
3.
3 
18
.3
 
0 
5.
0 
0 
0 
3.
3 
Bu
rt
 e
t a
l. 
[1
2]
 
19
94
 - 
20
00
 
A
 
3 
4 
H
ig
h 
D
 
18
4 
7.
1 
26
.1
 
N
A
 
N
A
 
16
.3
 
N
A
 
N
A
 
N
D
 
98
1 
2.
0 
10
.5
 
N
A
 
N
A
 
3.
1 
N
A
 
N
A
 
Fu
st
er
 e
t a
l. 
[4
] 
19
91
 -
19
97
 
B 
1 
1b
 
Lo
w
 
D
 
20
 
0 
0 
0 
N
A
 
0 
0 
0 
N
D
 
20
 
0 
10
 
5 
N
A
 
10
 
0 
15
 
Li
u 
et
 a
l.[
 7
] 
19
99
 - 
20
02
 
C 
1 
1b
 
Lo
w
 
D
 
52
 
5.
8 
3.
8 
5.
8 
3.
8 
3.
8 
1.
9 
19
.2
 
N
D
 
52
 
1.
9 
0 
1.
9 
0 
0 
0 
11
.5
 
A
ld
am
eh
 e
t a
l.[
5]
 1
99
9 
- 
20
02
 
A
 
3 
4 
H
ig
h 
D
 
12
6 
1.
6 
1.
6 
N
A
 
3.
2 
2.
4 
N
A
 
6.
3 
N
D
 
85
 
1.
2 
4.
7 
N
A
 
3.
5 
1.
2 
N
A
 
16
.5
 
Su
n 
et
 a
l.[
 8
] 
20
04
 - 
20
05
 
A
 
1 
1b
 
Lo
w
 
D
 
60
 
0 
6.
7 
1.
7 
0 
3.
3 
2.
0 
5.
0 
N
D
 
60
 
1.
7 
5.
0 
0 
0 
0 
0 
3.
3 
Lu
 e
t a
l.[
 2
7]
 
20
02
 - 
20
04
 
A
 
3 
4 
H
ig
h 
D
 
35
7 
0.
6 
5.
6 
0.
3 
1.
7 
2.
0 
0.
8 
3.
4 
N
D
 
10
5 
0 
3.
8 
0 
0 
1.
0 
1.
0 
0 
Bu
tt
e 
et
 a
l. 
[2
6]
 
20
07
 - 
20
14
 
A
* 
2 
4 
H
ig
h 
D
 
87
 
4.
6 
8 
N
A
 
4.
6 
N
A
 
N
A
 
N
A
 
N
D
 
11
2 
0 
8 
N
A
 
4.
5 
N
A
 
N
A
 
N
A
 
Br
oo
ke
-S
m
ith
 e
t 
al
. [
25
] 
20
10
 - 
20
11
 
A
 
2 
4 
H
ig
h 
D
 
60
3 
N
A
 
9.
2 
N
A
 
11
 
N
A
 
N
A
 
N
A
 
N
D
 
34
5 
N
A
 
5.
8 
N
A
 
1 
N
A
 
N
A
 
N
A
 
Pr
es
en
t s
tu
dy
 
20
05
 - 
20
15
 
A
 
3 
4 
H
ig
h 
N
D
 
53
8 
2.
6 
12
.0
 
2.
1 
6.
2 
7.
7 
2.
3 
5.
7 
D
, D
ra
in
ag
e 
gr
ou
p.
 N
D
, N
on
-d
ra
in
ag
e 
gr
ou
p.
 N
A,
 N
ot
 A
va
ila
bl
e.
 C
T,
 C
om
pu
te
r T
om
og
ra
ph
y.
 U
S,
 U
ltr
as
ou
nd
.  
H
ep
at
ic
 re
se
ct
io
n:
 (A
) A
ll 
he
pa
tic
 re
se
ct
io
ns
, (
B)
 A
ll 
he
pa
tic
 re
se
ct
io
ns
 fo
r h
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a 
in
 c
irr
ho
tic
 p
at
ie
nt
s,
 (C
) A
ll 
he
pa
tic
 re
se
ct
io
ns
 in
 p
at
ie
nt
s 
w
ith
 c
hr
on
ic
 li
ve
r d
is
ea
se
.  
 
Ty
pe
: (
1)
 R
an
do
m
iz
ed
 c
on
tr
ol
le
d 
tr
ia
l (
RC
T)
, (
2)
 P
ro
sp
ec
tiv
e 
co
ho
rt
 s
tu
dy
, (
3)
 R
et
ro
sp
ec
tiv
e 
co
ho
rt
 s
tu
di
e.
 #
 L
ev
el
 o
f e
vi
de
nc
e:
 a
cc
or
di
ng
 to
 th
e 
O
xf
or
d 
Ce
nt
re
 fo
r E
vi
de
nc
e-
Ba
se
d 
M
ed
ic
in
e[
24
]
Chapter 6 
116 
Prophylactic abdominal drainage after hepatic surgery 
117 
The retrospective analysis of prospectively collected data is a limitation of this study. 
Although all liver resections in the study period were registered, the final results may 
have been prone to a form of selection bias, because a small subset of patients was 
excluded from analysis. This excluded group received an abdominal drain by discre-
tion of the operating surgeon within the studied period. Although no biliary recon-
structions were performed in these patients, drains were placed because of major 
combined procedures, major central liver resections, intraoperative leaks of the bile 
duct, pancreatic damage and repeat hepatectomy. 
The findings of this cohort study confirm the findings of available RCT’s[4, 7, 13] and 
a Cochrane review[11] that routine drainage after uncomplicated liver resection is 
not necessary. The results of this study show that a no-drain policy is safe and feasi-
ble after liver surgery within an ERAS environment. Placement of a prophylactic drain 
is unlikely to prevent reinterventions for complications and a no-drain policy seems 
justified in the majority of patients. At most, placement of a drain allows liver sur-
geons to detect complications in an earlier phase, but routine placement subjects a 
large group of patients to potential risks and discomfort. Further studies are still nec-
essary and should focus on specific patient groups with predefined risk factors (e.g. 
underlying liver disease, major resections, biliary reconstructions, intraoperative 
blood loss and operating time) or should validate risk factors. 
CONCLUSION 
A selective no-drain policy within an ERAS environment resulted in a rate of post-
operative complications, reinterventions and mortality that is comparable to previ-
ously published studies. The routine use of prophylactic abdominal drains after liver 
surgery therefore seems unnecessary. In patients that undergo a major liver resec-
tion, which is an independent risk factor for RSR-related complications, preemptive 
post-operative imaging can be considered. In a small group of selected patients 
known to have a high risk of anastomotic leakage, prophylactic drains still have their 
place, e.g. in the case of biliary reconstruction. 
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ABSTRACT 
BACKGROUND 
The objective of this study was to provide a systematic review on the introduction of 
laparoscopic liver surgery in the Netherlands, to investigate the initial experience 
with laparoscopic liver resections and to report on the current status of laparoscopic 
liver surgery in the Netherlands. 
 
METHODS 
A systematic literature search of laparoscopic liver resections in the Netherlands was 
conducted using PubMed/MEDLINE. Analysis of initial experience with laparoscopic 
liver surgery was performed by case-control comparison of patients undergoing 
laparoscopic left lateral sectionectomy matched with patients undergoing the open 
procedure in the Netherlands between the years 2000 and 2008. Furthermore, a 
nationwide survey was conducted in 2011 on the current status of laparoscopic liver 
surgery. 
 
RESULTS 
The systematic review revealed only 6 Dutch reports on actual laparoscopic liver 
surgery. Matched case-control comparison showed significant differences in the 
length of hospital stay, blood loss and operation time. Complications did not differ 
significantly between the two groups (26 vs. 21%). The 2011 survey showed that 21 
centres in the Netherlands performed formal liver resections and that 49 (5% of total) 
laparoscopic liver resections were performed in 2010. 
 
CONCLUSION 
The systematic review revealed that very few laparoscopic liver resections were per-
formed in the Netherlands in the previous millennium. The matched case-control 
comparison of laparoscopic and open left lateral resection showed a reduction in 
hospital length of stay with comparable morbidity. The laparoscopic technique has 
been slowly adopted in the Netherlands, but its popularity seems to increase in re-
cent years. 
  
Laparoscopic liver resection in the Netherlands 
125 
INTRODUCTION 
In the past two decades, the popularity of laparoscopic surgery has grown. The in-
troduction of laparoscopic cholecystectomy [1, 2] has led to an increasing number of 
indications for this technique, and has encouraged surgeons to develop a laparo-
scopic approach for many procedures including liver resections.[3] Laparoscopic liver 
resections are technically demanding and thought to be time-consuming [4, 5] but 
may have several important benefits for the patient compared to open liver sur-
gery.[6–8] The putative advantages of this minimally invasive procedure include 
reduced blood loss [6, 7] , less post-operative pain [5, 9, 10] , earlier recovery and 
shorter post-operative hospital stay [5, 7–12] , and improved cosmetic aspects.[9, 12] 
Reoperations are reported to be easier due to reduced adhesions. [9–12] Also, open-
close procedures with large incisions can be avoided when peritoneal metastases are 
detected at laparoscopy. 
In the Netherlands, the gold standard for liver resection for liver tumours still is the 
open approach. There is no best level of evidence (level 1) to underpin the supposed 
major benefits of the laparoscopic approach, but the latter has been proven to be 
feasible and safe in many international expert centres. A recent consensus statement 
on laparoscopic liver resections states that resection of segments 2 and 3 by the 
laparoscopic approach should be the standard if experience is available.[13] In addi-
tion, the largest reviews hitherto conducted concluded that laparoscopic liver sur-
gery is feasible and safe in minor as well as major liver resections when performed in 
experienced centres.[14, 15] However, randomized trials comparing the open and 
laparoscopic technique for liver resections are still lacking. 
The purpose of our study was (1) to provide a historical overview on the introduction 
and initial experience of laparoscopic liver surgery in the Netherlands against the 
background of the latest international developments, (2) to report on the present 
state of laparoscopic liver surgery in the Netherlands, and (3) to provide insight into 
current and future developments of the minimally invasive liver resection technique 
within the Netherlands. To this purpose, a systematic review of all Dutch papers re-
porting on laparoscopic liver surgery was done and key leaders were informally ap-
proached. A matched case-control comparison was carried out of laparoscopic versus 
open liver resections in the Netherlands performed from 2000 to 2008. Finally, recent 
advances made in the Dutch surgical field of laparoscopic hepatectomies were inves-
tigated by means of a nationwide survey. 
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METHODS 
SYSTEMATIC REVIEW OF LAPAROSCOPIC LIVER SURGERY IN THE NETHERLANDS - 
PAST EXPERIENCE 
An online search was performed in PubMed/Embase databases for reports of Dutch 
groups on their experience with laparoscopic liver surgery in humans. Databases 
were searched from the earliest data available until 1 June 2011 on a combination of 
the following search keywords: ‘laparoscopy’, ‘liver surgery’, ‘hepatic surgery’, ‘hepat-
ic resection’, ‘hepatectomy’, ‘minimally invasive liver surgery’, ‘minimally invasive 
hepatic resection’, ‘Dutch’, ‘The Netherlands’. Biliary tumours were excluded. Titles 
and abstracts were screened (E.W.L.H.) and relevant articles selected. The full text of 
eligible papers was attempted to be retrieved to provide a historical overview. The 
reference lists of retrieved articles were reviewed for additional potentially relevant 
studies. To complete the historical picture, key leaders in gastrointestinal surgery 
were informally queried about their past experience and recollection of the evolution 
of laparoscopic liver surgery in the Netherlands. 
INITIAL EXPERIENCE WITH LAPAROSCIPIC LIVER RESECTIONS AND CASE- 
CONTROLE COMPARISON – PRESENT STATE 
Patients 
All major liver centres in the Netherlands were contacted during 2008 by phone 
and/or e-mail and asked to participate in this study. Of the fourteen major HPB cen-
tres in the Netherlands, only seven had performed laparoscopic liver resections. Six 
of these centres agreed to collaborate. Data were obtained retrospectively from six 
separate prospectively collected databases used in these six HBP units and were 
pooled for further analysis. All patients who underwent laparoscopic left lateral sec-
tionectomies of the liver in the six centres between 2000 and 2008 were included in 
this multicentre study. The laparoscopic group of patients was compared in a case-
matched comparison approach with a group of patients undergoing the same type 
of liver resection as an open procedure in that era in the 6 participating centres in a 
proportion of 1: 3. This approach and the choice to only include left lateral sectionec-
tomies were felt to be justified to eliminate bias as much as possible and increase the 
external validity of the conclusions. The investigators (J.H.M.B.S. and I.L.) were una-
ware of the primary outcome or secondary outcomes during the selection process. 
Patients undergoing left lateral resections in combination with colonic resections 
were excluded. 
In each unit, patients were preoperatively discussed in a multidisciplinary meeting, 
after evaluation of liver function tests and radiologic liver workup including ab-
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dominal ultrasonography, CT, MRI and/or CT-PET scan. Patients with benign as well 
as malignant solid liver lesions were included in this study. Patients with cystic le-
sions of the liver were excluded. Laparoscopic liver resection was considered if the 
lesion was located in the left lateral segments (segment 2 and 3 according to 
Couinaud’s classification). The choice to perform either a laparoscopic or open pro-
cedure was at the discretion of the attending surgeon in consent with the patient. 
Preoperative information consisted of medical history, preoperative diagnosis and 
American Society of Anesthesiologists (ASA) classification. 
Surgical Procedures 
The open procedure was started with a 15- to 25-cm incision according to the prefer-
ence of the surgeon. During operation, the left liver was mobilized, and central ve-
nous pressure was maintained at 2–6 mm Hg. Transection of the liver was performed 
according to the preference of the surgeon: the Cavitron Ultrasonic Surgical Aspira-
tor (CUSA ; Valleylab, Boulder, Colo., USA) and argon beam coagulator (Bircher Ind., 
Ltd., Englewood, Colo., USA) with or without the use of Pringle’s maneuver, Ultraci-
sion Harmonic ACE (Ethicon Endosurgery, Johnson & Johnson, USA) or Ligasure 
(Covidien, USA). Only occasionally was the clampcrush technique used. Minor cross-
ing vessels and biliary radicals were divided using polypropylene sutures or clips. The 
portal pedicles and hepatic veins were divided and ligated with a running polypro-
pylene suture. In some procedures, vascular staplers such as e.g. Autosuture EndoGIA 
(Covidien) were used. After removal of the liver specimen, the raw surface of the liver 
remnant was subjected to argon beam coagulation and sealed with TachoSil (Ny-
comed, Zurich, Switzerland) or Tissuecoll (Baxter, Vienna, Austria) if considered ap-
propriate. 
The laparoscopic procedure was performed as described in detail previously.[16] The 
patient was in the supine French position and abdominal access was achieved by 
transumbilical open insertion of a laparoscope. Pneumoperitoneum was kept at 10–
14 mm Hg; three or four additional 12-mm trocars were added, and a 30° laparo-
scope was used routinely. The central venous pressure was maintained at 2–6 mm 
Hg. Hepatic transection of parenchyma and minor crossing vessels and biliary radi-
cals was mainly performed with harmonic scalpel (Ultracision, Ethicon Endosurgery, 
Johnson & Johnson, USA) or the Ligasure (Covidien). The segmental portal pedicles 
and left hepatic vein were stapled using a vascular stapler (EndoGIA Autosuture, 
Covidien). Resected specimens were placed in a plastic bag (Endocatch Autosuture, 
Covidien) and removed through a separate incision. 
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Parameters and Outcome 
Peri- and post-operative parameters included type of resection, operation time, blood 
loss, need for transfusion, conversion of laparoscopic to open procedure, post-
operative complications, post-operative length of hospital stay and pathologic assess-
ment of the resected liver segment. Blood loss was measured by the suction device and 
the weight of the gauzes and recorded in operation notes and/or anaesthesia reports. 
In case of discrepancy, the highest amount was used. Data on surgical technique con-
sisted of information about type of incisions, type of liver resection, method of liver 
transection, hemorrhage control, use of hemostatic agents, Pringle maneuver, and 
method of extraction of surgical specimen. In one centre (Maastricht University Medical 
Centre, MUMC), a multimodal perioperative enhanced recovery program (ERAS) was 
followed for all patients undergoing liver surgery.[16, 17] This was also recorded as a 
parameter. Criteria for discharge in the ERAS setting were described previously.[16, 17] 
Discharge in the traditional setting was at the discretion of the attending surgeon. 
Primary outcome of the study was hospital length of stay. Secondary outcome 
measures comprised complications (including mortality and conversion rates), dura-
tion of operation and blood loss. Post-operative complications were defined accord-
ing to the international grading system of Dindo et al.[18] 
CURRENT STATUS OF LAPAROSCOPIC LIVER SURGERY – FUTURE DEVELOP- 
MENTS 
To get an indication of the volumes currently being operated on in Dutch hospitals, 
and to see whether they had increased in the years following the introduction of the 
minimally invasive technique, we approached all Dutch hospitals that indicated to 
perform liver surgery in January 2011 by e-mail. This contained three questions sur-
veying on (1) whether the hospital performed formal liver resections (not only 
deroofing of cysts), (2) how many open/laparoscopic major or minor hepatic resec-
tions were performed in 2010, and (3) whether the provided data were real or esti-
mated numbers. Centres that did not reply on the request to complete the survey 
were approached by phone in February 2011. 
Statistical Analysis 
Data were analysed by J.S., I.L. and R.V; if necessary, an independent statistician was 
consulted. Continuous variables are expressed as mean (± standard error of the 
mean). Data were analysed according to the intention to treat principle. Univariable 
analysis was performed using Pearson’s X2 test (or Fisher’s exact test where appro-
priate) to investigate differences between open and laparoscopic procedures regard-
ing sex, indication, pathology, resection margins, ERAS, use of Pringle maneuver, 
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method of liver transection, hemorrhage control and hemostatic agents, use of sta-
plers and complications. The Mann-Whitney U test was used for univariable analysis 
to investigate differences between open and laparoscopic surgery regarding age, 
ASA classification, tumour diameter, type of incision, complication classification, 
hospital length of stay (days), duration of operation (min), blood loss (ml) and num-
ber of transfusions. The relation between patient characteristics and operative strat-
egy and length of hospital stay was analysed with univariable linear regression analy-
sis. All independent variables with a two-tailed p value below 0.200 were included 
into a multivariable linear regression model using backward analysis to assess which 
parameters were significantly and independently related to length of hospital stay. 
Also, the group effect of open versus laparoscopic resections on post-operative he-
moglobin was analysed using multivariable linear regression analysis correcting for 
preoperative hemoglobin levels. A p value below 0.05 was considered to indicate 
statistical significance. Statistical analyses were performed using SPSS software (ver-
sion 15; SPSS Inc., USA). 
RESULTS 
SYSTEMIC REVIEW OF LAPAROSCOPIC LIVER SURGERY IN THE NETHERLANDS– 
PAST EXPERIENCE 
A total of 91 abstracts were retrieved that met the search terms, and after review 19 
abstracts remained eligible. Of these 19 articles, 6 reported on actual laparoscopic 
liver surgery, 12 described the use of laparoscopy and/or laparoscopic ultrasound for 
staging in patients with hepatic tumours, and one article provided a literature review 
on liver resection and laparoscopy (Fig. 1 ). The informal interviews and articles eligi-
ble for review revealed that the first two laparoscopic liver resections were per 
formed in Amsterdam in 1995 by the group of Cuesta et al.[19] In the following years, 
only one article from the same group was published reporting on a series of laparo-
scopically operated patients (n = 10). Seven underwent a minor laparoscopic resec-
tion and three underwent fenestration of hepatic cysts.[20] After these initial reports 
on minimally invasive liver surgery, three articles were published with regard to lapa-
roscopic treatment of polycystic liver disease. [21–23] Later series of 26 laparoscopic 
liver resections provided evidence that this procedure could be performed safely in 
the Netherlands. [16] 
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INITIAL EXPERIENCE WITH LAPAROSCOPIC LIVER RESECTIONS AND CASE- 
CONTROLE COMPARISON – PRESENT STATE 
Patient’s Characteristics Between 2000 and 2008, the laparoscopic approach for he-
patic left lateral sectionectomy was performed in 30 patients in 6 centres in the Neth-
erlands (mean age 50 ± 3 years) and completed laparoscopically in 27 patients. Five of 
the laparoscopic liver resections were performed hand-assisted. In the open group, 90 
patients were matched for the same type of resection (mean age 52 ± 2 years). Demo-
graphic data of both groups are reported in Table 1. There were no significant differ-
ences in age, ASA classification, indication, resection margins and tumour size. 
 
 
Figure 1. Selection of studies eligible for review. 
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Table 1. Clinical and pathological features of the control study 
 Laparoscopic group 
n = 30 
Open group 
n = 90 
p-value 
 
Male / femalea 5/25 35/55 0.043 
Age, yearsb 50 (3) 52 (2) 0.584 
ASA 1b,c 
ASA 2 
ASA 3 
ASA 4 
10 
16 
2 
0 
18 
38 
16 
1 
0.625 
Indication (malignant/benign)a 11/19 39/51 0.091 
Tumour size, cmb 4.8 ± 0.5 5.3 ± 0.4 0.673 
Pathology (malignant/benign)a,c 7/22 48/42 0.007 
Resection margins (R0/R1/R2)a,c,d 19/1/1 64/8/2 0.597 
ERAS (yes/no)a 11/19 8/92 0.001 
Values for tumour size are expressed as mean 8 standard error of mean. 
a Pearson’s _2 test (or Fisher exact test where appropriate). 
b Mann-Whitney U test. 
c Results do not add up to total values as a result of missing data. 
d In the laparoscopic group, two (R1 and R2) resection margins were positive, both in patients with benign 
disease (adenoma and hemangioma, respectively). In the open control group the R2 resections were 
suspected to be benign lesions preoperatively. However, one of these R2 resections proved to be malig-
nant (hepatocellular carcinoma). Of the R1 resection margins, 3/8 were malignant tumours. 
Surgical Procedures and Parameters 
The Pringle maneuver was only used during open surgery (Table 2). The method of 
liver transection in the open group was different from the approach in the laparo-
scopic group. Mostly, the CUSA and/or argon beam was used in the open group for 
liver transection. 
Outcome Parameters 
Mean hospital length of stay was 6.0 (± 0.4) days in the laparoscopic group versus 8.1 
(± 0.4) days in the open group (p ! 0.001). Complication rates did not differ signifi-
cantly between the laparoscopic and the open group (26 vs. 21%), neither did they 
differ significantly when complications were graded according to severity interven-
tion score. Three laparoscopic procedures (10%) were converted to an open proce-
dure (table 3). Reasons for conversion were hemorrhage, an additional lesion in seg-
ment IV or the close relation to the left hepatic vein. There were no deaths in the 
laparoscopic group. In the open group, one of the 90 patients (1.1%) died due to 
multiple organ failure after sepsis. 
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Table 2. Operative details on transection and hemostasis techniques and use of devices 
 Laparoscopic group n = 30 (%) Open group n = 90 (%) 
Use of Pringle manoeuvre 1 (3)a 20 (22) 
Liver transection     
Cusa ± argonbeam  3 (10) 55 (61) 
Ultracision 21 (70) 4 (4) 
Ligasure 4 (13) 7 (8) 
Hydrojet   2 (2) 
Cusa + ligasure   8 (9) 
Diathermia ± endogia   4 (4) 
Kelly clamp   1 (1) 
Endogia 2 (7) 4 (4) 
Haemorrhage controlB     
Diathermia ± argonbeam 6 (20) 4 (4) 
Clips 6 (20) 15 (17) 
Prolene 4 (13) 23 (26) 
Clips and prolene 1 (3) 39 (43) 
Other: use of device 9 (30) 3 (3) 
Use of staplers (yes/no) B 22/3* 19/68 
Haemostatic agents B     
None 19 (63) 39 (43) 
Tachosyl 4 (13) 17 (19) 
Tissuecoll 4 (13) 25 (28) 
Surgicell 1 (3) 1 (1) 
Unknown 1 (3) 7 (8) 
Figures in parentheses indicate percentages. 
a Following conversion to open. 
b Results do not add up to total values as a result of missing (non-reported) data. 
 
There was significantly less blood loss in the laparoscopic group compared to the 
open group (p < 0.001; Table 3). When corrected for preoperative hemoglobin level, 
multivariable analysis showed that open resection was significantly related to a de-
crease in post-operative hemoglobin levels compared to the laparoscopic group (OR 
= –0.520, CI –1.022 to –0.18, p = 0.043). None of the patients in the laparoscopic 
group needed a blood transfusion post-operatively in contrast to 22 blood transfu-
sions in the open group. However, this difference was not significant. The mean du-
ration of operation in the laparoscopic group was significantly shorter than in the 
open group (p < 0.001; Table 3).  
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Univariable regression analyses showed that several variables were related to differ-
ences in length of hospital stay (Table 4). However, after multivariable regression 
analysis, only ASA classification (OR = 1.598, CI 0.738–2.458, p < 0.001), complication 
grade (OR = 1.680, CI 1.124–2.235, p < 0.001) and ERAS (OR = –2.502, CI –4.032 to –
0.972, p = 0.002) were independently and significantly related to length of hospital 
stay. 
 
Table 3. Primary and secondary outcomes (mean 8 SEM) 
 Laparoscopic group 
n = 30 (%) 
Open group 
n = 90 (%) 
p-value 
Length of stay (days)a 6.0 ± 0.4 8.1 ± 0.4 <0.001 
Complicationsb 5 (26) 19 (21) 0.620 
Complications (grade)a   0.832 
Grade 1 4 (13) 8 (9)  
Grade 2  4 (4)  
Grade 3a  3 (3)  
Grade 3b 1 (3)   
Grade 4a  2 (2)  
Grade 4b  1 (1)  
Grade 5  1 (1)  
Conversions 3 (10)   
Reoperationb 1 (3) 3 (3) 0.589 
Blood loss (mls)a 288 ± 99 608 ± 97 <0.001 
Operation time 
(minutes)a 
160 ± 13 231 ±11 <0.001 
Figures in parentheses indicate percentages. 
a Mann-Whitney U test. 
b Pearson’s X2 test (or Fisher exact test where appropriate). 
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Table 4. Univariable linear regression analysis of length of hospital stay 
Variable Odds ratio 95% CI P-value 
Age (years) 0.040 0.001 to 0.079 0.047 
Sex (male/female) 1.374 0.022 to 2.276 0.046 
Group (open/closed) 2.012 0.571 to 3.452 0.007 
Indication (malignant/benign) 1.419 0.154 to 2.684 0.028 
Pathology (malignant/benign) 1.762 0.501 to 3.023 0.007 
Tumour diameter (cm) 0.091 -0.129 to 0.311 0.413 
Complicationa 1.559 1.025 to 2.093 <0.001 
Duration (minutes) 0.008 0.001 to 0.015 0.020 
ERAS (yes/no) -1.392 -3.136 to 0.352 0.117 
Reoperation 0.961 -4.092 to 6.014 0.707 
ASAb 1.840 0.849 to 2.830 <0.001 
Stapler (yes/no) -1.637 -3.014 to -0.261 0.020 
Pringle (yes/no) -0.762 -2.130 to 0.606 0.272 
Transection       
Cusa 1.523 -1.803 to 4.848 0.366 
Ultracision 0.120 -3.373 to 3.613 0.946 
Ligasure 0.309 -3.536 to 4.155 0.874 
Hydrojet 1.400 -4.565 to 7.365 0.643 
Cusa and ligasure 1.525 -2.540 to 5.590 0.459 
Other -0.35 -5.133 to 4.433 0.885 
Kelly 1.400 -6.410 to 9.210 0.723 
Endogia 0.567 -3.751 to 4.884 0.795 
Haemorrhage control       
Diathermia -1.992 -4.545 to 0.560 0.125 
Clips -0.942 -3.320 to 1.435 0.433 
Prolene 1.197 -0.606 to 3.000 0.191 
Other -1.276 -3.653 to 1.102 0.289 
Haemostatic agents       
Tachosyl -0.024 -5.387 to 5.340 0.993 
Tissuecol 0.121 -5.178 to 5.419 0.964 
Surgicell 3.000 -4.248 to 10.248 0.414 
None -0.114 -5.328 to 5.100 0.965 
a Complication according to Dindo et al. [18]; increase per unit increase severity. 
b Increase per unit increase severity. 
CURRENT STATUS OF LAPAROSCOPIC LIVER SURGERY – FUTURE DEVELOPMENTS 
The response rate to the nationwide survey was 81%; 30 out of 37 approached hospi-
tals responded. The seven non-responding centres were all district general hospital 
centres, except one university medical centre. In total, 21 centres performed formal 
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liver resections in 2010, the remaining 9 centres only performed deroofing proce-
dures. The total number of hepatic resections performed in 2010 by the responding 
centres in the Netherlands was 966. This total number of resections consisted of 444 
major and 522 minor hepatectomies (Fig. 2). During 2010, all Dutch hospitals togeth-
er performed only 49 laparoscopic liver resections; 5% of all resections (Fig. 3). All 
these minimally invasive surgical procedures were reported to be minor hepatic 
resections. 
 
 
Figure 2. Results of a nationwide survey of laparoscopic and open liver resections performed during 2010 
in the Netherlands. 
DISCUSSION 
This study provides a historical overview and reports on the initial experience and 
the current status of laparoscopic liver surgery in the Netherlands. A systematic re-
view of the literature showed that the laparoscopic approach for hepatic resection 
was introduced in the Netherlands during the 1990s and that some, but limited expe-
rience has been gained. It is clear from the data and from additional information 
obtained by interviewing key leaders that only very few laparoscopic livers were 
performed in the previous millennium. 
Compared to countries that have traditionally always played a pioneering role in 
(laparoscopic) liver surgery, such as France, the Netherlands have fallen behind with 
regard to the implementation of the minimally invasive technique. Many surgeons 
considered an open partial liver resection to be major surgery associated with signifi-
cant mortality and morbidity. Dutch surgeons remained reluctant to perform this 
type of surgery.[24] Illustrating this fact is that only 110–130 partial liver resections 
(including benign tumours) were performed between 1984 and 1987. At the end of 
the 1980s and 1990s, several series on the experience with open hepatic resection 
were published by different Dutch centres.[25, 26] 
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Figure 3. Results of a nationwide survey of total laparoscopic (minor) liver resections performed during
2010 in the Netherlands per centre. 
 
The laparoscopic technique for liver resections was introduced in the Netherlands 
during the 1990s for diagnostic laparoscopies and liver biopsies. Later, the indications 
were extended to fenestration of liver cysts and anatomic liver resections. [27–32] The 
group of Cuesta et al. [19] was in 1995 the first to report two cases of limited laparo-
scopic liver surgery of segment II and IV in the Netherlands. A few years later, in 2001, 
a small retrospective series (n = 10) was published that demonstrated encouraging 
results concerning operative blood loss, post-operative complications and hospital 
length of stay after wedge and left lateral hepatectomy. Furthermore, they concluded 
that laparoscopic treatment should be considered in selected patients with benign 
and malignant lesions in the left lobe or frontal segments of the liver.[20] 
While the first limited laparoscopic liver resection in the Netherlands was performed 
in 1995, the first laparoscopic liver resection worldwide, a wedge resection, had al-
ready been performed by Gagner’s group in 1992. Four years thereafter, Azagra’s 
group reported the first anatomic liver resection.[3] In the following few years, the 
minimally invasive technique was further developed and adopted, resulting in the 
first laparoscopic left lateral sectionectomy for living liver donation[33] and the first 
reports on robotic liver surgery.[34, 35] Initially, laparoscopic liver resection was chal-
lenging because of the difficulties concerning safe mobilization and exposure of this 
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fragile and heavy organ.[3, 36, 37] Small, superficial and peripheral lesions in anterol-
ateral segments were considered most amenable to laparoscopic liver resection. 
Surgeons with extensive experience in laparoscopy and hepatic surgery have per-
formed laparoscopic major hepatic resections with satisfactory outcomes.[28, 38, 39] 
Recent large reviews by Reddy et al.[15] and Nguyen et al.[14] show favorable out-
comes after laparoscopic resection.[14, 15] Patient benefits included less operative 
blood loss[6, 7] , less post-operative pain[5, 9, 10] and narcotic requirement, improved 
cosmetic aspects[9, 12] and a shorter length of hospital stay [5, 7–12] with post-
operative morbidity and mortality comparable to open liver resection. In addition, the 
minimally invasive approach seems to be cost-effective.[40, 41] Potential limitations 
and disadvantages of laparoscopic liver resection include a significant learning curve, 
potential bleeding which may be more difficult to control laparoscopically, inade-
quate assessment of the liver for additional lesions, and increased risk for gas embo-
lism.[15, 42] Air embolism may occur when high- pressure pneumoperitoneum is 
used.[36, 43] However, gas embolism is rare and usually well tolerated.[5] Other con-
cerns have been raised about the potential dissemination of malignant cells during 
laparoscopic resection.[44–46] Some authors have suggested that tumour dissemina-
tion does not increase by laparoscopy [47–49], and recent reports regarding this sub-
ject show long-term survival rates comparable to open surgery [12, 37, 50, 51] . 
At present, after more than 10 years of experience and following advances in laparo-
scopic technology, the surgical community has accepted that laparoscopic liver sur-
gery is feasible and safe.[3, 7, 8, 10, 51–53] This is especially true for resection of left 
lateral segments and right anterior segments.[4, 9, 11, 54] Some of the advantages 
reported in literature were also found in the present study. The present multicentre 
case-control study on laparoscopic left lateral sectionectomies in the Netherlands be-
tween 2000 and 2008 demonstrated that length of hospital stay for the laparoscopic 
approach for left lateral sectionectomies was reduced by 2 days. Furthermore, the lapa-
roscopic approach resulted in faster procedures with reduced blood loss, no occur-
rence of gas embolisms and comparable morbidity. In a multivariable analysis, length 
of hospital stay appeared to be related to ASA classification, complications and ERAS. 
Left lateral sectionectomy currently is the most common laparoscopic liver resection 
for solid tumours in the Netherlands. However, only a minority of left lateral sec-
tionectomies were performed laparoscopically between 2000 and 2008. The laparo-
scopic approach has gained gradual acceptance by Dutch surgeons, but is still not a 
standard. A structured implementation may allow the Dutch surgical community to 
catch up with international developments. Recently, van Dam and Topal performed 
the first major laparoscopic liver resection in the Netherlands (anatomical right hem-
ihepatectomy, Maastricht, 2011). 
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The question remains why the laparoscopic left sectionectomy in this study proved 
to be faster than the open counterpart. Differences in technique in transection of the 
liver parenchyma and the vascular and biliary structures may have added to a faster 
transection. Reduced blood loss, either caused by different transection devices or 
pneumoperitoneum, may reduce the need for prolene stitches and hemostatic clips, 
which can be time consuming. Lastly, there is no need to close the abdomen after 
the procedure. 
The survey results demonstrate an increase in both totally laparoscopic and totally 
open liver resections performed in the Netherlands. Although more centres have 
adopted the laparoscopic approach in recent years, individual centre volumes re-
main low. Only 5% of all liver resections were performed laparoscopically, which is 
significantly less compared to other countries where average percentages of laparo-
scopic hepatic resections range between 20 and 80%.[13] If surgeons in the Nether-
lands aim to increase the portion of laparoscopic liver resections, liver surgery should 
be further centralized. Furthermore, a central training, proctoring and credentialing 
infrastructure should be developed to improve the quality of outcome parameters 
and to allow units to become (high-volume) expert centres. 
The foundation of the Dutch Liver Collaborative Group in 2003 gave a new impulse 
to minimally invasive liver surgery, and is in concordance with recently made rec-
ommendations that national and international societies, as well as governing boards, 
should become involved in the goal of establishing training standards and creden-
tialing.[13] Goals of this workgroup are to facilitate collaboration of medical centres 
in the field of hepatic surgery, initiate and facilitate research in liver surgery (especial-
ly multicentre trials), facilitate training, education and adoption and to establish a 
quality control and auditing system for Dutch liver surgery centres. 
In conclusion, minimally invasive liver surgery is gradually being adopted in the 
Netherlands. The laparoscopic (left-sided) liver resection is a safe procedure, and it 
probably results in a shorter hospital length of stay with comparable morbidity. Lapa-
roscopic liver resections appear to be faster. More importantly, ASA classification, 
complications and ERAS proved to be important prognostic variables for reduced 
length of hospital stay in Dutch hospitals. In the future, the Dutch Liver Collaborative 
Group should continue to play an important role in the further adoption and central-
ization of minimally invasive liver surgery. Conducting an RCT on laparoscopic liver 
resection may add to the body of evidence supporting broader introduction of min-
imally invasive liver surgery. 
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ABSTRACT 
BACKGROUND 
The use of laparoscopic liver resection in terms of time to functional recovery, length 
of hospital stay (LOS), long-term abdominal wall hernias, costs and quality of life 
(QOL) has never been studied in a randomised controlled trial. Therefore, this is the 
subject of the international multicentre randomised controlled ORANGE II trial. 
 
METHODS 
Patients eligible for left lateral sectionectomy (LLS) of the liver will be recruited and 
randomised at the outpatient clinic. All randomised patients will undergo surgery in 
the setting of an ERAS programme. The experimental design produces two random-
ised arms (open and laparoscopic LLS) and a prospective registry. The prospective 
registry will be based on patients that cannot be randomised because of the explicit 
treatment preference of the patient or surgeon. Therefore, all non-randomised pa-
tients undergoing LLS will be approached to participate in the prospective registry, 
thereby allowing acquisition of an uninterrupted prospective series of patients. The 
primary endpoint of the ORANGE II trial is time to functional recovery. Secondary 
endpoints are post-operative LOS, percentage readmission, (liver-specific) morbidity, 
QOL, body image and cosmetic result, hospital and societal costs over 1 year, and 
long-term incidence of incisional hernias. It will be assumed that in patients undergo-
ing laparoscopic LLS, length of hospital stay can be reduced by two days. A sample 
size of 55 patients in each randomization arm has been calculated to detect a 2-day 
reduction in LOS (90% power and alfa = 0.05 (two-tailed)). 
 
CONCLUSION 
The ORANGE II trial is a multicentre randomised controlled trial that will provide evi-
dence on the merits of laparoscopic surgery in patients undergoing LLS within an 
enhanced recovery ERAS programme. 
 
Trial registration: ClinicalTrials.gov NCT00874224. 
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BACKGROUND 
Liver resection for colorectal metastasis is the only potentially curative therapy, and 
has become the standard of care in appropriately staged patients, offering 5-year 
survival rates of approximately 35-40%.[1] For symptomatic benign lesions and those 
of uncertain nature or large size, liver resection is also a widely accepted treatment. 
Within the framework of optimizing post-operative recovery and/or producing a 
shorter length of stay (LOS) in hospital, laparoscopic surgery and enhanced recovery 
programmes have recently been introduced for liver surgery. 
Laparoscopic liver resection was first described in 1995.[2] Over the past decade the 
method has gained wide acceptance for various liver resection procedures. [3-9] 
Multiple retrospective case series and reviews comparing open with laparoscopic 
liver resection indicate that laparoscopic liver resection can be used safely for both 
malignant and benign liver lesions.[10-15] Recent publications from expert centres 
show that a substantial part of the total volume of major and minor liver resections is 
performed laparoscopically, and results are good.[16,17] Laparoscopic liver resection 
is associated with shorter LOS, less post-operative pain, earlier recovery, and better 
quality of life (QOL).[9,13,18,19] Comparing patients undergoing an open left lateral 
sectionectomy (LLS) of the liver with those undergoing laparoscopic LLS, both 
Vigano et al. and Carswell et al.[20,21] found no significant difference in operating 
time between the two groups. In addition, the median length of post-operative LOS 
was significantly less (6 vs. 9 days, P < 0.01) after laparoscopic resection.[3] Further-
more, no evidence of a compromised oncologic clearance in laparoscopic liver resec-
tion has been found.[3,13] However, recovery and LOS are not only dependent on 
the type of surgery or procedure, and other variables should also be taken into ac-
count. 
The Enhanced Recovery After Surgery (ERAS) programme has been introduced to 
improve post-operative care. This multimodal programme, derived from Kehlet’s 
pioneer work in the 1990s for multimodal surgical care, involves optimization of sev-
eral aspects of the perioperative management of patients undergoing major ab-
dominal surgery. In patients undergoing segmental colectomy, the ERAS programme 
enabled earlier recovery and consequently shorter LOS [22-25]. Furthermore, a re-
duction of post-operative morbidity in patients undergoing intestinal resection was 
reported [26-29]. These results stimulated liver surgeons of the ERAS-group (Maas-
tricht, Edinburgh and Tromsö) to adapt the ERAS programme to patients undergoing 
open liver resection. Van Dam et al. [30] found a significantly reduced LOS after open 
liver resection when patients were managed within a multimodal ERAS programme. 
Besides a reduction in median total LOS from 8 to 6 days (25%), the data also sug-
gested that a further reduction in stay could be possible as there was a delay be-
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tween the recovery and actual discharge of the patients [30]. Moreover, Stoot et al. 
found retrospectively that there was a further reduction in LOS from 7 days to 5 days 
when patients were operated laparoscopically and managed within an ERAS pro-
gramme.[31] In that study there was also a delay between recovery and actual dis-
charge of the patients. Previously, Maessen et al. reported a median delay to dis-
charge of 2 days after patients had functionally recovered after colonic surgery man-
aged within an ERAS programme.[32] This delay is often linked to patient age, hospi-
tal logistics, and absence of social and/ or homecare support. 
In most reported trials aiming at earlier recovery or a reduction in LOS, type of sur-
gery and/or perioperative management were not standardized. In addition, the add-
ed value of laparoscopic LLS compared with open left lateral sectionectomy within 
an ERAS programme in terms of time to functional recovery, LOS in hospital, costs, 
and QOL has never been studied in a randomised controlled trial (RCT). However, 
randomization of patients undergoing open or laparoscopic liver resection is hazard-
ous. It is to be expected that experienced centres will be reluctant to randomize pa-
tients because of the absence of clinical and patient equipoise for laparoscopic resec-
tion. To capitalize on both centres with and without preference for laparoscopic liver 
surgery, and to thereby acquire an uninterrupted prospective series of patients, an 
alternative trial design with two randomization arms (open versus laparoscopic sur-
gery) and a prospective registry has been constructed for the ORANGE II trial. The 
combination of an RCT and a prospective registry will improve overall power and 
strengthen the external validity and generalizability of study results.[33-35] 
METHODS 
ETHICS APPROVAL 
The study has been approved by the Medical Ethical Review Board of the Maastricht 
University Medical Centre, Maastricht, The Netherlands trial number NL 25591.068.08 
/ MEC 08-2-110. Ethics consent will also be obtained from the national or regional 
ethics boards in each participating country. Patients willing to participate in this trial 
will receive both verbal and written information at the time of recruitment in the 
outpatient clinic. In accordance with the local medical ethics committee all partici-
pating sites will provide an independent surgeon or physician if needed. An inde-
pendent surgeon (M. Poeze) has been appointed for the Maastricht University Medi-
cal Centre to answer questions. Confidentiality is guaranteed by assigning the partic-
ipators an encoded trial number. This indicates that only the physician with the de-
coding ‘key’ will know which code number has been assigned to any patient. All trial 
data will be saved during the trial and stored on a server, and patients will be asked 
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to consent to future analysis of these data. Withdrawal from the trial at any time or 
for any reason will not hold any form of consequences for the patient, and data from 
these patients will be deleted. 
STUDY DESIGN 
The ORANGE II trial is a prospective superiority study with an experimental design, 
using two double-blinded randomised controlled arms and a prospective registry to 
determine whether laparoscopic surgery is to be preferred over open surgery in pa-
tients undergoing LLS and participating in an enhanced recovery programme. In the 
participating randomizing centres, patients, nurses and the ward physician (but not 
the operating surgeon) will be blinded for the type of intervention up to and includ-
ing post-operative day (POD) 3. They will record the functional recovery criteria twice 
daily. Only the investigator and operating surgeons will know the actual procedure. 
The blinded ward physician(s) will decide on whether a patient will be discharged or 
not. 
However, randomization of patients undergoing open or laparoscopic liver resection 
is hazardous as previously explained. Moreover, another potential source of bias 
exists when randomizing patients with a strong treatment preference. When patients 
cannot be blinded to their treatment allocation (POD 3) they may be resentful and 
demoralized if they do not receive their preferred treatment, and consequently they 
may have poor compliance. By contrast, patients receiving their preferred treatment 
may have above-average compliance. Thus to capitalize on centres both with and 
without preference for laparoscopic liver surgery, and thereby to acquire an uninter-
rupted prospective series of patients, all non-randomized patients undergoing a LLS 
will be approached to participate in the prospective registry. Registration of these 
patients is imperative to guarantee a consecutive series of patients and also because 
the absence of such a series may restrict generalization of the results, as randomised 
participants may not in fact be representative.[36] The combination of an RCT and a 
prospective registry will improve overall power and strengthen the external validity 
and generalizability of study results.[33-35] This non-randomised registry group will 
be analysed for centre and centre by treatment interaction as an observational study. 
Medical centres that wish to participate in this trial, but with liver surgeons early in 
the laparoscopic learning curve, will be accompanied during the procedure by an 
experienced proctoring laparoscopic HPB-surgeon. 
PRIMARY & SECONDARY ENDPOINTS 
The primary endpoint of the ORANGE II trial is time to functional recovery. A patient 
is fully functionally recovered when all of the following five criteria are satisfied: 1) 
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adequate pain control with oral analgesia; 2) restoration of mobility to an independ-
ent level; 3) absence of intravenous fluid administration; 4) ability to eat solid foods; 
and normal or decreasing serum bilirubin level and international normalized ratio. 
It is medically justified to discharge patients when the criteria for full functional re-
covery are met and if the patient is willing to go home. Secondary endpoints include 
post-operative LOS in hospital, percentage of readmissions, total morbidity (both 
general and procedure related), composite endpoint of liver-surgery-specific morbid-
ity, QOL, body image and cosmesis, reasons for delay of discharge after functional 
recovery, hospital and societal costs over 1 year, and long-term incidence of incision-
al hernias. 
Morbidity 
The preoperative morbidity status of patients will be measured using the American 
Society of Anaesthesiologists (ASA) scale. The Portsmouth modification of the Phys-
iological and Operative Severity Score for the Enumeration of Mortality and Morbidi-
ty (P-POSSUM) will be used to evaluate the risk of perioperative morbidity and mor-
tality. Post-operative morbidity is rationally predictable, with hemorrhagic complica-
tions occurring predominantly during surgery or in the early post-operative phase, 
and biliary complications, intra-abdominal abscess, or liver failure in the later post-
operative phase. Wound infection and sepsis will be additional complications that 
require monitoring. Morbidity will be classified and analysed according to the vali-
dated classification for post-operative morbidity as described by Dindo et al.[37] 
Liver Resection-Specific Composite Endpoint 
In this trial, we will also use a well-defined liver surgery specific composite endpoint, 
as suggested by van den Broek et al.[38] This endpoint is a parameter composed of a 
combination of procedure-specific complications, which is considered as a single, 
dichotomous outcome: operative mortality, intra-abdominal haemorrhage, ascites, 
bile leakage, intra-abdominal abscess, and post-resectional liver failure. These com-
ponents, which are all specific to liver surgery and have substantial clinical relevance, 
reflect complications rated as Dindo grade 3–5. A composite score of 1 (failure) will 
reflect the occurrence of at least one of the above liver-specific complications, and a 
score of 0 (success) will be assigned if none of these occur. 
Quality of Life 
To assess QoL in patients undergoing laparoscopic versus open LLS, the Dutch ver-
sion of the EuroQol five dimension (EQ-5D) status test in Dutch centres and the trans-
lated EQ-5D for international centres will be used. The EQ-5D is a standardized in-
strument for use as a measure of health outcome, which consists of the five dimen-
sions of mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression, 
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with three levels each and a rating on the EQ visual analogue scale (VAS; 0–100).[39-
41] Furthermore, the European Organization for Research and Treatment (EORTC) 30-
item post-cancer QOL questionnaire (QLQ-C30; with the liver metastases (LM21) 
module will be used for liver-specific treatment measurements.[42] Assessment of 
the patients’ QOL will be performed at the time of consent, discharge and 10 days, 3, 
6 and 12 months after discharge. 
Body Image and Cosmesis 
To evaluate differences in post-operative body image and cosmesis, the Body Image 
Questionnaire (BIQ) will be used [43,44], which consists of eight questions about 
body image and cosmesis. The body image assessment will be performed preopera-
tively at time of consent. Both the body image and cosmesis assessment will take 
place at discharge, and at 10 days, 3 months, 6 months and 12 months after dis-
charge. 
Hospital and Societal Costs 
The economic evaluation will include a cost-utility analysis from a Dutch societal 
perspective. The incremental costs per quality adjusted life year (QALY) gained will 
be based on utility scores from the EQ-5D.[39-41] All hospital expenses (direct and 
indirect) related to both interventions will be monitored. In addition, a cost ques-
tionnaire offered at the regular follow-up consultation (3, 6 and 12 months) will help 
assess the societal and individual costs outside health care relating to patients’ ab-
sence, impaired mobility, work, or normal daily activities. Unit prices will be based 
either on prices from the participating hospital financial departments or will be ex-
trapolated using Dutch guidelines for cost calculation.[45] 
Incidence of Incisonal Hernias 
Incisional hernia after open surgery is a well-known complication of surgery, with an 
incidence of up to 20% after a 10-year period.[46] In patients undergoing a sigmoid 
resection, Anderson et al. found that laparoscopic resection led to a significantly 
lower incidence of incisional hernia compared with open surgery.[47] Furthermore, 
in two retrospectively analysed series of patients who received a partial hepatecto-
my, different types of incisions were compared. D’Angelica et al. reported that the 
common incisions used for partial hepatectomy were the Mercedes incision and 
extended right subcostal (ERSC) incision, and that the ERSC incision provides ade-
quate, safe access and is associated with fewer long-term wound complications 
(9.8% vs 4.8%, P<0.001).[48] More recently, Togo et al. reported frequencies of inci-
sional hernia after median, J-shaped, right transverse incision with a vertical exten-
sion at the midline from the subumbilical region to the xiphoid process (RTVE), and 
reversed T incisions to be 6.3%, 4.7%, 5.4%, and 21.7%, respectively. A diagnosis of 
‘no hernia’ required a minimum follow-up of 12 months.[49] 
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To assess the incidence of incisional hernias in patients undergoing laparoscopic and 
open LLS, they will be contacted at a mean time of 1 year after resection to undergo 
ultrasonography or CT-scan to assess the incidence of incisional hernia. 
STUDY POPULATION 
Every patient requiring LLS will be identified and informed at the outpatient clinic 
about open and laparoscopic liver resection. Only patients meeting the inclusion and 
exclusion criteria will be approached for randomization. After reading the ORANGE II 
trial patient information and being allowed 1 week for consideration, patients will be 
asked for their informed consent. All patients ineligible for randomization due to 
patient or surgeon preference will be approached for participation in the prospective 
registry. If patients express an explicit preference, they will be allocated to the pro-
spective registry and interviewed to ascertain the reasons for their preferences. Per-
sonal written informed consent will be obtained for all groups. Randomization will be 
carried out through the ORANGE II trial website using web-based randomization 
software (TENALEA; www.tenalea.com) (see Figure 1 for trial flow-chart). Patients will 
be approached for randomized inclusion if they meet each of the following inclusion 
criteria: require LLS; willingness to participate in the study; able to understand the 
nature of the study and what will be required of them; are men or non-pregnant, 
non-lactating women between the ages of 18 and 80 years of age; have a body mass 
index of between 18 and 35; and have ASA grading of I to III. 
The exclusion criteria are: liver resection other than LLS; underlying liver disease; 
unwillingness to participate; inability to give written informed consent; and ASA 
grading of IV to V. 
ERAS-PROGRAMME 
All patients will participate in the ERAS liver programme, with a standardized periop-
erative management. For daily guidelines of the pre- and post-operative care of pa-
tients undergoing liver resection (Figure 2). 
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Figure 1. Orange II-Trial Flowchart. 
 
 
Patients eligible for left lateral hepatic sectionectomy 
Check in- and exclusion criteria 
Randomisation Registry  
(open & laparoscopic LLS) 
In hospital: 
- ERAS – information 
- Preoperative patient characteristics 
- Surgical and anaesthetic parameters 
- Patient journal  
- Milestone Checklist  
- Functional Recovery Checklist 
- Discharge criteria 
- Hospital length of stay 
- Quality of Life (EQ-5D, QLQ-LM21)  
  at admission and discharge 
- Body image + cosmesis (BIQ)  
  at admission and discharge  
- (Serious) Adverse Events 
- Direct healthcare costs  
Informed consent  
Out of hospital: 
- 10 days, 3, 6, 12 months after 
  discharge: Quality of Life (EQ-5D, 
  QLQ-LM21), Body Image Question- 
  naire  (BIQ) 
- Indirect + direct costs outside 
  health care (cost questionnaire) at 
  3, 6 and 12 months after discharge 
- US for incidence of incisional hernias 
  after 1 year 
- (Serious) Adverse Events  
- Readmission 
Open LLS Laparoscopic LLS 
ERAS – Programme  
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Figure 2. Daily guideline of post-operative care of patients undergoing a hepatectomy in the ERAS pro-
gramme 
FUNCTIONAL RECOVERY CRITERIA 
The evaluation of time to functional recovery will start on POD 0 and will be scored 
twice daily until discharge from the hospital. The discharge process starts at the pre-
admission counseling session, during which any special needs of the patients will be 
determined (for example, homecare or social support, transport. Before admittance, 
any problem that could delay discharge will be identified and addressed. Patients will 
only be discharged when they have met the five functional recovery criteria and are 
willing to go home. Reasons to delay discharge after functional recovery will be mon-
itored and documented. Functional recovery criteria and LOS in hospital will be in-
dependently monitored and analysed. 
 
Day before surgery: 
Normal oral nutrition up to 6 hours 
before surgery 
No pre-anaesthetic medication 
Laboratory tests 
 
Day of surgery 
Carbohydrate drinks up to 2 hrs prior to 
surgery 
Midthoracic epidural analgesia (low 
local anaesthetic + low dose opioid)    
Short-acting i.v. anaesthetic agent 
Preferably no nasogastric drainage, but 
when used remove after surgery 
Use warm i.v. fluids and upper and 
lower body air-warming device 
Avoid excessive i.v. fluids (CVP during 
transection <5 mmHg) 
No routine drainage of the peritoneal 
cavity 
Patient sent to recovery ward 
Restart oral intake of water / nutrition 
 
Post Operative Day (POD) 1 
Patient sent to surgical ward 
Patient mobilizes a minimum of four 
times a day 
Discontinuation of i.v. fluids 
Patient drinks at least 1.5 litre 
Normal diet 
Continue portable epidural analgesia 
(local  
anaesthetic-low dose opioid) or PC A 
Remove urinary catheter 
 
 
1000 mg aminocetophen 6 hourly 
Start laxatives 
Laboratory tests 
 
POD 2 
Continue portable epidural analgesia or 
PCA 
Stop low dose opioids 
Continue mobilization a minimum of 
four times per day 
1000 mg aminocetophen 6 hourly 
Normal diet 
Laxatives 
 
POD 3 
Stop epidural analgesia or PCA 
Start NSAID’s 
Continue mobilization 
Normal diet 
Laxatives 
Laboratory tests 
Check discharge criteria 
Outpatient appointment made on 
postoperative day 10,11 or 12 
 
POD 4 
Check discharge criteria 
Patient receives cell phone number 
HPB-surgeon on duty 
Discharge 
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Criterion I: Adequate pain control with oral analgesics 
Post-operative pain will be systematically registered twice daily using the validated 
verbally administered 11-point numeric rating scale (NRS-11, 0 to 10).[50-53] Mem-
bers of a specialized pain team will ask patients to rate the intensity of their current 
pain on a scale of 0 (no pain) to 10 (worst possible pain), with pain rated as ‘mild’ (1 to 
3) ‘moderate’ (4 to 6) or ‘severe’) 7 to 10 [54]. The NRS-11 seems to be better accepted 
by most patients and to be at least as sensitive and valid as the more traditional VAS 
ratings.[53] 
Criterion II: Independently mobile or at preoperative level 
To assess the difference between the preoperative and post-operative mobility level, 
the ERAS Mobility Scale (EMS) has been developed from the Groningen Activity Re-
striction Scale.[55] The EMS assesses 10 basic actions to compare the level of mobility 
before and after surgical intervention. When the patient is able to perform 8 of the 10 
items, they are independently mobile. Patients will be assessed whether they are 
able or not to independently perform these basic actions fully. Daily the assessment 
will be repeated and compared with the preoperative baseline score until mobility at 
an independent or preoperative level is achieved. 
Criterion III: No intravenous fluids or medication administration 
 
Criterion IV: Tolerance of solid food 
Fluid and solid food intake will be monitored and must return to normal, that is, 
when oral intake of water or normal food is resumed and continued for at least 24 
hours. Furthermore the incidence of post-operative nausea and vomiting, which 
obviously influences intake, will be monitored post-operatively until day 6 using a 
scale ranging from 0 (no nausea) to 10 (worst possible nausea), and where necessary, 
be countered prophylactically by antiemetic treatment. 
Criterion V: Normal or decreasing serum bilirubin level and INR 
STATISTICAL ANALYSIS 
Sample size 
Because laparoscopic liver surgery focuses on accelerated recovery, time to function-
al recovery is used as the primary outcome parameter. Owing to the lack of hard 
evidence about the reduction in time to functional recovery after liver surgery, we 
have chosen to use the parameter that most accurately approaches our primary 
endpoint for our power calculation (LOS). Based on a retrospective analysis of 31 
patients in both ERAS and non-ERAS settings, who have undergone LLS from 1990 to 
the present time, the mean ± SD post-operative hospital stay for a LLS in the Maas-
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tricht University Medical Centre is 6 ± 2.73. It therefore seems that that in patients 
undergoing laparoscopic LLS, time to functional recovery is reduced in comparison 
to patients undergoing the open procedure. We are aiming for a reduction in time to 
functional recovery of 2 days. A sample size of 2 × 40 patients in the randomization 
arms will be sufficient to show a 2-day reduction with a power of 90% and a level of 
significance at alfa = 0.05 (two-tailed, given a within-arm SD of 2.73 with effect size d 
= 0.73). Assuming an expected withdrawal rate of ≤ 10% during the trial, the partici-
pation of at least 10 centres, and the required addition of one randomised patient 
per arm for every additional participating centre (C) to compensate for the loss of 
degrees of freedom incurred in the data analysis, which takes centre and treatment × 
centre effects into account, a total sample size of 110 (n = 2 × 55) will be required. 
For all secondary outcome measures, the power will be 75% after correction for mul-
tiple testing with two-tailed alfa = 0.01, assuming the same effect size (d = 0.73) as for 
the primary outcome. An interim analysis of the primary outcome, using Snapinn’s 
method, will be performed after inclusion of 50% of the sample to avoid unnecessary 
inclusion of too many patients in this ORANGE II trial.[56] 
Descriptive statistics 
The primary outcome parameter of time to functional recovery and the secondary 
parameter of LOS in hospital will be given in days, with a median and range. Morbidi-
ty will be classified according to the classification described by Dindo et al. and de-
fined as a dichotomous composite endpoint, while readmission will be given as a 
percentage. Scores for quality of life, body image and cosmesis will be given as mean 
and standard deviation per time point per treatment arm. Hospital costs will be given 
as median and range. Long-term incidence of incisional hernia will be reported and 
analysed. 
Univariate analysis 
The primary outcome measure of time to functional recovery will be measured in 
days, and will be analysed with fixed-effect regression that will take centre and 
treatment × centre interaction into account as fixed effects. If the actual number of 
centres and the sample size per centre allow random effects analysis, this will also be 
performed and this analysis will have the same power as the planned fixed effects 
analysis if the design effect does not exceed 1.2. With a sample size of 10 patients per 
centre, the design effect is 1.2 if the intraclass correlation (ICC) is 0.02, where the ICC 
is based on treatment × centre interaction.[57] 
All secondary outcomes as measured at discharge will be analysed by fixed-effect 
regression using linear regression for quantitative outcomes and logistic regression 
for binary outcomes, and including the baseline measure as a covariate to improve 
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power and precision. In addition to P-values, confidence intervals for all effects will 
be reported. Morbidity will be classified as described by Dindo et al., but will be pre-
sented as raw data only because the required sample size for intervention effects on 
morbidity is much larger than the calculated sample size for this trial.[58] 
ECONOMIC EVALUATION 
The economic evaluation will include a cost-utility analysis from a societal perspec-
tive. The time horizon of this evaluation will be the same as the duration of the trial, 
that is, 12 months. All costs (direct and indirect) related to both interventions will be 
calculated. The final cost calculation of unit costs will be based on a combined bot-
tom-up and top-down approach. In accordance with Dutch guidelines for cost calcu-
lation, indirect healthcare costs will not be taken into account. In addition, resource 
use will be measured by use of primary data that is registered in our case record 
forms (CRFs) by use simple checklists. Furthermore, a questionnaire will be used to 
survey the direct non-healthcare costs related to travelling, impaired mobility and 
domiciliary care (for normal daily activities). The incremental, indirect non-healthcare 
costs per QALY gained will be based on the utility scores from the EQ-5D.[39-41] For 
all direct healthcare costs, the unit prices will be based either on prices from the hos-
pital financial department or the Dutch guidelines for cost calculation.[45] 
REGISTRY 
The prospective registry of patients who cannot be randomized because of explicit 
treatment preference on the part of the patient or surgeon will be analysed as an 
observational study. In addition, data from the registry will be analysed for interac-
tion between treatment, centre, and study type (randomised or not). On condition 
that there is no interaction between treatment, centre, and study type, and that the 
observational study does not suffer from severe confounding (because adjusting for 
that strongly reduces the power of the observational study), pooling of both studies 
should give more power than separate analyses of either study. Possible confounders 
will be registered in the CRFs. The inclusion of the prospective registry in the trial 
design will create an uninterrupted case series, which will increase external validity 
and generalizability. 
DATA COLLECTION 
Data concerning patient characteristics, functional recovery, surgical and anaesthesi-
ologic parameters, morbidity, LOS, QOL, patient compliance, and costs will be pro-
spectively collected using both paper CRFs and an open source clinical trial software 
platform (OpenClinicaW; Ikaza Research, Cambridge, MA, USA) that uses e-CRFs for 
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electronic data capture and clinical data management, which are validated and 
stored in compliance with good clinical practice guidelines. The e-CRFs will be stored 
in a secured database (Oracle Cor., Redwood Shores, CA, USA), and as stated previ-
ously, all patient data will be encoded to ensure privacy. 
MONITORING 
For this trial, a Data and Safety Monitoring Board (DSMB) has been appointed that 
will consist of three members: a chairperson, an independent statistician, and a med-
ical specialist. In a concerted effort a DSMB charter will be developed, and all three 
members will sign a non-competing interest form. The DSMB will be responsible for 
safeguarding the interests of trial participants, assessing the safety and efficacy of the 
interventions during the trial, and monitoring the overall conduct of the clinical trial. 
INTENTION TO TREAT 
Analysis of all patients will be performed according to the intention-to-treat princi-
ple: patients will be analysed as randomized or as planned in the non-randomized 
prospective registry, and all patients will be included in the data analysis with proper 
methods for handling missing data. 
DISCUSSION 
Several authors have indicated that laparoscopic liver resection has many benefits 
over conventional open liver resection. However, this has never been proven in an 
RCT, and what the primary endpoint should be for an RCT comparing open and lapa-
roscopic liver resection is a subject to debate. Using either liver surgery-related mor-
tality or liver surgery-specific morbidity as an endpoint is not feasible, because pa-
tient accrual would take many years and be a logistically major global effort [58]. LOS 
in hospital, time to recovery, long-term incisional hernias, body image, and costs are 
potential candidates because improvements in these are some of the possible bene-
fits. Laparoscopic liver resection is appealing for many surgeons and patients, but the 
learning curve for the surgeon is thought to be long and costly for hospital budgets. 
However, operating times in laparoscopic LLS tend to be shorter, and may compen-
sate for expenses in technology and consumables.[31,59] Moreover, the existing 
trials in liver surgery have not evaluated time to recovery or LOS in hospital after 
laparoscopic liver resection within an enhanced recovery programme. The more 
rapid recovery reported after enhanced recovery programmes may be further accel-
erated as a consequence of small incisions in laparoscopic surgery. In addition, learn-
ing curves for laparoscopic left lateral resection or anterior segments seem to be 
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reasonably short for liver surgeons with advanced laparoscopic experience.[60] The 
question remains whether an RCT is necessary to prove that laparoscopy should be 
accepted as the preferred method to perform liver resection. In the Louisville con-
sensus meeting on laparoscopic liver surgery, it was stated that laparoscopic LLS 
should be standard practice in experienced hands.[61] However, this may have been 
a subjective vision of a subset of opinion leaders, because long experience with both 
open and laparoscopic liver surgery was the main characteristic of those attending 
the meeting. Undoubtedly, the dissemination phase of laparoscopic liver surgery has 
started, and it is to be expected that many surgeons will adopt this technique in the 
future. A multinational multicentre prospective registry, a well-organised multicentre 
RCT, training programmes, and quality control measures are of great importance 
during this adoption period. [33] 
It is well recognized that a well-conducted double-blind RCT provides the highest 
level of evidence to prove the possible benefits of laparoscopic liver resection. How-
ever, performing an RCT in surgery is not without difficulties, and alternative trial 
designs may be necessary.[33,34,62] First, the intervention needs to be tested in a 
standardized environment, and the properties of the intervention should remain 
unchanged during the trial period. This seems impossible for an intervention such as 
laparoscopic liver surgery in a multicentre RCT. Experience varies between participat-
ing centres, and will vary over time. Moreover, local standards for perioperative care 
are different. Both LLS and the ERAS protocol provide the standardization needed. 
The learning curve of LLS is short in centres with experience in liver surgery and ad-
vanced laparoscopy. The use of proctor surgeons in centres with limited experience 
in laparoscopic liver surgery the operative techniques can be reasonably standard-
ized, and this should eliminate learning curve influences on outcome parameters. 
Quality of the surgery can be assured by digital video recording. 
Second, the intervention should be double-blinded. Although double blinding in a 
surgical trial is difficult, using a fixed abdominal dressing for 3 days after surgery is 
feasible, and should prevent both ward caregivers and patients from knowing the 
type of intervention. Third, it is reasonable to query whether this is now the right 
time to perform an RCT and whether the results of the trial will be valid for the more 
general surgical community. A recent review of the results of laparoscopic liver resec-
tion in 2,804 patients showed that laparoscopic liver resection in expert centres is 
feasible and safe for both minor and major liver resections.[36] The percentages of 
liver resections performed laparoscopically now range from 25% to 65% in high-
volume expert centres such as University Hospital Southampton NHS (Southampton, 
UK), Henri Mondor (Paris, France), UPMC (Pittsburgh, USA), UZ Leuven (Leuven, Bel-
gium) and Rikshospitalet (Oslo, Norway).[36,63] Although it is to be expected that 
many centres worldwide will adopt laparoscopic liver resection as a more or less 
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standard procedure in the near future, there are still many patients and surgeons that 
prefer the open procedure long beyond the learning curve. In parallel with the de-
velopment of laparoscopic liver surgery, ‘fast-track’ programmes in various areas of 
surgery, including liver surgery, are gaining popularity. Therefore, this seems to be 
the right time for this RCT to be performed. The multicentre character of the ORANGE 
II trial with randomization of patients and surgeons with treatment equipoise and a 
prospective registry to cover both surgeons who believe that based on their laparo-
scopic experience randomization is not ethically justified and patients with a strong 
treatment preference will provide external validity. This trial design capitalizes on 
rather than ignores the differences between patients, will provide more robust out-
come data, and should lead to continuous performance monitoring after the tri-
al.[35,62] 
The key question clearly is as to whether this RCT is really necessary. The benefits of 
laparoscopic liver resection are not beyond reasonable doubt, and although data are 
becoming increasingly available, recent publications do not provide sound data on 
time to recovery. Worldwide, median LOS in hospital for open and laparoscopic re-
sections varies from 4 to 8 days.[17, 30, 64-66] Reasons for delay in discharge and 
discharge location are often absent, and a clear definition of recovery has not been 
used to date in any of the publications. Departing from the standpoint that an RCT 
should be conducted, the question is which sample size should be used? In our opin-
ion, a reduction of only 1 day in time to recovery or LOS in hospital after laparoscopic 
resection would be a disappointingly low gain. To prove such a reduction, 320 pa-
tients would be needed (alfa = 0.05 and power of 90%), making the trial unlikely to 
be accomplished. Based on available reports, a 2-day reduction should be possible 
[17, 31, 66], and reduces the sample size to 110 patients undergoing LLS. This num-
ber is reasonably moderate, and it is to be expected that patient accrual will be ac-
complished within 1–2 years. 
It should be realized that many centres have introduced laparoscopic liver surgery 
programmes in the absence of a central reporting or certifying agency. In our opin-
ion, laparoscopic LLS should function as a model for further dissemination of laparo-
scopic techniques in hepatic surgery. The left lateral segment of the liver has been a 
natural first step for a laparoscopic resection given the peripheral anatomical loca-
tion (thin liver segment, minimal requirement for biliary dissection, and ease of con-
trolling the left portal pedicles and left hepatic vein), and has been proven to be safe 
and feasible with reproducible results.[20,36] The implementation of the laparoscop-
ic LLS may not only serve as a guide to develop and master programmes for major 
laparoscopic hepatic resections, but may also be used as an introduction for centres 
new to laparoscopic approaches in liver surgery. To adopt laparoscopic liver resec-
tion safely, certification for centres, surgeons, and units should be available through 
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the International Hepatobiliary (HPB) Association, and national and international HPB 
associations should become involved in the goal of establishing training standards 
and credentials to ensure a high and consistent outcome. The ORANGE II trial in 
which techniques are standardized and a training and proctor programme is availa-
ble, combined with the hybrid design of randomization and registry may help to 
provide a framework for controlled and safe implementation of laparoscopic liver 
resection across participating centres. 
CONCLUSION 
The international multicentre randomised controlled ORANGE II trial is based on the 
observations of more rapid recovery and discharge after laparoscopic liver resection, 
and more rapid recovery and discharge after open liver resection within an enhanced 
recovery programme. This is the first RCT to provide evidence on the merits of lapa-
roscopic surgery in patients undergoing LLS within an enhanced recovery pro-
gramme. 
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ABSTRACT 
BACKGROUND 
Laparoscopic left lateral sectionectomy (LLLS) has been associated with shorter hos-
pital stay and reduced overall morbidity compared with open left lateral sectionec-
tomy (OLLS). Strong evidence has not, however, been provided.  
METHODS 
In this multicentre double-blind RCT, patients (aged 18–80 years with a BMI of 18–35 
kg/m2 and ASA fitness grade of III or below) requiring left lateral sectionectomy (LLS) 
were assigned randomly to OLLS or LLLS within an enhanced recovery after surgery 
(ERAS) programme. All randomized patients, ward physicians and nurses were blind-
ed to the procedure undertaken. A parallel prospective registry (open non-
randomized (ONR) versus laparoscopic non-randomized (LNR)) was used to monitor 
patients who were not enrolled for randomization because of doctor or patient pref-
erence. The primary endpoint was time to functional recovery. Secondary endpoints 
were length of hospital stay (LOS), readmission rate, overall morbidity, composite 
endpoint of liver surgery-specific morbidity, mortality, and reasons for delay in dis-
charge after functional recovery. 
RESULTS 
Between January 2010 and July 2014, patients were recruited at ten centres. Of these, 
24 patients were randomized at eight centres, and 67 patients from eight centres 
were included in the prospective registry. Owing to slow accrual, the trial was 
stopped on the advice of an independent Data and Safety Monitoring Board in the 
Netherlands. No significant difference in median (i.q.r.) time to functional recovery 
was observed between laparoscopic and open surgery in the randomized or non-
randomized groups: 3 (3–5) days for OLLS versus 3 (3–3) days for LLLS; and 3 (3–3) 
days for ONR versus 3 (3–4) days for LNR. There were no significant differences with 
regard to LOS, morbidity, reoperation, readmission and mortality rates.  
CONCLUSIONS 
This RCT comparing open and laparoscopic LLS in an ERAS setting was not able to reach 
a conclusion on time to functional recovery, because it was stopped prematurely owing 
to slow accrual.  
Registration number: NCT00874224 (https://www.clinicaltrials.gov). 
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INTRODUCTION 
The left lateral segments of the liver can be resected by both open and laparoscopic 
approaches. The latter has become increasingly popular after the Louisville State-
ment of 2008, where experts concluded that laparoscopic left lateral sectionectomy 
(LLS) was a safe and effective approach for the management of surgical liver disease 
in the hands of experienced hepatobiliary and laparoscopic surgeons.[1] Later re-
views, based mainly on retrospective data, showed favourable clinical outcomes after 
laparoscopic resection.[2,3] Studies specifically comparing open and laparoscopic 
LLS have hitherto been based on retrospective designs or with small sample size.[4,5] 
A meta-analysis of non-randomized studies showed a reduction in duration of opera-
tion, shorter overall length of hospital stay (LOS) and reduced morbidity after laparo-
scopic LLS.[6] This difference in LOS was, however, associated with significant heter-
ogeneity among the included studies. 
Enhanced recovery after surgery (ERAS) programmes have been introduced in pa-
tients undergoing minor and major liver resections. Multiple studies [7–15] have 
shown that these programmes are feasible, safe and effective in reducing median 
LOS in both open and laparoscopic resection. Data available at the time of design of 
this study also suggested that a further reduction in LOS after liver resection could be 
achieved when the observed delay between patient recovery and actual discharge 
was minimized, as reported for colonic resections.[10,16] Day of discharge from hos-
pital is dependent on multiple factors, including patient expectations, local discharge 
logistics and cultural differences between countries, hospitals and surgeons. LOS 
may therefore be considered an inappropriate endpoint for comparison of surgical 
interventions. Within the ERAS programme for liver surgery, a composite endpoint 
has been defined: time to functional recovery. This endpoint, representing medical 
readiness for discharge, consisted of clear and objectively measurable criteria. A pa-
tient was considered functionally recovered if they had a normal or decreasing serum 
bilirubin level, good pain control with oral analgesia only, tolerance of solid food, no 
intravenous fluid support and independent mobility at the preoperative level.[10] 
Functionally recovered patients were generally capable of independently performing 
activities of daily living and were independent of hospital care. 
The aim of this study was to compare open and laparoscopic liver surgery in a ran-
domized, controlled, multicentre and blinded setting, in which all patients received a 
standardized liver resection within a standardized perioperative care programme, 
based on a standardized recovery outcome measure. A parallel registry to the ran-
domized controlled arms was created to study an uninterrupted series for external 
validity. The hypothesis was that in patients undergoing laparoscopic LLS (LLLS), 
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time to functional recovery would be reduced by 2 days compared with that in those 
having open LLS (OLLS). 
METHODS 
STUDY DESIGN AND PARTICIPANTS 
This study (ORANGE II) was designed as a double-blind RCT with a parallel prospec-
tive registry of patients who could not be randomized owing to patient or surgeon 
preference. Patients were eligible for inclusion in the randomization if they required a 
liver LLS for accepted indications, if they were men or non-pregnant, non-lactating 
women aged 18–80 years with a BMI of 18–35 kg/m2 and an American Society of 
Anesthesiologists (ASA) grade of III or less. Exclusion criteria were: planned liver re-
section other than LLS, ASA grade above III, and underlying liver disease diagnosed 
before surgery. 
Representatives of the ORANGE II study group from Maastricht University Medical 
Centre coordinated the trial and analysed the data. The study protocol was approved 
by medical ethics committees at each participating centre. Centres were approached 
by e-mail and could participate if laparoscopic and open liver surgery were per-
formed on a routine basis and if an ERAS liver programme had been implemented. 
Fourteen European sites obtained ethical approval to enroll patients; twelve were 
located in the Netherlands, one in Germany and one in Italy. The study protocol was 
registered online at ClinicalTrials.gov (NCT00874224), and has been published.[17] 
The aim of the study was to compare LLLS with OLLS in terms of time to functional 
recovery (primary endpoint). The hypothesis was that time to functional recovery 
would be reduced by 2 days in patients undergoing LLLS. 
RANDOMISATION AND MASKING 
Patients were approached for participation in the outpatient clinic. All provided writ-
ten informed consent before preoperative assessment. They received information 
and counselling related to the study intervention, ERAS programme and other study-
related procedures. Patients were assigned randomly before admission in a 1:1 ratio 
to either OLLS or LLLS. Randomization was performed by each local study coordina-
tor using a web-based system (TENALEA®; FormsVision, Abcoude, The Netherlands) 
and block randomization. Randomization was stratified according to treatment, cen-
tre, sex and ASA grade. The allocated procedure was communicated to the operating 
surgeon(s). All randomized patients, ward physicians and nurses were blinded to the 
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type of intervention by the use of a large fixed abdominal dressing until post-
operative day (POD) 3. Non-randomized patients were asked for permission to use 
their data. In doing so, they were assigned to the open non-randomized (ONR) or 
laparoscopic non-randomized (LNR) arm of the prospective registry, on the basis that 
this registry might increase the external validity of results obtained in the random-
ized study.[18,19] 
PROCEDURES 
The intraoperative surgical technique was not standardized; surgeons in participat-
ing centres were free to use their preferred technique and devices to gain intra-
abdominal access, perform hepatic parenchymal transection and maintain vascular 
control. Surgeons in each participating centre performed the allocated intervention 
based upon availability. Medical centres with liver surgeons early in the laparoscopic 
learning curve were assisted during the procedure by an experienced proctoring 
laparoscopic hepatopancreatobiliary (HPB) surgeon. Perioperative care for all pa-
tients in the study was standardized according to the ERAS programme and the peri-
operative care provided was based on daily guidelines (Table 1). 
OUTCOMES 
The primary outcome measure of this study for both the randomized and parallel 
cohorts was time to functional recovery. A patient was considered functionally re-
covered when all of the following criteria were fulfilled: adequate pain control with 
oral analgesia only; restoration of mobility to an independent or preoperative level; 
absence of intravenous fluid administration; ability to eat solid foods; and normal or 
decreasing serum bilirubin level or international normalized ratio (INR). The evalua-
tion of time to functional recovery started on POD0 and was scored until discharge 
from hospital using a standard checklist and patient diary. Patients were considered 
ready for discharge when the primary endpoint had been met, although it was up to 
the local logistics of each centre to define the actual moment of discharge. The delay 
between time to functional recovery and actual discharge was recorded and reasons 
for this delay were obtained. 
Post-operative pain was registered twice daily using the validated, verbally adminis-
tered, 11-point (0–10) numerical rating scale (NRS-11).[20,21] Centres were free to 
provide either epidural or intravenous patient-controlled analgesia. No indwelling 
wound catheters were used in participating centres. Members of a specialized pain 
team asked patients to rate the intensity of their current pain on a scale from 0 (no 
pain) to 10 (worst possible pain). A score of 1–3 was considered to be mild, 4–6 mod-
erate and 7–10 severe.[22] 
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To report the difference between preoperative and post-operative level of mobility, 
the ERAS Mobility Scale (EMS), derived from the Groningen Activity Restriction Scale 
[23], was used. The EMS utilizes ten items of basic actions to compare the level of 
mobility before and after surgical intervention. When the patient reached the pre-
operative EMS level, or had a positive score for eight of ten items, they were consid-
ered independently mobile. 
Fluid and solid food intake was monitored, and a normal tolerance was required 
before discharge. Tolerance was considered to be normal when oral intake solid food 
was resumed and continued for at least 24 h. At the time of design of the study it was 
decided to monitor the post-operative serum bilirubin concentration and INR to 
ensure that no patient was discharged with impaired liver function. Serum bilirubin 
levels and INR were measured before surgery and on POD1 and 3. Secondary out-
comes were post-operative LOS, readmission rate, total morbidity according to the 
Clavien–Dindo classification [24], composite endpoint of liver surgery-specific mor-
bidity [25], mortality, and reasons for delay in discharge after functional recovery. 
DATA COLLECTION AND PATIENT SAFETY 
Data were collected using both paper case report forms (CRFs) and an open-source 
clinical trial software platform (OpenClinica®; Ikaza Research, Cambridge, Massachu-
setts, USA) in compliance with good clinical practice guidelines. The e-CRFs were 
stored in a secured database (Oracle Corporation, Redwood Shores, California, USA). 
A baseline assessment of mobility was performed on the day of admission. Venous 
blood samples were drawn before and after surgery, on POD1 and 3. During admis-
sion, surgical details, data on time to functional recovery and complications were 
collected with a patient diary, a milestone checklist and standardized adverse event 
forms. 
An independent Data and Safety Monitoring Board (DSMB) in the Netherlands evalu-
ated the progress and quality of the trial and examined safety endpoints for each 
consecutive group of 25 patients. Baseline characteristics and serious adverse events 
were listed and presented in an unblinded fashion. Recommendations made by the 
DSMB were communicated to the medical ethics review committee of Maastricht 
University Medical Centre and all participating centres. 
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Table 1 Perioperative care according to the enhanced recovery after liver surgery programme 
 Daily guideline 
Day before surgery Normal oral nutrition up to 6 h before surgery No preanaesthetic medication 
Laboratory tests 
Day of surgery Carbohydrate drinks up to 2 h before surgery Mid-thoracic epidural analgesia (local 
anaesthetic  
 + low-dose opioid) 
Short-acting i.v. anaesthetic agent 
Preferably no nasogastric drainage, but when used remove after surgery 
Use warm i.v. fluids, and upper and lower body air-waming device 
Avoid excessive i.v. fluids 
CVP during transection<5mmHg 
No routine drainage of peritoneal cavity Patient sent to recovery ward 
Restart oral intake of water/nutrition 
POD 1 Patient sent to surgical ward 
Patient mobilizes a minimum of four times a day Discontinuation of i.v. fluids 
Patient drinks at least 1.5 litres Normal diet 
Continue portable epidural analgesia (local anaesthetic + low-dose opioid) or PCA 
Remove urinary catheter 1000mg paracetamol 6-hourly Start laxatives 
Laboratory tests 
POD 2 Continue portable epidural analgesia or PCA Stop low-dose opioids 
Continue mobilization a minimum of four times daily 1000mg paracetamol 6-hourly 
Normal diet Laxatives 
POD 3 Stop epidural analgesia or PCA Start NSAIDs 
Continue mobilization Normal diet Laboratory tests 
Check discharge criteria 
Outpatient appointment made for POD10, 1 or 12 
POD 4 Check discharge criteria 
Patient given mobile phone number of HPB surgeon on duty 
Discharge 
i.v., Intravenous; POD, post-operative day; CVP, central venous pressure; PCA, patient-controlled analgesia; 
NSAID, non-steroidal anti-inflammatory drug; HPB, hepatopancreatobiliary. 
STATISTICAL ANALYSIS 
Time to functional recovery was used as the primary endpoint. Owing to lack of data 
on the reduction in time to functional recovery after liver surgery in an ERAS pro-
gramme, a decision was made to use LOS for the purpose of power calculation, be-
cause this approached the primary endpoint most accurately. Based on a retrospec-
tive analysis of 31 patients in both ERAS and non-ERAS settings, who had undergone 
LLS from 1990 to 2010, the mean(s.d.) value for post-operative LOS after LLS in Maas-
tricht University Medical Centre was 6.0(2.7) days. Thus a reduction in time to func-
tional recovery of 2 days seemed feasible. 
At 90 per cent power and alfa=0.05 (two-tailed), a sample size of 2 × 40 patients in 
the randomization arms would be sufficient to detect this difference (two-tailed test-
ing was planned to allow detection of an (unexpected) increase in time to functional 
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recovery after LLLS compared with OLLS, and to be consistent with the two-sided 
confidence intervals to be reported). Assuming an expected withdrawal rate of 10 
per cent or less, the participation of at least ten centres, and the required addition of 
one randomized patient per arm for every additional participating centre to com-
pensate for the loss of degrees of freedom incurred in the data analysis (which takes 
centre and treatment × centre effects into account), a total sample size of 110 (2 × 
55) was required. Patients were analysed according to the intention-to-treat princi-
ple, and analysis was performed with SPSS® software using Windows® version 21.0 
(IBM, Armonk, New York, USA). 
After each group of 25 included patients, a report was sent to the DSMB. An interim 
analysis was planned after randomization and completion of follow-up of 50 per cent 
of the total sample size. The DSMB provided the principal investigator with recom-
mendations: no action needed, early stopping (due to clear benefit/ harm of a treat-
ment, futility, or new external evidence), extending recruitment or follow-up, stop-
ping a single arm of the multi-arm trial, or sanctioning and/or proposing protocol 
changes. Assumption of normality was checked using the Shapiro–Wilk test. Contin-
uous numerical data were summarized by the median (i.q.r.) value per treatment arm. 
Analysis was performed with X2 or Fisher’s exact tests for binary outcomes, and 
Mann–Whitney U or t tests for continuous outcomes, depending on their normality. 
For the primary outcome time to functional recovery alfa=0.05 (two-tailed) and for 
the secondary outcomes alfa=0.01 (two-tailed) were used to correct for multiple 
testing. 
Post hoc analyses to assess milestones during recovery of patients and compliance 
with elements of the ERAS protocol were also performed. To describe the compliance 
with individual ERAS elements per study group and centre, an overall compliance 
and the between-centre range was used. Per element, an 80 per cent cut-off value 
was set to qualify as compliant. 
The outcome analyses were repeated with multiple linear regression to adjust for 
patient age, sex, ASA grade and centre effects. Differences between individual sur-
geons within the same centre with respect to time to functional recovery, LOS, and 
difference between time to functional recovery and LOS were also examined. 
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RESULTS 
ENROLMENT AND RANDOMISATION 
From January 2010 to 1 July 2014, ten of 14 centres that had ethical approval recruit-
ed patients for this study. A total of 104 patients were assessed for eligibility and 97 
were included (Fig 1). Only 29 participants were randomized: 14 to OLLS and 15 to 
LLLS. The remaining 68 patients were included in the prospective registry. Some five 
patients were excluded after randomization: four required a larger hepatic resection 
and surgery was postponed in one woman because of pregnancy. One patient in the 
open arm of the prospective registry was also excluded after a preoperative change 
of procedure. No 30-day dropouts were observed in the RCT or prospective registry. 
A total of 91 patients (24 randomized and 67 prospective registry) were included in 
the intention-to-treat analysis. The DSMB did not express any objections to continua-
tion of the trial after the first two reports (October 2012 and April 2013). In the third 
report of January 2014, however, the DSMB expressed concerns about the ORANGE II 
study group, because of an accrual rate of 24 per cent in the RCT. 
In accordance with recommended criteria for accrual and scientific progress [26], a 
trial should be closed if it is open for more than 24 months with an accrual rate of less 
than 25 per cent. Therefore, the DSMB advised continuation of the trial for a maxi-
mum of 6 months. Because enrolment remained slow, a decision was made by the 
investigators to stop the trial on 1 July 2014. 
PREFERENCE 
Sixty-seven (73.6 per cent) of the 91 included patients in this study had surgery based 
on preference for either the open or laparoscopic procedure, usually surgeon prefer-
ence: nine of 13 patients (69 per cent) in the open arm and 39 of 54 (72 per cent) of 
those in the laparoscopic arm of the prospective registry. 
PATIENT DEMOGRAPHICS AND SURGICAL OUTCOME 
Baseline patient characteristics (Table 2) and surgical outcomes (Table 3) were dis-
tributed equally between the groups in the randomized part study (OLLS versus 
LLLS), as well as in the prospective registry (ONR versus LNR). There appeared to be 
more patients with a history of previous abdominal surgery in the LNR group and a 
longer median duration of surgery in the LLLS group, but after correction for multiple 
testing these differences were not significant. 
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Figure 1. CONSORT diagram for the trial. LLS, left lateral sectionectomy; OLLS, open left lateral sectionec-
tomy; LLLS, laparoscopic left lateral sectionectomy 
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Table 2. Patient demographics 
 RCT Registry 
OLLS (n=11) LLLS (n=13) P# ONR (n=13) LNR (n=54) P# 
Age (years)* 58 (52–70)‡‡ 67 (55–73)‡‡ 0.361** 53 (46–64) 63 (45–72) 0.219** 
Sex ratio (M: F) 5 : 6 9 : 4 0.408 8 : 5 26 : 28 0.386†† 
BMI (kg/m2)* 28.7  
(25.5–33.9)‡‡ 
27.1  
(25.3–28.5)‡‡ 
0.361** 23.5 
(22.0–27.2) 
24.7 
(22.5–29.2) 
0.306** 
ASA fitness grade   0.252**   0.851** 
I 3 (27) 1 (8)  4 (31) 17 (31)  
II 7 (64) 9 (69)  8 (62) 30 (56)  
III 1 (9) 3 (23)  1 (8) 7 (13)  
Indication for surgery   0.182   0.267†† 
Colorectal metastasis 6 (55) 11 (85)  7 (54) 20 (37)  
Other 5 (45)† 2 (15)‡  6 (46)§ 34 (63)¶  
Previous abdominal 
surgery 
9 (82) 11 (85) 1.000 9 (69) 24 (44) 0.048†† 
Preoperative chemo- 
therapy 
3 (27) 9 (69) 0.100 3 (23) 14 (26) 1.000 
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). OLLS, open 
left lateral sectionectomy; LLLS, laparoscopic left lateral sectionectomy; ONR, open non-randomized left 
lateral sectionectomy; LNR, laparoscopic non-randomized left lateral sectionectomy. †Adenoma (2), hepa-
tocellular carcinoma (HCC) (1), haemangioma (1), focal nodular hyperplasia (FNH) (1); 
‡HCC (1), multilocular biliary cyst (1); §HCC (3), metastatic melanoma (1), liver abscess (1), metastatic breast 
cancer (1); ¶HCC (3), haemangioma (4), adenoma (5), FNH (7), inflammatory lesions (2), echinococcosis (1), 
hepatic cyst (1), haemangioma (1). #Fisher’s exact test, except **Mann–Whitney U test and †† X2 test (all 
two-tailed). ‡‡Variable with normal distribution: Shapiro–Wilk P >0.050; Mann–Whitney U test results are 
shown, but t test leads to the same conclusion. alfa=0.01 for all baseline variables to correct for multiple 
testing. 
PRIMARY OUTCOME 
Time to functional recovery did not significantly differ between OLLS and LLLS 
groups, or between ONR and LNR groups (Table 4). In the OLLS group, the median 
time to functional recovery was 3 (3–5) days, compared with 3 (3–3) days in the LLLS 
group (P =0.284). The same median time to functional recovery was found in the 
registry groups: 3 (3–3) days for ONR versus 3 (3–4) days for LNR (P =0.529). Subanal-
ysis of individual functional recovery criteria revealed quicker tolerance of solid food 
in favour of the LNR group (2 (1–2) days versus 1 (1–1) day following ONR; P =0.002) 
SECONDARY OUTCOMES 
Median LOS did not differ significantly following OLLS compared with LLLS: 4.5 (4–6) 
versus 4 (3–5) days respectively (P =0.049) (note that alfa=0.01 for secondary out-
comes in view of multiple testing). Median LOS in the prospective registry was also 
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comparable: 5 (4–7) days for ONT versus 4 (3–5) days for LNR (P =0.064). The reasons 
for delayed discharge after functional recovery per group are shown in Table 4. Over-
all 39, 18 and 10 per cent of the delay was logistical or medical in nature, or based on 
patient request, respectively. 
 
Table 3. Surgical outcomes 
 RCT Registry 
OLLS (n = 11) LLLS (n = 13) P‡‡‡ ONR (n = 13) LNR (n = 54) P‡‡‡ 
Type of liver 
resection 
      
LLS 10 (91) 11 (85)  10 (77) 46 (85)  
LLS + wedge 1 (9)† 2 (15)‡  3 (23)§ 2 (4)¶  
Segment III 0 (0) 0 (0)  0 (0) 1 (2)  
Conversion to open  
surgery 
 0 (0)   5 (9)#  
Additional 
procedures 
      
Cholecystectomy 1 (9) 1 (8)  1 (8) 3 (6)  
Lymph node  
dissection 
0 (0) 0 (0)  1 (8)** 1 (2)††  
Hernia correction 0 (0) 0 (0)  0 (0) 2 (4)  
Other 1 (9)‡‡ 1 (8)§§  0 (0) 2 (4)¶¶  
Duration of surgery 
(min)* 
110  
(92–125)¶¶¶ 
156  
(112–176)¶¶¶ 
0.023§§§ 206  
(118–255)¶¶¶ 
148  
(118–202)¶¶¶ 
0.082§§§ 
Blood loss (ml)* 100 (100–350) 50 (18–200) 0.063§§§ 250 (225–300) 200 (100–300) 0.191§§§ 
Vascular control 2 (18)## 0 (0) 0.199 2 (15)*** 5 (9)††† 0.614 
Placement of 
abdominal drain 
0 (0) 1 (8) 1.000 5 (38) 12 (22) 0.289 
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). OLLS, open 
left lateral sectionectomy; LLLS, laparoscopic left lateral sectionectomy; ONR, open non-randomized left 
lateral sectionectomy; LNR, laparoscopic non-randomized left lateral sectionectomy; LLS, left lateral sec-
tionectomy. †Segment IVB; ‡segment IVB (2); §segments V, IVB and VIII; ¶segment VI and segment IVB (2). 
#Reason for conversion: tumour to close to vascular structures (1), adhesions (1), bleeding from aberrant 
left hepatic artery (1), size of lesion (1), infiltration of diaphragm (1). 
**Hepatoduodenal ligament+omentum minus+left gastric artery+coeliac artery+gastroduodenal artery. 
††Omentum minus; ‡‡adhesiolysis; §§transversostomy; ¶¶radiofrequency ablation (1), partial diaphragm 
resection (1). ##Pringle (1), Kelly clamp (1); ***Pringle (2); 
†††Pringle (5). ‡‡‡Fisher’s exact test, except §§§Mann–Whitney U test (both two-tailed). 
¶¶¶Variable with normal distribution: Shapiro–Wilk P >0.050; Mann–Whitney U test results are shown, but 
t test leads to the same conclusion. alfa=0.01 for all secondary outcomes to correct for multiple testing. 
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Table 4. Functional recovery and length of hospital stay 
 RCT Registry 
RCT Registry P‡‡‡ ONR (n = 13) LNR (n = 54) P‡‡‡ 
 OLLS (n = 11) LLLS (n = 13) P† ONR (n = 13) LNR (n = 54) P† 
Functional recovery 
(days) 
3 (3–5) 3 (3–3) 0.284 3 (3–3) 3 (3–4) 0.529 
Adequate pain control 
with oral analgesia 
only 
3 (2–3) 3 (2–3) 0.539 3 (3–4) 2 (2–3) 0.017 
Independent mobility 
or preoperative level 
3 (3–4) 3 (2–3) 0.071 3 (3–4) 3 (2–3) 0.240 
No intravenous fluid 2.5 (2–3)§ 2 (1–3)§ 0.273 2 (1–4) 2 (1–2) 0.308 
Tolerance of solid food 1 (1–1) 1 (1–1) 0.738 2 (1–2) 1 (1–1) 0.002 
Normal or decreasing 
serum bilirubin level 
2.5 (1–3) 1 (1–3) 0.232 0 (0–1) 1 (0–2) 0.161 
Post-operative 
milestones (days) 
      
Free oral fluids 0 (0–1) 0 (0–0) 0.563 1 (0–1) 1 (0–1) 0.202 
Removal of indwelling 
urinary catheter 
3 (2–3) 2·5 (1–3) 0.140 3 (3–6) 2 (1–3) 0.031 
First flatus 1 (1–2) 1 (1–2) 0.446 2 (1–3) 2 (1–2) 0.076 
First stool 3 (2–4)§ 2 (2–3)§ 0.307 3 (3–4)§ 2 (2–3)§ 0.138 
LOS (days) 4.5 (4–6) 4 (3–5) 0.049 5 (4–7) 4 (3–5) 0.064 
Difference (LOS − 
functional recovery) 
(days) 
1 (0–3) 1 (1–2) 0.832 2 (1–3) 1 (0–2) 0.042 
Delay in discharge* 8 (73) 9 (69) 1.000‡ 11 (85) 23 (43) 0.090‡ 
Reasons for delay in 
discharge* 
      
Logistical 2 of 10 (20) 5 (38)  6 (46) 11 (20)  
Medical 3 of 10 (30) 1 (8)  2 (15) 5 (9)  
Patient preference 2 of 10 (20) 2 (15)  0 (0) 2 (4)  
Unknown 1 of 10 (10) 1 (8)  3 (23) 15 (28)  
Values are median (i.q.r.) unless indicated otherwise; *values in parentheses are percentages. †One patient 
died in hospital and was never discharged. OLLS, open left lateral sectionectomy; LLLS, laparoscopic left 
lateral sectionectomy; ONR, open non-randomized left lateral sectionectomy; LNR, laparoscopic non-
randomized left lateral sectionectomy; LOS, length of hospital stay. ‡Mann–Whitney U test, except 
§Fisher’s exact test (both two-tailed). ¶Variable with normal distribution: Shapiro–Wilk P >0.050; Mann–
Whitney U test results are shown, but t test leads to the same conclusion. alfa=0.05 for primary outcome, 
and alfa=0.01 for all secondary outcomes to correct for multiple testing. 
 
Overall morbidity was the same for open and laparoscopic procedures, with no sig-
nificant differences between Clavien–Dindo complication severity grades [24] or the 
composite endpoint for liver surgery-related morbidity (Table 5). 
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Table 5. Complications 
 RCT Registry 
OLLS (n = 11) LLLS (n = 13) P‡ ONR (n = 13) LNR (n = 54) P‡ 
Overall morbidity 4 (36) 1 (8) 0.141 2 (15) 7 (13) 1.000 
Clavien–Dindo grade       
No morbidity 7 (64) 12 (92)  1 (85) 47 (87)  
I 1 (9) 0 (0)  0 (0) 0 (0)  
II 2 (18) 0 (0)  1 (8) 5 (9)  
III 0 (0) 1 (8)  1 (8) 1 (2)  
IV 0 (0) 0 (0)  0 (0) 1 (2)  
V (30-day mortality) 1 (9) 0 (0)  0 (0) 0 (0)  
Major morbidity (≥ 
grade III) 
1 (9) 1 (8) 1.000 1 (8) 2 (4) 0.482 
Composite endpoint* 1 (9) 0 (0) 0.458 1 (8) 2 (4) 0.482 
Readmission in < 30 
days 
0 (0) 0 (0)  0 (0) 1 (2) 1.000 
Complications       
Wound infection 1 (9) 1 (8)  0 (0) 1 (2)  
Pneumonia 0 (0) 0 (0)  0 (0) 2 (4)  
Intra-abdominal  
haemorrhage 
0 (0) 0 (0)  1 (8) 0 (0)  
Intra-abdominal  
abscess 
0 (0) 0 (0)  0 (0) 1 (2)  
Postresectional liver  
failure 
0 (0) 0 (0)  0 (0) 1 (2)  
Pulmonary embolism 1 (9) 0 (0)  0 (0) 0 (0)  
Cardiac arrest 1 (9) 0 (0)  0 (0) 0 (0)  
Other† 2 (18) 0 (0)  2 (15) 3 (6)  
Values in parentheses are percentages. OLLS, open left lateral sectionectomy; LLLS, laparoscopic left lateral 
sectionectomy; ONR, open non-randomized left lateral sectionectomy; LNR, laparoscopic non-randomized 
left lateral sectionectomy. *Ascites, postresectional liver failure, bile leakage, intra-abdominal haemor-
rhage, intra-abdominal abscess and operative mortality. †Persistent pain (2), hypertension (2), infected 
epidural insertion site (1), urinary tract infection (1), dyspnoea of unknown origin (1). ‡Fisher’s exact test 
(two-tailed). alfa=0.01 for all secondary outcomes to correct for multiple testing. 
 
 
A total of five patients developed major morbidity (grade III or above). One patient in 
the open arm of the RCT died after developing a pulmonary embolism and cardiac 
arrest. One randomized patient developed a wound infection after LLLS, which was 
re-explored under local anaesthesia. In the open arm of the registry, one patient 
required surgery after a post-operative intra-abdominal bleed with haemodynamic 
instability. In the laparoscopic arm of the registry, one patient was admitted to the 
ICU for postresectional liver failure, and one was readmitted and received percuta-
neous radiological drainage after developing an intra-abdominal abscess. 
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COMPLIANCE WITH THE ERAS PROTOCOL 
No group was fully compliant with all protocol items. The OLLS, LLLS, ONR and LNR 
groups were compliant (more than 80 per cent) with between 10 and 14 of the 22 
ERAS elements (Table 6). Post-operative epidural analgesia was provided to 82, 69, 77 
and 65 of patients in the OLLS, LLLS, ONR and LNR groups respectively. No data were 
available to score the elements ileus prevention (laxatives) and provision of oral an-
algesia on POD1. 
REGRESSION ANALYSES 
Repeating the outcome analyses with multiple linear regression to adjust for patient 
age, sex, ASA grade and centre effects essentially confirmed the results of the Mann–
Whitney U tests. However, analysis of residuals showed a clear outlier in both the 
open surgery arm of the RCT and the registry with respect to the outcome LOS. 
Therefore, all analyses, non-parametric as well as regression, were repeated. Without 
those outliers, the new results increased both P values for LOS to greater than 0.100. 
Finally, owing to the very small sample size, differences between surgeons within the 
same centre could not be evaluated. 
DISCUSSION 
This RCT comparing open and laparoscopic LLS in an ERAS setting was not able to 
reach a meaningful conclusion on time to functional recovery because it had to be 
stopped prematurely owing to poor recruitment. No difference in time to functional 
recovery was found after LLLS compared with the OLLS in the randomized trial, but 
this analysis is underpowered. A prospective registry of all patients not randomized 
due to surgeon or patient preference also failed to show a difference in functional 
recovery. Considering the secondary endpoints, no differences between surgical 
procedures were observed with regard to blood loss, duration of surgery, LOS, mor-
bidity, reoperation, readmissions and mortality rates. 
The main contributor to poor recruitment was individual surgeons’ preference for 
the laparoscopic procedure. This lead to a preference : randomization ratio of almost 
3 : 1. Clinical equipoise was assumed at the time of design and start of this study. 
Based on a worldwide survey among HPB surgeons, an RCT and prospective register 
comparing open and laparoscopic techniques was considered necessary.[27] The 
majority of participating centres in the study had indicated that they considered a 
trial to be feasible and were willing to randomize patients. It was on this basis that it 
was deemed not necessary to perform a feasibility study. It is clear, however, that 
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clinical equipoise was no longer present during the recruitment period. A recent 
expert statement from the International Consensus Conference for Laparoscopic 
Liver Resection held at Morioka, Japan, in 2014 stated that minor laparoscopic liver 
resection, including LLS, has become standard practice [28], and this evolving 
change in surgical attitudes is likely to have influenced the present study. 
 
Table 6. Overall compliance to elements of the enhanced recovery after surgery protocol per study group 
 RCT Registry 
OLLS (n = 11) LLLS (n = 13) ONR (n = 13) LNR (n = 54) 
Preoperative     
Counselling 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
Minimal preoperative fasting 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
No anxiolytic premedication 82 (0–100) 77 (0–100) 85 (0–100) 78 (33–100) 
Perioperative     
Thoracic epidural analgesia/i.v. PCA 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
Prevention of hypothermia 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
CVP monitoring (< 5 mmHg) 36 (0–50) 31 (0–100) 62 (0–100) 91 (20–95) 
No drainage of peritoneal cavity 100 (100–100) 92 (0–100) 62 (57–100) 59 (33–100) 
No standard nasogastric drainage 91 (86–100) 100 (100–100) 85 (0–100) 78 (88–100) 
Commence intake of water/free fluids 64 (0–86) 85 (50–100) 13 (0–100) 98 (19–100) 
Early mobilization 27 (0–100) 77 (50–100) 31 (0–100) 87 (52–100) 
PONV prophylaxis 55 (0–100) 77 (0–100) 54 (17–100) 63 (17–100) 
Antithrombotic prophylaxis 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
Antibiotic prophylaxis 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
POD 1–3     
Daily review of discharge criteria 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 
Ileus prevention (laxatives) – – – – 
Free fluids/normal diet on POD 1 100 (100–100) 100 (100–100) 92 (50–100) 98 (95–100) 
Intravenous fluids discontinued on 
POD 1 
9 (0–14) 31 (0–50) 23 (0–50) 28 (17–67) 
Oral analgesia on POD 1 – – – – 
Normal diet on POD 2 100 (100–100) 100 (100–100) 77 (0–100) 93 (50–100) 
Removal of urinary catheter on POD 3 27 (0–43) 46 (0–100) 8 (0–50) 37 (0–100) 
Stop epidural/i.v. PCA on POD 3 73 (50–100) 100 (100–100) 54 (0–100) 76 (50–100) 
Full mobilization on POD 3 55 (0–100) 92 (50–100) 77 (0–100) 78 (50–100) 
Values are percentages with between-centre ranges in parentheses. OLLS, open left lateral sectionectomy; 
LLLS, laparoscopic left lateral sectionectomy; ONR, open non-randomized left lateral sectionectomy; LNR, 
laparoscopic non-randomized left lateral sectionectomy. i.v., Intravenous; PCA, patient-controlled analge-
sia; CVP, central venous pressure; PONV, post-operative nausea and vomiting; POD, post-operative day. 
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The slow accrual might also be related to the lower incidence of LLS than an antici-
pated 10 per cent of the total volume of liver resections. Replacement of LLS by pa-
renchyma-saving strategies using metastasectomy or local ablation procedures may 
also have been a contributing factor to slow recruitment. 
Despite these limitations, the study has several strengths. No RCT has compared 
open and laparoscopic liver surgery. Other studies comparing open and laparoscopic 
LLS [4,5,29–31] were of relatively small size and retrospective in nature. The addition 
of a prospective registry of patients who were not randomized owing to surgeon or 
patient preference was of value, reflecting daily practice in many units performing 
liver surgery.[18,19] 
In the present series of 67 LLLS and 24 OLLS procedures undertaken in conjunction 
with an ERAS programme, patients were functionally recovered after 3 days. Alt-
hough median LOS tended to be slightly shorter in the laparoscopic groups, this 
difference was not significant, and the study was not powered to detect a difference 
in LOS. The clinical relevance of a difference of less than 1 day can be questioned. A 
delay to discharge after functional recovery was observed in all groups, and there is 
clearly the opportunity for a further reduction in LOS if discharge logistics could be 
optimized.[14,16] Minimization of this gap between recovery and discharge could 
reduce hospital costs. 
Lessons learned from this trial could prove valuable for the design and execution of 
future surgical trials. Surgical RCTs are often difficult to undertake successfully and 
pose particular practical and methodological challenges.[32] Blinding is frequently 
difficult to perform, and care must be taken to choose an objectively measurable 
outcome.[33] The present study, however, confirmed the practicality of blinding 
patients through the use of large abdominal dressings.[34,35] Double-blinding could 
not be guaranteed as ward physicians read operation details accidentally. A proctor-
ing surgeon assisted surgeons in their learning curve to ensure quality. Regression 
analyses in this study revealed no influence of individual surgeons on the primary 
outcome, supporting the view that this approach may overcome the surgical learn-
ing curve as a confounder.[32] The timing of the conduct of a surgical trial is also 
important.[32] When a new technique is introduced, there is a window of opportuni-
ty to conduct a trial. Once surgeons believe the new intervention is superior, ran-
domization becomes difficult. This surgeon preference was the major cause of failure 
to recruit to this RCT. It is important that investigators ensure the presence of clinical 
equipoise. To assess this adequately, a feasibility study seems generally advisable to 
generate objective evidence that the main trial will not fail, at least due to a per-
ceived lack of equipoise. 
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SUMMARY AND DISCUSSION 
Liver resection gives patients with colorectal liver metastases the only change of 
cure. Also for primary malignancies and benign lesions liver resection is a widely 
accepted treatment. To offer patients the best chance of successful recovery after 
liver surgery, surgeons not only have to choose the best surgical procedure, but they 
must also aim for optimal pre-, intra- and post-operative conditions. The laparoscopic 
technique has been added to the liver surgeon’s armamentarium and may be better 
than the standard technique of open liver resection. An Enhanced Recovery After 
Surgery (ERAS) programme can standardize and optimize perioperative elements 
during the patient’s admission and support the patient towards a full and accelerat-
ed recovery. Perhaps the combination of both laparoscopic liver surgery and an ERAS 
programme could result in the best outcomes for the patient. Since minimal incisions 
are a key element of ERAS, minimal invasive surgery may be a key element itself. 
This thesis focuses on the current role, dissemination and worldwide adoption of an 
ERAS programme in liver surgery, the investigation and evaluation of the potential 
role of specific (new) elements in an ERAS protocol (Part I), the implementation sta-
tus of (laparoscopic) liver surgery from a Dutch and international perspective, and 
comparison of open and laparoscopic liver surgery in a randomised controlled set-
ting (Part II). 
PART I: OPTIMIZED RECOVERY AFTER HEPATIC SURGERY 
Chapter 1 presents an overview of the elements of the Enhanced Recovery After 
Surgery (ERAS) programme for liver surgery. For each element the quality of evidence 
is discussed with a recommendation (Table 1). 
Chapter 2 describes the results of an international survey on ways to enhance pa-
tient recovery after liver surgery. The survey was sent to hepatopancreatobiliary cen-
tres worldwide and questioned liver surgeons on their experience with enhanced 
recovery programmes and laparoscopic liver surgery. Both strategies are associated 
with faster recovery and may work synergistically. Results showed that a large majori-
ty of HPB centres had experience with laparoscopic liver surgery. The liberal adoption 
of laparoscopic liver surgery, even in low-volume HPB centres, seemed in conflict 
with standards of evidence-based practice in the medical community. On the other 
hand, the dissemination of enhanced recovery programmes in liver surgery was still 
limited in 2010, although there was substantial support for implementation. Also, 
liver surgeons considered a randomized controlled trial or a prospective register 
necessary to compare the outcomes of open and laparoscopic techniques. In the 
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Netherlands the first laparoscopic liver resections were documented in 1990s, while 
the first laparoscopic liver resection within an ERAS programme was performed in 
2008. Gradually new initiatives have been designed to get prospective and con-
trolled data on open versus laparoscopic liver surgery. Currently, the results of two 
randomized controlled trials (ORANGE 2 Plus – Trial and Oslo – CoMet Study) are 
awaited and recently a new consensus statement of international liver surgeons has 
been published.[2] 
 
Table 1. ERAS liver programme recommendations 
Element Evidence level Recommendation grade 
Preoperative counselling C Strong 
Minimal preoperative fasting B Strong 
No pre-anaesthetic premedication A Weak 
Antithrombotic prophylaxis A Strong 
Antibiotic prophylaxis A Strong 
Balanced anaesthesia with short-acting agents C Strong 
Epidural anaesthesia / analgesia B Weak 
Balanced intraoperative fluid management A Strong 
Prevention of hypothermia A Strong 
PONV prophylaxis C Strong 
Incision of minimal length C Strong 
No routine drainage of the peritoneal cavity B Strong 
No nasogastric drainage A Strong 
Provision of oral analgesia A Strong 
Prevention of post-operative ileus C Weak 
Early removal of urinary catheter D Weak 
Early start oral intake A Strong 
Early mobilisation C Strong 
Quality of evidence and recommendations were evaluated according to the GRADE guideline]: A = High, B 
= Moderate, C = Low, D = Very low. 
 
To assess the outcomes of ERAS protocols applied in liver surgery and published until 
October 2011, a systematic review of the literature was performed in Chapter 3. In 
total six studies could be included in the analysis. It demonstrated that implementa-
tion of an ERAS programme did not affect morbidity, mortality or re-admission rates. 
Analysis also suggested a reduction in length of stay in favour of patients managed 
within an ERAS setting. It must be mentioned that the reporting of adherence to the 
various elements of the protocol was rather low in the included studies, and that this 
hampered a good comparisons of the studies. Two studies in the systematic review 
assessed the time to functional recovery, which was significantly lower than total 
length of stay and can be considered as a more objective outcome. The use of time 
to functional recovery as a primary outcome measure in future studies was advised in 
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order to enhance quality and comparability. Also, at the time of this systematic re-
view there were no RCTs available comparing fast-track with standard care. A recent 
systematic review with inclusion of two RCT’s comparing ERAS with conventional 
care supported the findings of a reduced length of stay and showed even a reduction 
in medical morbidity.[3] 
In Chapter 4, European HPB centres were evaluated to assess whether current peri-
operative practice in hepatic surgery was actually based on ERAS principles. The 
study was started with the assumption that many centres had already adopted ERAS 
elements in liver surgery after implementation of fast-track protocols for patients 
undergoing colonic resection or as part of evidenced-based treatment for patients. 
The study demonstrated a substantial variation of perioperative care among centres 
that perform liver resections. Some elements of the ERAS program, e.g., preoperative 
counseling and minimal preoperative fasting, had already been generally adopted. 
However, other elements in the perioperative phase, such as avoidance of drains and 
nasogastric tube, and post-operative phase, e.g. early resumption of oral intake, early 
mobilization, and use of recovery criteria, could be further optimized. In line with 
previously reported data, a delay was found between discharge and time to func-
tional recovery (FR).[4, 5] A limitation of the assessment is mainly the retrospective 
design. However, this design was deliberately chosen so as to not influence the be-
havior of medical and nursing staff in perioperative care during a full prospective 
assessment. 
An important aspect after liver surgery is safe and effective pain control. Not only will 
it reduce numerous post-operative complications, it can also facilitate early mobiliza-
tion and may result in earlier recovery. Pain relief may be a powerful technique to 
modify surgical stress responses, and it may thereby reduce incidence of post-
operative organ dysfunction and improve outcome. Adequate analgesia may also 
reduce pulmonary complications and post-operative paralytic ileus.[6] Traditionally, 
post-operative pain is managed with intravenous patient-controlled analgesia (PCA) 
or with continuous indwelling epidural catheters. In Chapter 5 we examine the value 
of intramuscular continuous infusion of bupivacaine (CIB) via a wound catheter com-
bined with intravenous PCA, compared with epidural analgesia after major hepatic 
surgery. A risk after major liver surgery is the development of post-operative coag-
ulopathy. The use of epidural analgesia may therefore be contraindicated. The com-
bination of CIB + PCA in this study provided pain control equivalent to that of con-
tinuous epidural analgesia. No significant differences in the numbers of patients 
experiencing severe pain were observed between the two groups. Importantly, pa-
tients in the CIB + PCA group consumed lower total volumes of opioids, had lower 
post-operative morbidity and a decreased length of stay. The partly retrospective 
design and an inherent bias of surgeon preference may have influenced results. On 
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the other hand, the investigation of a large and uninterrupted cohort of patients 
submitted to major hepatectomy, and thus at risk for post-operative coagulopathy 
and the development of epidural hematoma, receiving this type of analgesia has not 
been previously reported. Continuous infusion of bupivacaine combined with PCA 
can replace epidural analgesia and can avoid the occurrence of rare complications of 
epidural analgesia. 
The use of abdominal drains is another element in liver surgery still subject of debate. 
The ERAS programme advocates abandoning standard prophylactic abdominal 
drainage after partial hepatectomy. Routine drainage may be unnecessary, possibly 
harmful and uncomfortable for patients. In Chapter 6 we describe the 10-year expe-
rience of tertiary referral centre with a no-drain policy in an ERAS environment with 
90-day resection-surface-related (RSR) morbidity and RSR-reinterventions as primary 
endpoints. An overall 20% surgical morbidity, 15% RSR-complication, and 12% RSR-
reintervention rate was observed in 538 patients. The majority of RSR-complications 
could be managed with radiologic drainage and reoperations were only rarely neces-
sary. Major liver resection was identified as an independent risk factor for RSR-
significant morbidity and RSR-reinterventions. These results are in line with results 
published by other HBP-centres[7-12] and confirm the safety and feasibility of a no-
drain policy after partial hepatectomy in an ERAS-based care programme. 
PART II: LAPAROSCOPIC LIVER SURGERY 
In Chapter 7 we present a historical overview on the introduction of laparoscopic 
liver surgery in the Netherlands. In 1990s the first laparoscopic hepatectomies were 
performed, but only limited experience was gained in the decade thereafter. Com-
pared to other pioneering countries the Netherlands seemed slow with the imple-
mentation of the minimally invasive technique. The initial experience with laparo-
scopic liver resections was further evaluated with a case-control comparison of pa-
tients undergoing open and laparoscopic left lateral sectionectomy (LLS) during 
2000-2008. A significant difference in length of hospital stay, blood loss and opera-
tion time could be demonstrated in favour of the laparoscopically operated patients 
without compromising morbidity. Finally, the implementation status of laparoscopic 
liver surgery during 2010 was examined with a nationwide survey. The 30 out of 37 
responding centres performed 966 hepatic resections of which only 49 were laparo-
scopic resections (5%). 
To prospectively evaluate the merits of laparoscopic liver surgery a randomized con-
trolled trial was designed. Chapter 8 shows the protocol for an international multi-
centre randomized controlled study comparing open versus laparoscopic left lateral 
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sectionectomy (LLS) within an ERAS programme: ORANGE II – Trial. This investigated 
the added value of laparoscopy in minor hepatectomy. A prospective registry of all 
patients that were not randomised because of surgeon or patients preference was 
added to the design of the trial to allow acquisition of an uninterrupted prospective 
series of patients. Primary endpoint of the trial was time to functional recovery (com-
posite endpoint defined by five criteria). It was hypothesized that time to functional 
recovery could be reduced by two days in patients undergoing laparoscopic LLS 
compared to open LLS. 
In Chapter 9 we present the results of the ORANGE II – Trial. From January 2010 to 
July 2014 a total of 91 patients (24 randomised and 67 prospective registry) were 
prospectively studied. Although the results showed no reduced time to functional 
recovery in favour of the laparoscopic group, this first RCT comparing open and lapa-
roscopic LLS in an ERAS setting was not able to definitively conclude on the primary 
endpoint: time to functional recovery. It had to be stopped prematurely due to slow 
accrual in the RCT. The main reason for the slow accrual was a clear surgeon’s prefer-
ence for the laparoscopic procedure. Also, this study showed that laparoscopic LLS 
could be performed with low morbidity, reoperation, readmission and mortality 
rates. To date there has not been an RCT in liver surgery comparing open and laparo-
scopic liver surgery and this multicentre attempt to provide strong evidence on open 
versus laparoscopic LLS is not likely to be repeated. The prospective registry of pa-
tients that could not be randomised increases the external validity of this study. 
Long-term follow up results of this study are awaited. 
Finally, in Chapter 10 we present a protocol for an international randomised con-
trolled trial comparing open versus laparoscopic hemihepatectomy (i.e. major hepa-
tectomy) within an ERAS programme. This study was designed to provide the HPB 
surgical community with level A evidence on the value of laparoscopic hemihepatec-
tomy. The open procedure to resect the left or right hemiliver is already an accepted 
treatment for the resection of liver tumours (mostly colorectal liver metastases). 
There is still debate on the value of laparoscopic technique in major liver resections. 
It was demonstrated that in expert hands major anatomical laparoscopic liver resec-
tions were feasible with good efficacy and safety. However, the results are based on 
case-series and no prospective controlled evidence is available on short-term, onco-
logic and patient reported outcomes. The ORANGE II PLUS – trial is now running in 
several international expert centres and will provide evidence on the primary end-
point: time to functional recovery. Other endpoints to be studied are hospital length 
of stay, morbidity, mortality, operative parameters (intraoperative blood loss, opera-
tion time), patients-reported outcomes (quality of life, body image), oncologic out-
comes (time to adjuvant chemotherapy initiation, resection margin, overall five-year 
survival) and costs. 
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In summary, this thesis outlines that in modern liver surgery several elements of the 
proposed ERAS programme have already been implemented. Full use of a fast-track 
liver protocol is advisable to optimize and accelerate patient recovery. Good adher-
ence to all elements of such a protocol is essential. In addition, new evidence on 
(liver-surgery) specific perioperative care elements needs to be appreciated and 
adopted into protocols if feasible. In the Netherlands laparoscopic liver surgery was 
only minimally implemented compared with other countries until 2010. A controlled 
comparison of open versus laparoscopic left lateral sectionectomy was unable to 
definitively concluded on the primary endpoint, time to functional recovery, as the 
study was stopped prematurely due to slow accrual in the RCT and a clear surgeon 
preference for laparoscopy. Furthermore, laparoscopic liver surgery has gained 
popularity among Dutch liver surgeons, and minor laparoscopic liver surgery is now 
considered standard of care in line with international consensus.[2] Long-term fol-
low-up and ongoing randomized controlled trials will provide more definitive evi-
dence on the merits of major laparoscopic liver surgery, oncologic outcome and 
patient-reported outcomes. 
FUTURE PERSPECTIVES 
OPTIMIZED RECOVERY AFTER SURGERY 
Abundant evidence has been presented that ERAS protocols are safe and effective. 
[3] Surprisingly, an ERAS protocol for liver surgery has not yet been formally estab-
lished and published. The ERAS society is a leading international body and it has 
published several evidence-based protocols to support surgeons and other profes-
sionals. To ensure standardization of care and to provide patients with optimal peri-
operative care, it is desirable that a consensus guideline for enhanced recovery after 
liver surgery is developed by experts. A recent review[3], including recent prospec-
tive (randomized controlled) studies[14-16], again confirms improvement of length 
of stay and post-operative morbidity. Not only is it important for an ERAS liver proto-
col to be published and embraced by international liver surgeons, it is also key to 
periodically and systematically re-evaluate elements of the protocol to ensure the 
protocol is up-to-date and supported by recent literature. New evidence should be 
evaluated and, if necessary, elements of the protocol should be revised or newly 
added. The ERAS society should adopt a leading role in this process, thereby propa-
gating standardization and an evidenced-based approach of patient care. 
In the introduction current elements of the ERAS protocol in liver surgery have been 
described and assessed based on the available evidence. Examples of new elements 
that could be evaluated for adoption in previously described ERAS liver protocols[5, 
Chapter 11 
214 
14, 15, 17] are the use of a pulmonary recruitment manoeuvre (manual inflations of 
the lung with the patient in Trendelenburg position) to reduce post-operative pain 
after liver surgery[18], stimulation of gut function with gum chewing[19], other 
methods of post-operative analgesia with fewer side-effects (transversus abdominis 
plane block[20], wound catheters[21-23]), and medication attenuating the stress 
response[24]. Most post-operative elements are introduced to the patient upon re-
turn on the ward. However, some patients stay up to 24 hours in the recovery room. 
Besides provision of good pain control, it may be possible to implement other ele-
ments already in the recovery room. ERAS elements that may be introduced there are 
early intake, providing chewing gum and early mobilization. Some individual ele-
ments in fast-track programmes, such as advancement of oral intake, early mobiliza-
tion and laparoscopic surgery, have been associated with early recovery after colon 
cancer surgery[25]. However, if all elements are successfully achieved, it is more likely 
that not one single element in the multimodal ERAS programmes will result in the 
much desired accelerated recovery of patients, but the implementation of a pro-
gramme as a whole. As shown in colorectal surgery, there may also be a synergetic 
effect of ERAS combined with laparoscopy.[26]  
Once a protocol has been implemented it is important to maintain a good adherence 
to the protocol to ensure consistent benefit for the patient.[27] This adherence, how-
ever, is the main problem in optimization of recovery. During the initial phase of 
implementation all involved personnel are keen and alert to adhere to all elements. 
After the initial implementation adherence to the protocol guidelines should be 
maintained by post-implementation strategies, such as periodic evaluation and edu-
cation.[28] It has already been proven in colonic surgery, that a structured implemen-
tation strategy can result a good sustainability.[29] 
LAPAROSCOPIC LIVER SURGERY 
The minimally invasive approach for liver surgery is here to stay. The last few years it 
several studies have shown that, besides minor laparoscopic liver surgery, also major 
laparoscopic liver surgery is associated with similar or improved short-term outcome 
compared with open major hepatectomy.[30] In expert hands intraoperative blood 
loss, complications, and conversions rate are more than acceptable for laparoscopic 
left hemihepatectomy.[31] A recent meta- analysis comparing case-matched laparo-
scopic liver resections to open liver resections (N = 2900 cases) demonstrated no 
increased mortality and significantly less complications, transfusions, blood loss, and 
hospital stay in favor of laparoscopic liver resection.[32] In the recent Morioka con-
sensus minor laparoscopic liver resection was confirmed to be standard practice. A 
still increasing number of surgeons are adopting the laparoscopic technique. With 
regards to major laparoscopic liver resection experts judged that the introduction is 
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still in an exploration phase, and cautious diffusion is still warranted.[2] The interna-
tional experts joining the consensus further advised participation and encouraged 
participation in already open prospective trials and registries. Currently on-going 
trials are therefore supported by the experts in the field of (laparoscopic) liver sur-
gery. In the near future more evidence on the value of laparoscopic hepatectomy will 
be provided by the results of the ORANGE 2 Plus - Trial (Chapter 10) and the Oslo-
CoMet study[33]. The ORANGE 2 Plus – Trial compares open versus laparoscopic 
hemihepatectomy within an ERAS programme and the Oslo-CoMet study compares 
laparoscopic versus open liver resection for colorectal metastases. Both studies will 
give liver surgeons more solid evidence regarding laparoscopic major liver surgery, 
oncologic outcome, long-term follow-up, costs and patient-reported outcomes. 
During the conception of this thesis there has also been a shift in surgical strategy 
regarding the extent of hepatic resection. Besides the discussion on the technique 
(laparoscopic versus open), there is also an increasing interest in parenchymal saving 
strategies.[34, 35] A two-stage approach or formal liver resection may be less fre-
quently required with the advancements of intraoperative imaging and operating 
techniques.[36] Occurrence of post-operative liver failure is to be prevented, but 
oncologic margins should be respected.[37, 38] A parenchyma-sparing strategy and 
accurate preoperative prediction of the function of the future remnant liver are the 
future for a tailored approach for each patient. 
Improved levels of evidence, standardized reporting of outcomes, and assuring 
proper training are the next challenges of laparoscopic liver surgery.[32] Not only can 
RCT’s or other prospective studies add to the continuing development of laparoscop-
ic liver surgery, also the critical appraisal of hepatectomies performed in the past can 
improve quality. Auditing by national or international associations will give liver sur-
geons insight into the quality of their own operations, but also into the performance 
of other colleagues. (International) benchmarks may be defined for outcome param-
eter, such as mortality, morbidity and R0-resection margins. Ultimately, this continu-
ing evaluation could result in centralization of (laparoscopic) liver surgery, as large 
volume centres may perform better than centres performing only a limited number 
of (laparoscopic) resections per year. A good example of a well functioning auditing 
system is the Dutch Institute for Clinical Auditing (DICA). On 1st July 2013 the Dutch 
Hepatobiliary Audit (DHBA) was started, which resulted in the publication of the first 
annual report. Future reports will provide insight in the actual quality of liver surgery 
in the Netherlands. 
The ultimate goal for a surgeon would be to have a tailored approach for each can-
didate for liver surgery. This is a future in which the surgeon is able to select patients 
fit enough to undergo surgery, in which he is able to predict individual operative 
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risks and in which he is able to predict post-operative outcomes. The selection of 
patients in liver surgery is an important issue. Not only do surgeons have to deter-
mine resectability, it is also vital to assess the patient’s ability to tolerate the opera-
tion and to predict whether removal of liver disease will improve long-term surviv-
al.[39] Recent developments aim on assessing and improving the patients’ preopera-
tive fitness before surgery. A 4-week prehabilitation programme can improve cardio-
pulmonary exercise testing and QoL before liver resection. Consequently, this may 
impact on perioperative outcome.[40] Further studies are necessary, but in the future 
a predefined cut-off value in patients undergoing hepatic resection may be used for 
predicting which patients will experience morbidity or are fit enough to undergo 
surgery.[41] A completely different approach to select patient for liver surgery and to 
predict outcome is the use of “big” data. Nowadays patient data is more and more 
readily available in digital patient files, electronic case record forms and prospective 
registries. These data could lead to large database that may be used for risk-
modelling. 
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SAMENVATTING EN DISCUSSIE 
Leverresectie biedt patiënten met colorectale levermetastasen de enige vorm van 
behandeling met kans op genezing. Ook voor primaire maligniteiten en goedaardige 
tumoren is leverresectie een algemeen geaccepteerde behandeling. Om patiënten 
een zo goed mogelijke kans op herstel te bieden, moeten chirurgen niet alleen kie-
zen voor de beste operatieve benadering, ze dienen ook te streven naar optimale 
pre-, intra- en postoperatieve condities. De laparoscopische techniek is de afgelopen 
decennia toegevoegd aan het armentarium van de leverchirurg en deze laparoscopi-
sche benadering is mogelijk beter dan de standaard open leverresectie. Een Enhan-
ced Recovery After Surgery (ERAS) programma, ookwel fast-track of versneld herstel 
na chirurgie protocol genoemd, zorgt voor de standaardisatie en optimalisatie van 
elementen in de zorg rondom leverchirurgie en draagt bij aan een sneller herstel. 
Mogelijk zorgt de combinatie van laparoscopische leverchirurgie met een ERAS pro-
gramma voor de beste uitkomsten voor de patiënt.  
Dit proefschrift onderzoekt de huidige rol, disseminatie en wereldwijde adoptie van 
het ERAS programma binnen de leverchirurgie, bekijkt en evalueert de potentiële rol 
van specifieke (nieuwe) elementen binnen een ERAS protocol (Deel I), bestudeert de 
rol van (laparoscopische) leverchirurgie vanuit een Nederlands en internationaal 
perspectief, en vergelijkt open en laparoscopische leverchirurgie in een gerandomi-
seerde en gecontroleerde omgeving (Deel II). 
DEEL I: VERBETERD HERSTEL NA LEVERCHIRURGIE  
Hoofstuk 1 biedt een overzicht van de elementen binnen het Enhanced Recovery 
After Surgery (ERAS) programma voor leverchirurgie. Voor elk element wordt er een 
aanbeveling gegeven op basis van de kwaliteit van het beschikbare wetenschappe-
lijk bewijs (Tabel 1). 
Hoofdstuk 2 beschrijft de resultaten van een internationale enquête over optimali-
satie van herstel na leverchirurgie. Deze enquête werd wereldwijd verstuurd naar 
hepatopancreatobiliaire (HPB) chirurgische centra en vroeg leverchirurgen naar hun 
ervaringen met ERAS programma’s en laparoscopische leverchirurgie. Beide strate-
gieën worden geassocieerd met sneller herstel en mogelijk werken ze synergistisch. 
De resultaten van de enquête toonden aan dat een grote meerderheid van de HPB 
centra al ervaring had met laparoscopische leverchirurgie. Deze liberale adoptie van 
laparoscopische leverchirurgie, zelfs in laag-volume centra, leek tegen de standaard 
van de evidence-based werken binnen de gezondheidszorg in te gaan. Opmerkelijk 
is dat, ondanks het feit dat er voldoende wetenschappelijk bewijs voor handen is, in 
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2010 de disseminatie van ERAS programma’s binnen de leverchirurgie nog beperkt 
was. Verder gaven de leverchirurgen aan dat een gerandomiseerde studie of een 
prospectieve registratie noodzakelijk was om de uitkomsten na open en laparoscopi-
sche leverchirurgie goed met elkaar te kunnen vergelijken.  
 
Table 1. ERAS liver programma aanbevelingen 
Element Bewijs niveau Aanbevelings graad 
Preoperatieve voorlichting C  Sterk 
Beperkt preoperatief vasten  B Sterk 
Geen anesthesiologische premedicatie A Zwak 
Antitrombose profylaxe A Sterk 
Antibiotica profylaxe A Sterk 
Evenwichtige anesthesie met kortwerkende medicatie C Sterk 
Epidurale pijnstilling B Zwak 
Gebalanceerde intra-operatieve vochttoediening A Sterk 
Preventie van hypothermie A Sterk 
PONV profylaxe C Sterk 
Incisies van minimale lengte C Sterk 
Geen standaard gebruik van abdominale drain B Sterk 
Geen neus-maagsonde A Sterk 
Standaard orale pijnstilling A Sterk 
Preventie van postoperatieve ileus C Zwak 
Vroege verwijdering van urinekatheters D Zwak 
Vroege start van orale intake A Sterk 
Vroege mobilisatie C Sterk 
Kwaliteit van bewijs en aanbevelingen volgens de GRADE richtlijnen: A = Hoog, B = Gemiddeld, C = Laag, 
D = Zeer laag. 
 
In Nederland werden de eerste laparoscopische leverresecties uitgevoerd in de jaren 
‘90, terwijl de eerste laparoscopische leverresectie binnen een ERAS porgamma pas 
in 2008 werd verricht. Geleidelijk zijn er nieuwe initiatieven ontstaan om prospectie-
ve en gecontroleerde data te verkrijgen om open en laparoscopische leverchirurgie 
met elkaar te vergelijken. Momenteel worden de resultaten van twee gerandomi-
seerde controleerde studies (ORANGE 2 Plus – Trial en Oslo – CoMet Study) verwacht 
en is er recentelijk een consensus statement van een internationale groep leverchi-
rurgen gepubliceerd.[2] 
Om het resultaat van de invoering van het ERAS programma binnen de leverchirur-
gie te kunnen evalueren, hebben we een systematische review van de literatuur tot 
en met oktober 2011 verricht in Hoofdstuk 3. In deze systematisch review konden 6 
studies worden geïncludeerd voor verdere analyse. Het werd duidelijk dat de imple-
mentatie van een ERAS programma binnen de leverchirurgie geen nadelige effecten 
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had op de morbiditeit, mortaliteit of het aantal heropnames. De analyse liet ook een 
mogelijk reductie van de opnameduur zien na implementatie van een ERAS pro-
gramma. Hierbij dient wel te worden opgemerkt dat de zorg, zoals beschreven in de 
elementen binnen het ERAS protocol, niet altijd goed werd nageleefd in de verschil-
lende onderzoeken. Door de verschillende mate van compliance binnen de verschil-
lende studies zijn de geïncludeerde studies minder goed met elkaar te vergeleken. 
Twee studies in de systematische review bekeken de tijd tot functioneel herstel 
(functional recovery, FR). Deze bleek significant korter dan de totale opnameduur en 
FR kan worden beschouwd als een objectievere uitkomstmaat. We adviseren om in 
toekomstige studies tijd tot functioneel herstel als primaire uitkomstmaat te gebrui-
ken om zo de kwaliteit en vergelijkbaarheid te verbeteren. Een recentere systema-
tisch review, waarin twee RCT’s werden opgenomen waarin ERAS met conventionele 
zorg werd vergeleken, ondersteunt de eerder aangetoonde afname in opnameduur 
en een reductie in morbiditeit.[3] 
In Hoofdstuk 4 hebben we onderzocht of Europese HPB centra daadwerkelijk peri-
operatieve zorg aanbieden die gebaseerd is op de ERAS principes. De studie ging uit 
van de hypothese dat de meeste centra elementen uit het ERAS programma al had-
den geïmplementeerd binnen de leverchirurgie, aangezien ook het ERAS program-
ma voor colorectale chirurgie al binnen deze ziekenhuizen was ingevoerd. Binnen de 
onderzochte ziekenhuizen was er substantiële variatie in de perioperatieve zorg bij 
leverchirurgie. Bepaalde elementen van het ERAS programma, zoals preoperatieve 
voorlichting en beperkte preoperatief vasten, waren algemeen ingevoerd. Van ande-
re elementen binnen de perioperatieve en postoperatieve zorg bleek daarentegen 
dat ze verder geoptimaliseerd konden worden. Wij observeerden bijvoorbeeld, dat 
drains en neus-maagsondes nog frequent standaard werden gebruikt, dat er post-
operatief geen gebruik werd gemaakt van ontslagcriteria, dat patiënten pas laat 
mobiliseerden en dat patiënten pas laat tijdens hun opname een normaal dieet werd 
aangeboden. Ook werd er vertraging gezien tussen het moment van functioneel 
herstel en het daadwerkelijk ontslag. Dit komt overeen met resultaten van eerdere 
studies.[4, 5] Een beperking van deze studie is de retrospectieve opzet, echter hier is 
met opzet voor gekozen om het gedrag van de medische staf en verpleging niet te 
beïnvloeden. 
Een belangrijk aspect na leverchirurgie is veilige en effectieve pijnstilling. Goede 
pijnstilling kan de chirurgische geïnduceerde stress beïnvloeden en zal niet alleen 
zorgen voor een afname van postoperatieve complicaties, het kan ook zorgen voor 
snellere mobilisatie en een mogelijk sneller herstel. Zo kan adequate pijnstilling zor-
gen voor een afname in pulmonale complicaties en het optreden van postoperatieve 
ileus (stoppen of vertragen van darmpassage).[6] Traditioneel wordt postoperatieve 
pijnstilling verstrekt via intraveneuze patiënt-gecontroleerde pijnstilling (PCA) of via 
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epidurale katheters. In Hoofdstuk 5 onderzoeken we de waarde van intramusculaire 
continue infusie van bupivacaïne (CIB) via wondkatheters gecombineerd met intra-
veneuze PCA versus epidurale pijnstilling na majeure leverresectie (≥3 segmenten). 
Een risico na majeure leverresectie is het optreden van een postoperatieve stollings-
stoornis. Om deze reden kan epidurale pijnstilling gecontra-indiceerd zijn. De com-
binatie van CIB + PCA bleek, vergeleken met epidurale pijnstilling, equivalente pijn-
stilling te kunnen bieden. Er waren geen significante verschillen tussen in het aantal 
patiënten met ernstige postoperatieve pijn. De patiënten in de CIB + PCA groep kre-
gen totaal minder opiaten, hadden minder complicaties en een kortere opnameduur. 
Het retrospectieve design en de aanwezigheid van een chirurg-bias kan de resultaten 
hebben beïnvloed. Anderzijds, een groot en ononderbroken cohort van patiënten 
met dit type postoperatieve analgesie (CIB + PCA) die een majeure leverresectie on-
dergingen is niet eerder beschreven. Continue infusie van bupivacaïne gecombi-
neerd met PCA lijkt een goed alternatief te zijn voor epidurale pijnstilling en mogelij-
ke zeldzame complicaties van epidurale analgesie kunnen hiermee vermeden wor-
den. 
Het ERAS programma stelt dat er niet routinematig een abdominale drain moet wor-
den achtergelaten na partiële leverresectie (“no-drain” beleid). Het routinematig 
plaatsen van deze drains kan onnodig, mogelijk schadelijk en oncomfortabel zijn 
voor patiënten. Het gebruik van abdominale drains na leverchirurgie is nog steeds 
onderwerp van discussie. In Hoofdstuk 6 beschrijven we 10-jaar ervaring van een 
tertiair HPB-centrum met een “no-drain” beleid binnen een ERAS programma. Primai-
re uitkomstmaten van deze studie waren 90-dagen resectie-oppervlak gerelateerde 
(ROG) morbiditeit and ROG-reïnterventies. Totaal werd er 20% chirurgische morbidi-
teit, 15% ROG-complicaties en 12% ROG-reïnterventies geobserveerd bij 538 patiën-
ten die een leverresectie ondergingen. De meerderheid van de ROG-complicaties 
konden worden behandeld met radiologisch drainage en re-operaties waren maar 
zelden noodzakelijk. Majeure (≥3 segmenten) leverresectie werd geïdentificeerd als 
een onafhankelijk risicofactor voor het ontstaan van significante (≥Dindo-Clavien 
graad 3a) ROG-morbiditeit en de noodzaak van ROG-reïnterventies. De resultaten 
van deze studie komen overeen met de resultaten gepubliceerd door andere HPB-
centra [7-12] en bevestigen de veiligheid en haalbaarheid van een “no-drain” beleid 
binnen een ERAS programma. 
DEEL II: LAPAROSCOPISCHE LEVERCHIRURGIE 
Hoofdstuk 7 geeft een historisch overzicht van de introductie van laparoscopische 
leverchirurgie in Nederland. In de jaren ’90 werden de eerste laparoscopische lever-
resecties verricht, maar een decennium later was de ervaring met deze techniek nog 
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beperkt. Vergeleken met andere pionierende landen bleek Nederland langzaam met 
de implementatie van de minimaal invasieve techniek binnen de leverchirurgie. De 
initiële ervaring met laparoscopische leverchirurgie is verder geëvalueerd met een 
case-control onderzoek, waarin open en laparoscopische resecties van leversegment 
2 – 3 (laparoscopic left lateral sectionectomy (LLS)) tijdens 2000-2008 werden verge-
leken. We observerden een significant verschil in opnameduur, bloedverlies, en duur 
van de operatie in het voordeel van laparoscopische geopereerde patiënten. Tevens 
was de morbiditeit tussen de groepen vergelijkbaar. Tot slot is de implementatiesta-
tus van de laparoscopische leverchirurgie in 2010 onderzocht middels een nationale 
enquete. Er waren 30 responderende centra (37 centra aangeschreven) die in totaal 
966 leverresectie verichtten, echter maar 49 (5%) van deze resecties werden laparo-
scopisch uitgevoerd. 
Om prospectief de waarde van laparoscopische leverchirurgie te kunnen onder-
zoeken is er een gerandomiseerd onderzoek met controlegroep (RCT) opgezet. 
Hoofdstuk 8 toont het protocol voor deze internationale multicentrum studie. In 
deze studie wordt open met laparoscopische leversegment 2-3 resectie (= LLS, Left 
lateral resection) vergeleken binnen een ERAS programma: de ORANGE II – studie. 
Naast de gerandomiseerde groepen is er ook een prospectieve registratie van patiën-
ten, die niet gerandomiseerd konden worden door voorkeur van de chirurg of pati-
ent, toegevoegd. Deze toevoeging zorgt ervoor dat er een ononderbroken prospec-
tieve serie van patiënten kan worden onderzocht. Het primaire eindpunt van de 
studie is tijd tot functioneel herstel (een samengesteld eindpunt bestaande uit vijf 
criteria). De hypothese is dat de tijd tot functioneel herstel in de groep patiënten die 
een laparoscopische LLS ondergaat twee dagen korter is dan bij de patiënten in de 
open LLS groep. 
In Hoofdstuk 9 presenteren we de resultaten van de ORANGE II – studie. Tussen 
januari 2010 en juli 2014 werden in totaal 91 patiënten geïncludeerd (24 patiënten in 
de RCT en 67 patiënten in het prospectieve register). Hoewel de resultaten geen 
reductie in tijd tot functioneel herstel ten faveure van de laparoscopische groep 
lieten zien, kon uit deze eerste RCT waarin open met laparoscopische leverchirurgie 
werd vergeleken geen definitieve conclusie worden getrokken. De studie werd voor-
tijdig gestaakt door een te trage inclusie van gerandomiseerde patiënten. De belang-
rijkste reden van trage inclusie was een duidelijke voorkeur van chirurgen voor de 
laparoscopische procedure (laparoscopische LLS). Deze studie liet wel zien dat lapa-
roscopische leversegment 2-3 resecties konden worden uitgevoerd met een lage 
morbiditeit, weinig re-operaties en heropnames, en een lage mortaliteit. Tot op he-
den zijn er nog geen andere gerandomiseerde studies die open en laparoscopische 
leverchirurgie vergelijken. Deze multicentrum RCT zal waarschijnlijk niet nogmaals 
worden opgezet. De toevoeging van een prospectief register aan de studie zorgde 
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voor een verhoging van de externe validiteit. De lange-termijn resultaten van deze 
studie worden nog verwacht. 
Tot slot wordt er in Hoofdstuk 10 een protocol gepresenteerd voor een internatio-
nale RCT die open en laparoscopische hemihepatectomie vergelijkt binnen een ERAS 
programma (de ORANGE II Plus – studie). De open procedure om de linker of rechter 
hemilever te verwijderen is reeds een geaccepteerde operatie voor de behandeling 
van levertumoren (meestal colorectale metastasen). De waarde van laparoscopische 
leverchirurgie bij majeure resectie (>3 segmenten) is nog onduidelijk. In de handen 
van ervaren leverchirurgen lijkt majeure laparoscopische leverresectie ook veilig en 
haalbaar. De resultaten zijn echter gebaseerd op case-series en prospectief gecontro-
leerd bewijs ten aanzien van de korte termijn, oncologische en patiënt-
gerapporteerde resultaten is niet voorhanden. The ORANGE II PLUS – studie loopt 
momenteel in verschillende internationale HPB-centra en heeft als primair eindpunt: 
tijd tot functioneel herstel. Andere eindpunten die worden bestudeerd zijn de op-
nameduur, morbiditeit, mortaliteit, operatieve parameters (bloedverlies, operatie-
duur), patiënt-gerapporteerde uitkomstmaten (kwaliteit van leven, cosmetiek), onco-
logische uitkomsten (tijd tot start adjuvante chemotherapie, resectie marge, alge-
mene 5-jaars overleving) en kosten.  
Samenvattend laat dit proefschrift zien dat binnen de moderne leverchirurgie ver-
schillende elementen van een ERAS-programma al geïmplementeerd zijn. Een volle-
dige implementatie van een versneld herstel programma voor leverchirurgie wordt 
aanbevolen om het herstel van de patiënten te optimaliseren en te versnellen. Voor 
een optimaal resultaat is goede naleving essentieel en eventuele nieuwe evidence-
based inzichten ten aanzien van (nieuwe) elementen binnen de perioperatieve zorg 
moeten kritisch worden bekeken en toegepast.  
In Nederland was de laparoscopische leverchirurgie tot 2010 nog maar minimaal 
geïmplementeerd. Laparoscopische leverchirurgie is de laatste jaren populairder 
geworden onder Nederlandse leverchirurgen. Kleine leverresecties, waaronder de 
segment 2-3 resectie, dienen volgens een internationale consensus bij voorkeur 
laparoscopische uitgevoerd te worden.[2] Uit een prospectieve gecontroleerde stu-
die naar open versus laparoscopische segment 2-3 leverresecties konden helaas 
geen definitieve conclusies worden getrokken, omdat de studie voortijdig werd ge-
stopt door een te lage inclusie in de RCT en een duidelijke voorkeur van chirurgen 
voor de laparoscopische benadering. Een nog lopende RCT zal in de toekomst waar-
schijnlijk beter bewijs leveren over de waarde van laparoscopie bij majeure leverchi-
rurgie, oncologische en patiënt-gerapporteerde eindpunten. 
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TOEKOMSTIGE PERSPECTIEVEN 
OPTIMALISATIE VAN HERSTEL NA CHIRURGIE 
Er is inmiddels veel wetenschappelijk bewijs beschikbaar dat ERAS protocollen veilig 
en effectief zijn.[3] Het is daarom bijzonder dat een ERAS protocol voor leverchirurgie 
nog niet formeel is vastgelegd en gepubliceerd. De ERAS society is een toonaange-
vende internationale organisatie die een aantal evidence-based protocollen gepubli-
ceerd heeft om chirurgen en andere professionals te ondersteunen. Om de zorg 
rondom leverchirurgie te standaardiseren is het wenselijk dat er een consensusricht-
lijn voor optimaal herstel na leverchirurgie ontwikkeld wordt door deskundigen. Een 
recente review[3], inclusief recente prospectieve (gerandomiseerde gecontroleerde) 
studies [14-16], bevestigt opnieuw een kortere opnameduur en afname van postope-
ratieve morbiditeit. Het is niet alleen belangrijk dat een ERAS lever protocol wordt 
gepubliceerd en geaccepteerd door internationale leverchirurgen. Het is ook van 
belang om regelmatig en systematisch elementen van het protocol te evalueren om 
er zo voor te zorgen dat het protocol up-to-date is en ondersteund wordt door re-
cente literatuur. Onderdelen van het protocol dienen zo nodig te worden herzien en 
nieuw elementen kunnen worden toegevoegd. De ERAS society moet hierin een 
leidende rol nemen, zodat standaardisatie en een evidence-based benadering van de 
patiëntenzorg wordt uitgedragen. 
In de inleiding van dit proefschrift zijn de huidige elementen van het ERAS-protocol 
in de leverchirurgie beschreven en gewaardeerd op basis van de beschikbare publi-
caties. Voorbeelden van nieuwe elementen die mogelijk kunnen worden toege-
voegd aan eerder beschreven ERAS lever protocollen [5, 14, 15, 17] zijn: het gebruik 
van een pulmonale rekrutering manoeuvre (handmatig beademingen van de long 
met de patiënt in Trendelenburg) om postoperatieve pijn te verminderen chirurgie 
[18], stimulering van de darmfunctie met kauwgom [19], implementatie van andere 
methoden van postoperatieve pijnstlling met minder bijwerkingen (transversus ab-
dominis blokkade [20], wondkatheters [21-23]) en het gebruik van medicatie ter 
vermindering van de stressrespons[24]. De meeste postoperatieve elementen uit het 
ERAS programma worden geïntroduceerd bij terugkomst van de patiënt na zijn ope-
ratie op de afdeling. Sommige patiënten blijven echter tot 24 uur na de operatie op 
de verkoeverkamer. Naast het verschaffen van goede pijnbestrijding is het mogelijk 
om andere elementen al op de verkoeverkamer te introduceren: vroeg drinken van 
water, het kauwen van kauwgom en vroege mobilisatie. Bevordering van orale in-
name, vroege mobilisatie en laparoscopische chirurgie, zijn geassocieerd met vroeg 
herstel na een operatie.[25]  
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Indien alle elementen met succes worden nageleefd, is het waarschijnlijk dat niet een 
enkel element, maar het gehele multimodale ERAS programma leidt tot het gewens-
te versnelde herstel. Zoals aangetoond binnen de colorectale chirurgie, kan er ook 
een synergetisch effect ontstaan wanneer het ERAS protocol wordt gecombineerd 
met laparoscopie.[26] Na implementatie is het belangrijk om een zorgprogramma 
goed te blijven naleven zodat een blijvend voordeel voor de patiënt kan worden 
gegarandeerd.[27] Deze naleving van het protocol is helaas het belangrijkste pro-
bleem in het proces van optimalisatie van herstel. Tijdens de eerste fase van de uit-
voering van een nieuw zorgprogramma zijn alle betrokken medewerkers enthousiast 
en alert om zich te houden aan de richtlijn. Na de initiële implementatie dient nale-
ving te worden gehandhaafd met post-implementatiestrategieën, zoals periodieke 
evaluaties en onderwijs.[28] Er is al aangetoond in de colonchirurgie dat een gestruc-
tureerde implementatie strategie kan resulteren in een goede duurzaamheid.[29] 
LAPAROSCOPISCHE LEVERCHIRURGIE 
De minimaal invasieve benadering voor leverchirurgie is inmiddels niet meer weg te 
denken. De afgelopen jaren is aangetoond in verschillende case-series dat naast de 
kleine laparoscopische leverchirurgie, ook majeure laparoscopische leverresecties 
geassocieerd worden met gelijke of verbeterde korte termijn resultaten.[30] In erva-
ren handen zijn het intra-operatieve bloedverlies, de complicaties en het conversie 
percentage meer dan acceptabel voor de laparoscopische linker hemihepatecto-
mie.[31] Een recente meta-analyse, waarin laparoscopische leverresecties case-
matched werden vergeleken met open leverresecties (N = 2900), liet geen verhoog-
de mortaliteit en aanzienlijk minder complicaties, transfusies, bloedverlies en een 
korter verblijf in het ziekenhuis zien in het voordeel van laparoscopische chirur-
gie.[32] In de recente Morioka consensus werd bevestigd dat de laparoscopische 
benadering van kleine leverresecties als de standard dient te worden beschouwd. 
Met betrekking tot de majeure laparoscopische leverresecties (≥3 segmenten) oor-
deelden experts dat de introductie nog in een verkennende fase zit en dat voorzich-
tige disseminatie van de techniek nog steeds gerechtvaardigd is.[2] De internationale 
experts die betrokken waren bij de consensus adviseerden, dat participatie en deel-
name aan lopende prospectieve studies en registraties wenselijk is. In de nabije toe-
komst zal er meer wetenschappelijk bewijs beschikbaar komen over de waarde van 
laparoscopische leverresecties, zodra de resultaten van de ORANGE 2 Plus - Trial 
(hoofdstuk 10) en de Oslo-Comet studie [33] worden gepubliceerd. De ORANGE 2 
Plus - Trial vergelijkt open met laparoscopische hemihepatectomie binnen een ERAS-
programma en de Oslo-Comet studie vergelijkt laparoscopische versus open leverre-
secties voor colorectale metastasen. Beide studies zullen leverchirurgen vermoedelijk 
een beter inzicht verschaffen ten aanzien van de plaats van (majeure) laparoscopi-
Chapter 12 
228 
sche leverchirurgie op het gebied van oncologische uitkomsten, lange-termijn fol-
low-up, de kosten en de patiënt-gerapporteerde uitkomsten. 
Tijdens het schrijven van dit proefschrift is er een verschuiving van chirurgische stra-
tegie ontstaan ten aanzien van de omvang van de leverresectie. Naast de discussie 
over de techniek (laparoscopische versus open) is er ook een toenemende focus op 
leverparenchym besparende technieken.[34, 35] Een two-stage of formele leverre-
sectie blijkt minder vaak nodig te zijn door de verbetering van de intra-operatieve 
beeldvorming en technieken.[36] Tevens dient postoperatief leverfalen voorkomen 
te worden, maar moeten oncologische marges worden gerespecteerd.[37, 38] Een 
parenchym-sparende strategie met een nauwkeurige preoperatieve voorspelling van 
de functie van de toekomstige restlever lijkt de toekomst voor een “tailored” benade-
ring.  
Beter wetenschappelijke ondersteuning, gestandaardiseerde rapportage van de 
resultaten, en het garanderen van een goede training zijn de volgende uitdagingen 
voor de laparoscopische leverchirurgie.[32] Niet alleen RCT's of andere prospectieve 
studies kunnen bijdragen aan een verdere ontwikkeling van laparoscopische lever-
chirurgie, ook de kritische beoordeling van leverresecties uitgevoerd in het verleden 
kan de kwaliteit verbeteren. Controle door nationale of internationale verenigingen 
zal leverchirurgen inzicht geven in de kwaliteit van hun eigen operaties, maar ook in 
de prestaties van andere collega's. (International) benchmarks kunnen worden gede-
finieerd voor belangrijke uitkomsten, zoals mortaliteit, morbiditeit, en R0-
resectiemarges. Uiteindelijk kan deze continue evaluatie leiden tot centralisatie van 
(laparoscopische) leverchirurgie. Mogelijk presteren groot-volume centra beter dan 
centra met slechts een beperkt aantal (laparoscopisch) leverresecties per jaar. Een 
goed voorbeeld van een goed functionerend controlesysteem is het Nederlands 
Instituut voor Clinical Auditing (DICA). Op 1 juli 2013 werd de Nederlandse Lever- 
Audit (DHBA) gestart en dit heeft geresulteerd in de publicatie van de eerste rappor-
tages. Toekomstige verslagen zullen inzicht bieden in de werkelijke kwaliteit en 
kwantiteit van de leverchirurgie in Nederland. 
Het uiteindelijke doel is om een aanpak op maat te kunnen bieden voor elke patiënt 
die leverchirurgie dient te ondergaan. Dit is een toekomst waarin de chirurg in staat 
is om patiënten te selecteren die fit genoeg zijn om geopereerd te worden, waarin hij 
individuele operatie risico’s kan voorspellen en waarin hij de postoperatieve uitkom-
sten nauwkeurig kan inschatten. De selectie van patiënten in de leverchirurgie is een 
belangrijke kwestie. Niet alleen dienen chirurgen de resectabiliteit te bepalen, ook is 
het essentieel om in te kunnen schatten of een patiënt een operatie aankan. Tevens 
is het wenselijk om te kunnen voorspellen of de operatie de lange-termijn overleving 
verbetert.[39] Recente ontwikkelingen op dit gebied zijn gericht op de preoperatieve 
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beoordeling en verbetering van de conditie van de patiënt. Een 4-weeks prehabilita-
tie programma kan de cardiopulmonale inspanningstesten en de kwaliteit van leven 
voor leverresectie verbeteren. Dit kan vervolgens van invloed zijn op perioperatieve 
uitkomsten.[40] Verder onderzoek op dit gebied is nog noodzakelijk, maar in de toe-
komst kan mogelijk een vooraf gedefinieerde cut-off waarde worden gebruikt voor 
patiënten die leverchirurgie dienen te ondergaan om zodoende te kunnen voorspel-
len welke patiënten een verhoogd risico lopen op complicaties en welke patiënten fit 
genoeg zijn om geopereerd te worden.[41] Een geheel andere benadering om pati-
enten voor leverchirurgie te selecteren en om uitkomsten te voorspellen is het ge-
bruik van "big" data. Tegenwoordig zijn patiëntgegevens steeds directer beschikbaar 
in de digitale patiëntendossiers, elektronische onderzoeksformulieren en prospectie-
ve registers. Deze gegevens kunnen leiden tot grote databases die kunnen worden 
gebruikt voor het opstellen van risicomodellen. 
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VALORISATION 
INTRODUCTION 
Liver surgery can be performed for both benign and malignant tumours of the liver. 
Colorectal metastases are the indication for nearly 70% of all liver resections, and 
about 50% of all patients with a primary colorectal tumour will develop hepatic me-
tastases. Primary and benign liver tumours account for 17% and 8% of indications for 
liver surgery in the Netherlands, respectively. Despite the worldwide interest in lapa-
roscopic surgery, in 2014 the majority of all liver surgical procedures was still per-
formed as an open procedure. Only 11% of all liver resections was performed com-
pletely laparoscopically. It is essential not only to offer patients the best surgical pro-
cedure, but also to provide patients the best evidence-based perioperative care to 
accommodate a good and quick recovery. The trend in the Netherlands, but also in 
the rest of the world, is towards further adoption of the laparoscopic technique and 
implementation of a structured perioperative care programme in liver surgery. With 
the still increasing healthcare spending in the Netherlands all new developments 
and treatments face scrutiny over costs. Laparoscopic liver resection itself may be 
more expensive, but if the combination with Enhanced Recovery After Surgery pro-
tocols leads to a shorter hospital length of stay, lower morbidity or better survival, 
the overall costs may be equivalent or even lower. 
RELEVANCE OF SCIENTIFIC RESULTS IN THIS THESIS 
The results reported in this thesis may have both social and economical impact. Costs 
play an ever more pivotal role in modern (surgical) care. Not only do surgeons and 
other clinicians look for ways to optimize and shorten the duration of admission of 
patients, nowadays the government and insurance companies also look for ways to 
improve patient care and reduce costs. As described in this thesis, minimization of the 
delay between functional recovery and actual discharge could prove to be the easiest 
and most tangible way to reduce costs. The length of hospital stay can be reduced by 
implementation of an ERAS programme and may be reduced if patients are operated 
laparoscopically. Results presented in this thesis show a benefit of the ERAS pro-
gramme. However, this thesis has failed to demonstrate a reduced time to functional 
recovery and associated length of stay after laparoscopic left lateral sectionectomy. 
Future studies could and should be focused on finding the added value of laparosco-
py in liver surgery. If laparoscopy truly leads to a quicker recovery of the patient and 
cost-effectiveness analyses also confirm a benefit, laparoscopy is likely to become the 
preferred procedure for liver surgery. A one or two day reduction in length of hospital 
stay could prove to be of significant value regarding costs. Currently, laparoscopic 
procedures are still more expensive than open liver surgery. Equally, laparoscopic 
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procedures require more time in the operating room. This aspect of allocating more 
operating room time to liver resections, at a time where operating room capacity is 
scarce, may be important in future decision making. Waiting lists for cancer-related 
procedures may increase, if more procedures are done laparoscopically. If future stud-
ies fail to demonstrate a clinically significant difference in favour of laparoscopic liver 
surgery that also outweighs the costs, a situation could develop in which open liver 
surgery remains the standard. Laparoscopy may only be deemed beneficial in select-
ed liver surgical procedures. Perhaps insurance companies will no longer compensate 
for laparoscopic procedures in the absence of evidence. However, there is another 
aspect to the comparison of open versus laparoscopic liver surgery: patient opinion. 
Patient-reported outcomes are being valued more and more. Evidence on patient-
reported outcomes on open versus laparoscopic liver surgery is limited and future 
results of the ORANGE II trials on laparoscopic versus open liver surgery could provide 
additional leverage in the debate. 
TARGET POPULATION 
Liver surgeons, other specialists involved in the care of patients diagnosed with liver 
tumours and patients themselves can benefit from the results presented in this the-
sis. It offers them new insights into expert opinions, developments, comparison of 
operative techniques and perioperative care strategies. 
INNOVATION AND FUTURE 
Projects in this thesis have lead to the development and design of new studies and 
collaborations. The multicentre international design of the ORANGE II Trials has re-
sulted in a collaborating network of HPB-centres. A currently ongoing European mul-
ticentre study, the ORANGE II Plus – Trial, is a direct spin-off of the ORANGE II project. 
Through this spin-off, in which the merits of open and laparoscopic hemihepatecto-
my are compared, both surgeons and patients are likely to be presented with valua-
ble new evidence. In the world of hepatic surgery this research has the potential to 
make a lasting footprint. The first results of this collaboration are to be expected in 
2017. With a new network of expert HPB-centres in place, it seems inevitable that 
new multicentre research could get off to a flying start with broad European support. 
In addition, based on results from this thesis and recent literature the Enhanced Recov-
ery After Surgery (ERAS) programme for liver surgery is here to stay. There is robust evi-
dence that should advocate implementation of a structured and evidence-based peri-
operative care programme. In the future this must also be further supported and con-
trolled by the ERAS Society by the development and publication of official guidelines. 
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Eindelijk is het zover, het boek is af! 
Beste prof. Dejong, beste Kees, dank voor al het vertrouwen en de goede adviezen 
die je mij hebt gegeven. Ik bewonder je als promotor, professor van de HPB-groep, 
maar ook als mens om je altijd constructieve manier van communiceren, je humor en 
je leiderschap. Je was altijd snel met je feedback op projecten, waardoor het ook 
duidelijk was hoe mijn proefschrift eruit ging zien. Een van de eerste kennismakingen 
met de hele HPB-groep was een “Champagne-party”. Deze was een jaar eerder in het 
leven geroepen om samen de jaarlijkse successen te vieren onder het motto: wie 
schrijft die blijft. Ik leerde je kennen als een begenadigd spreker en samen met onze 
HPB-groep zijn er inmiddels vele flessen champagne leeg gedronken. 
Best dr. van Dam, Ronaldo, jij was het die toekomst in me zag als semi-arts op de 
afdeling Heelkunde in Maastricht. Je hebt daarna mijn inzet samen met Kees beloond 
door mij een promotieplek aan te bieden. Ik waardeer je creativiteit enorm en samen 
bedachten we projecten voor mijn promotie. Niet alle ideeën hebben het gehaald, 
maar je durft groots te denken en te dromen. Je stuurde me Europa in om een net-
werk op te bouwen en steun te krijgen voor onze projecten. De ORANGE 2 – studies 
zijn inmiddels uitgegroeid tot een veel groter internationaal Europees succes, waar 
leverchirurgen graag in participeren. Er was wat vertraging op het einde en jouw 
oude, zelfs ingelijste data: 10-10-10, 11-11-11, 12-12-12, 13-13-13 flitsten even voor-
bij. Nu is het dan eindelijk zover, geen revisies meer, geen nieuwe deadlines: het 
boekje is af. Naast je begeleiding wil ik je bedanken voor de mooie avonturen die we 
hebben meegemaakt in o.a. Parijs, Cape Town, Belgrado en Dublin. Ik hoop dat er 
nog meer volgen! 
De leden van de beoordelingscommissie wil ik graag bedanken voor hun tijd en het 
beoordelen van dit proefschrift, prof. Beets, prof. Buhre, prof. van der Hulst, prof. 
Primrose en dr. de Boer.  
Dear prof. Aldrighetti, Luca, we met during a congress in South Africa. You were will-
ing to participate in our newly launched ORANGE 2 Study and a collaboration was 
born. You warmly welcomed me during the initiation visit in Milan, Italy and your 
team has been off great support to our projects. As one of the main collaborators and 
centre with the biggest accrual I cannot thank you enough for your time and trust! 
Dear Mr. Rees, Merv, during a congress in Dublin you told me you had gathered some 
interesting data on post-operative analgesia after liver resection. The subject fitted 
perfectly into my PhD-thesis and twice I came and visited Basingstoke, UK. Our col-
laboration has result in a good publication. I sincerely thank you for your trust and for 
giving me the opportunity to come to your hospital in Basingstoke (UK). 
Dear prof Primrose, from the start you have been keen to be involved in the ORANGE 
collaboration and you have been the driving force behind the trial and funding in the 
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UK. I feel honoured to have you in my dissertation committee. Thank you for your 
time and support! 
Tevens bedank ik alle artsen, onderzoekers en ander personeel van de centra waar-
mee ik heb mogen samenwerken. In het bijzonder prof. Topal, prof. Busch, prof. 
Boermeester, prof Borel Rinkes dr. Terkivatan, prof. van Hillegersberg, prof. de Wilt, 
prof. Neumann, prof. Troisi, prof. Dagher, prof. Soubrane, prof. Neumann, prof. Lau-
rent, prof. Dagher, prof. Cherqui, prof. Scatton, prof. Soubrane, prof. Edwin, prof. van 
Breukelen, dr. Abu Hilal, dr. Sutcliffe, dr. Besselink, dr. Aroor, dr. Fretland,,, dr. d’Hondt, 
dr. Sergeant, dr. Fusai, dr. Slooter, dr. Klaase, dr. Ratti, dr. Welsh, dr Wells, dr. John, dr. 
Cresswell, dr. Hoekstra, dr. Huisman, dr. Tanis, dr Besselink, Mrs. Bonwitt, Mrs. Murray, 
Mrs. Mann en Mw. Stam. Zonder hen was dit proefschrift niet tot stand gekomen.  
Beste dr. Bosscha, beste Koop, allereerste bedankt voor de kans die je me hebt gege-
ven om mezelf te bewijzen binnen de Heelkunde in het JBZ. Aanvankelijk kwam ik 
studies in dit proefschrift uitvoeren in het JBZ, aansluitend was ik welkom als ANIOS. 
Korte tijd daarna heb je me gesteund tijdens de sollicitatie voor de opleiding. Tot op 
heden ben je mijn opleider en dank ik je voor al je vertrouwen en steun. 
Beste Joost, Jossos, het zit er op. Eindelijk is het deels door jouw opgestarte project 
afgerond. Als semi-arts heb je de fundering gelegd voor de ORANGE 2 – studie, maar 
ben je daarna een eigen succesvol pad gaan bewandelen via een promotie en oplei-
ding in de regio Leiden. Ik waardeer het heel erg dat je mijn paranimf bent. Sinds 
2003 zijn we vrienden en hebben we hebben talloze mooie momenten mogen de-
len. Van onze studententijd tot een promotie, de opleiding, vakanties en nu het 
stichten van een eigen gezinnetje. Dat er nog veel jaren mogen volgen! 
Beste Mark, Markie aka prof. Hazebroek. Ook aan mijn zijde als paranimf. We zijn 
vrienden sinds je komst in 2004 naar Maastricht. Nadat velen in onze omgeving wa-
ren weggetrokken uit Maastricht, bleef jij achter voor een promotie bij de Cardiolo-
gie met Gitte en de kids. Het gewenste eten kreeg je niet altijd thuis, dus kwam je 
graag bij mij een vorkje meepikken. Je hebt al een tijdje een mooi gezinnetje en ik 
vind het knap hoe je alles weet te combineren. Wat dat betreft ben je een voorbeeld 
voor me en ik stel onze vriendschap enorm op prijs. Jij gaat later dit jaar trouwen en 
kort daarna promoveren. Ik kijk erna uit om samen met je te proosten! 
Heren van het jaar 2003: Joost, Frank, Putten, Haan. We go way back. Alleen al over 
onze tijd in Maastricht kan een heel boek worden geschreven. In goede en slechte 
tijden zijn we er voor elkaar. Ik hoop dat dit nog lang zo mag blijven. 
Beste Sjoerd, oud-dispuutsgenoot, oud-huisgenoot, maar bovenal vriend. We ken-
nen elkaar sinds EP-4. Een huis waar vele mooie herinneringen en plannen zijn ont-
staan. De surfvakanties in Portugal zijn onvergetelijk. Ik ben jaloers op de manier 
waarop jij je leven vorm hebt weten te geven. Af en toe hard werken, maar vooral 
veel tijd voor plezier en genieten van het leven met Jolien en Mila. 
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Dear Mitch, you have always been a good friend to me since your arrival for your 
study in Maastricht. We have lived, enjoyed parties and travelled together. Since a 
couple of years you now happily live with Ruth en Emily in the USA, but we have 
always stayed in touch. I admire your open minded and worldly attitude. See you 
soon! 
Lieve (Bredase) vrienden, Mark, Eric, Moniek, Rick, Evelien, Fay, Luuk, Britt, Ellen, Jaap, 
Wendy, Mark, Paul, Bianca, Madelon, Tess, Ivan, Bart, Claar, Hilde, Alex, Janneke, Rod-
ney, Anne, Sandra, Jeroen, Nienke, Rob, Stephan, Maaike, Bryan, Marieke, Robbert, 
Eva en Erwin. Een deel heb ik enkele jaren geleden via Marieke leren kennen, maar 
sindsdien ben ik veel vrienden, gezellige feesten en etentjes rijker. 
Heren van Nondejuke. Geweldige jaren hebben we in Maastricht meegemaakt. Ik 
ben trots dat ik lid ben geweest van dit mooie dispuut. We zien elkaar snel tijdens het 
lustrum! 
Beste mannen van RBC 2012-2014, wat een mooie tijd was het om deel uit te maken 
van het voetbalteam. Een nieuwe uitdaging om “de club” weer op de kaart te zetten. 
Het eerste seizoen direct kampioen. Avonden stappen, de “autobusrally”, de kampi-
oensreis naar Malloroca. Het heen en weer reizen vanuit Maastricht naar Roosendaal 
was me het meer dan waard en ik had het voor geen goud willen missen! 
Beste Paul, Paulus, partners in crime, klaar om de chirurgische wereld te veroveren. 
Tijdens onze opleiding zijn de cursussen, congressen, promoties, diensten en festi-
vals een waar feest met jou. Ik waardeer onze vriendschap en ik kijk uit na de jaren 
die nog gaan volgen onder het moto “ Mucht to learn you still have.. my Padawan “. 
Beste Luc en Toine, niet alleen hebben jullie bijgedragen aan een belangrijk deel van 
dit proefschrift, ook onze avonturen bij de Chirurgencup, skydiven in Cape Town en 
de legendarische avonden en nachten in de Trinity, 31 en Cafe Caprice zal ik nooit 
vergeten. Luc, uiteindelijk heb je je promotie veel eerder afgerond, maar zijn we 
allebei nu in opleiding tot chirurg! Toine, je hebt een andere richting gekozen, maar 
ik wens je hierin ook veel success toe. 
Beste Victor, dank voor je hulp en samenwerking. Zonder jouw hulp was dit boekje er 
nu niet geweest. Naast de wetenschappelijke samenwerking hebben we ook meer-
dere malen op congressen mogen genieten van “avondjes uit” in bijvoorbeeld de 
legendarische boeventent in Belgrado. Ik wens je veel gezondheid toe en uiteraard 
ook veel succes met de afronding van je eigen promotie. 
Beste Robert, dank voor al je hulp aan en inzet voor het ORANGE-project. Als semi-
arts sprong je op een rijdende trein die inmiddels wereldwijd bekend is. Door jouw 
inzet is de ORANGE 2 Plus – studie nu bijna afgerond en zullen vele mooie publicaties 
volgen. Veel succes de komende tijd en ik kijk uit naar jouw boekje! 
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Alle andere oud-collega’s van de afdeling Heelkunde / het lab in het MUMC die ik 
nog niet heb genoemd, bedankt voor de fijne tijd. Prof. Olde Damink (Steven), Dr. 
Bemelmans (Marc), Dr. Stoot (Jan / Johnny Punch), Mariëlle, Liliane, Simon, Dirk, Ro-
bert-Jan, Aart, Freek, Froukje, Guy, Inca, Irene-Fleur, Irma, Mo, Joyce-Manyi, Maartje, 
Marlou, Kaatje, Kevin, Kim van Mierlo, Kim van Wijck, Kirsten, Lori, Luc, Mark, Nina, 
Robbert-Jan, Ruben, Kostan, Rutger en anderen die ik misschien nu vergeet. 
Beste (oud)-collega’s en staf van de afdeling Heelkunde in het JBZ. Wat een mooie 
plek om mijn opleiding te doorlopen. Ik geniet van de samenwerking en ben dank-
baar voor jullie ondersteuning en voor alles wat jullie mij leren. 
Lieve (schoon)familie, bedankt voor jullie interesse en steun die ik tijdens deze peri-
ode heb ervaren. Jullie bieden altijd een luisterend oor en ik ben blij dat we samen 
dit mooie moment kunnen delen. 
Ralph en Luc, mijn lieve broers. Ik ben zo trots op jullie. Ik kan altijd bij jullie terecht 
en we zijn er voor elkaar. Alle drie opgegroeid in een warm nest en uitgevlogen door 
drie compleet verschillende paden te bewandelen. Ralph, mijn tweelingbroer, ik 
bewonder je humor, je inzet en doorzettingsvermogen. Het heeft je nu eindelijk 
gebracht waar je wil zijn en na wat omzwervingen zie ik dat je nu je plek hebt ge-
vonden. Samen met Valerie vorm je een goed en gelukkig team en ik hoop dat de 
toekomst jullie veel goeds brengt. Luc, mijn broer(the), onze marketeer, sociaal 
beest, wat kan jij goed met mensen omgaan. Je bent een voorbeeld voor me met je 
creativiteit en door de manier waarop jij mensen benaderd en in hun waarde laat. 
Het maakt je niet voor niets zo succesvol in je huidige baan. Samen met Veronique 
ga je nieuwe avonturen aan en ik zal je daarin altijd steunen! 
Lieve papa en mama, waar zou ik zijn zonder jullie. Altijd zijn jullie er voor mij met 
jullie onvoorwaardelijke steun en liefde. Ik voel me bevoorrecht met jullie als ouders 
aan mijn zijde. Jullie hebben me alle kansen geboden om te zijn wie ik nu ben en 
zonder jullie was dit proefschrift er nooit geweest. Ik ben dankbaar dat jullie samen 
met mij dit moment kunnen delen en ik hoop dat we nog lang in goede gezondheid 
het leven delen. 
Lieve Marieke, mijn maatje, liefde van mijn leven. Sinds ik je ken is mijn leven veran-
derd en nooit meer hetzelfde geweest. Mooie, maar ook verdrietige momenten heb-
ben we samen gedeeld. Ik bewonder je altijd positieve houding, je glimlach, je door-
zettingsvermogen en je zorgzaamheid. Je geeft me de ruimte om te zijn wie ik ben. 
Je gaf me de ruimte in ons al drukke leven om aan mijn promotie te werken. Mijn 
proefschrift is nu eindelijk afgerond en ik kijk uit naar de nieuwe plannen die we 
samen zullen gaan maken. Inmiddels vormen we een gezinnetje met onze dochter 
Elise en er is een tweede kindje op komst. Ik kan me geen betere moeder voor onze 
kinderen wensen en hou zielsveel van je! Samen kunnen we de hele wereld aan! 
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